iKang Healthcare (KANG) 20-F 25 Jul 14 2013 FY Annual report (foreign) Financial data

Document_and_Entity_Informatio

Document and Entity Information	12 Months Ended
	Mar. 31, 2014	Jul. 24, 2014	Jul. 24, 2014
		Class A common shares	Class C common shares
Entity Registrant Name	'iKang Healthcare Group, Inc.	'	'
Entity Central Index Key	'0001524190	'	'
Document Type	'20-F	'	'
Document Period End Date	31-Mar-14	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--03-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Non-accelerated Filer	'	'
Entity Common Stock, Shares Outstanding	'	31,936,439	805,100
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2014	Mar. 31, 2013
In Thousands, unless otherwise specified
Current assets	'	'
Cash and cash equivalents	$30,221	$63,154
Restricted cash	16,007	'
Accounts receivable, net of allowance for doubtful accounts of $3,272 and $4,330 as of March 31, 2013 and 2014, respectively	37,619	30,189
Inventories	1,693	1,162
Deferred tax assets-current	3,991	2,874
Prepaid expenses and other current assets	20,012	6,616
Amount due from related parties	1,287	483
Total current assets	110,830	104,478
Equity method investment	6,220	'
Restricted cash-non-current	2,153	'
Property and equipment, net	63,644	32,572
Acquired intangible assets, net	17,530	4,480
Goodwill	41,412	17,791
Cost method investment	129	131
Deferred tax assets-non-current	2,007	1,456
Rental deposit and other non-current assets	6,301	4,453
TOTAL ASSETS	250,226	165,361
Current liabilities	'	'
Accounts payable (including accounts payable of the consolidated VIE entities without recourse to iKang Healthcare Group, Inc. of $8,370 and $14,599 of March 31, 2013 and 2014, respectively)	16,965	9,822
Accrued expenses and other current liabilities (including accrued expenses and other current liabilities of the consolidated VIE entities without recourse to iKang Healthcare Group, Inc. of $9,885 and $17,126 of March 31, 2013 and 2014, respectively)	24,275	17,191
Income tax payable (including income tax payable of the consolidated VIE entities without recourse to iKang Healthcare Group, Inc. of 2,085 and $5,299 of March 31, 2013 and 2014, respectively)	6,382	2,409
Amount due to related parties (including amount due to related parties of the consolidated VIE entities without recourse to iKang Healthcare Group, Inc. of $12,379 and$8,049 of March 31, 2013 and 2014, respectively)	8,049	12,379
Deferred revenues (including deferred revenues of the consolidated VIE entities without recourse to iKang Healthcare Group, Inc. of $19,183 and $22,234 of March 31, 2013 and 2014, respectively)	29,523	24,578
Deferred government subsidy-current (including deferred government subsidy - current of the consolidated VIE entities without recourse to iKangHealthcare Group, Inc. of $63 and $47 of March 31, 2013 and 2014, respectively)	47	63
Short term borrowings (including short term borrowings of the consolidated VIE entities without recourse to iKang Healthcare Group, Inc. of $5,482 and $17,717 of March 31, 2013 and 2014, respectively)	18,201	5,482
Convertible loan (including convertible loan of the consolidated VIE entities without recourse to iKang Healthcare Group, Inc. of nil and nil of March 31, 2013 and 2014, respectively)	'	2,000
Total current liabilities	103,442	73,924
Deferred government subsidy - non-current (including deferred government subsidy-non-current of the consolidated VIE entities without recourse to iKangHealthcare Group, Inc of $125 and $63 of March 31, 2013 and 2014, respectively)	63	125
Long term borrowings (including long term borrowings consolidated VIE entities without recourse to iKang Healthcare Group, Inc. of nil and $1,865 of March 31, 2013 and 2014, respectively)	1,865	'
Deferred tax liabilities-non-current (including deferred tax liabilities-non-current of the consolidated VIE entities without recourse to iKang Healthcare Group, Inc. of $483 and $2,929 of March 31, 2013 and 2014, respectively)	3,478	499
TOTAL LIABILITIES	108,848	74,548
Commitments and contingencies (Note 22)	'	'
iKang Guobin Healthcare Group, Inc. shareholders' equity	'	'
Additional paid-in capital	1,342	4,341
Statutory reserve	5,005	2,267
Accumulated deficit	-137,129	-135,390
Accumulated other comprehensive income	3,764	4,522
Total iKang Healthcare Group, Inc. shareholders' deficit	-126,957	-124,195
Non-controlling interest	3,818	1,030
TOTAL DEFICIT	-123,139	-123,165
TOTAL LIABILITIES, MEZZANINE EQUITY AND EQUITY	250,226	165,361
Series A convertible redeemable participating preferred shares	'	'
Mezzanine equity	'	'
Convertible redeemable participating preferred shares	6,496	6,496
Series B convertible redeemable participating preferred shares	'	'
Mezzanine equity	'	'
Convertible redeemable participating preferred shares	6,512	6,512
Series C1 convertible redeemable participating preferred shares	'	'
Mezzanine equity	'	'
Convertible redeemable participating preferred shares	5,700	5,700
Series C2 convertible redeemable participating preferred shares	'	'
Mezzanine equity	'	'
Convertible redeemable participating preferred shares	1,709	1,709
Series C3 convertible redeemable participating preferred shares	'	'
Mezzanine equity	'	'
Convertible redeemable participating preferred shares	4,157	4,157
Series D1 convertible redeemable participating preferred shares	'	'
Mezzanine equity	'	'
Convertible redeemable participating preferred shares	29,750	30,176
Series D2 convertible redeemable participating preferred shares	'	'
Mezzanine equity	'	'
Convertible redeemable participating preferred shares	11,300	12,356
Series E convertible redeemable participating preferred shares	'	'
Mezzanine equity	'	'
Convertible redeemable participating preferred shares	54,098	54,098
Series F convertible redeemable participating preferred shares	'	'
Mezzanine equity	'	'
Convertible redeemable participating preferred shares	144,795	92,774
Class A common shares	'	'
iKang Guobin Healthcare Group, Inc. shareholders' equity	'	'
Common shares	45	49
Class B common shares	'	'
iKang Guobin Healthcare Group, Inc. shareholders' equity	'	'
Common shares	$16	$16

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2014	Mar. 31, 2013
In Thousands, except Share data, unless otherwise specified
Allowance for doubtful accounts receivable	$4,330	$3,272
Accounts payable	16,965	9,822
Accrued expenses and other current liabilities	24,275	17,191
Income tax payable	6,382	2,409
Amount due to related parties	8,049	12,379
Deferred revenues	29,523	24,578
Deferred government subsidy - current	47	63
Short term borrowings	18,201	5,482
Convertible loan	'	2,000
Deferred government subsidy - non-current	63	125
Long term borrowings	1,865	'
Deferred tax liabilities - non-current	3,478	499
Common shares, par value (in dollars per share)	$0.01	$0.01
Common shares, authorized	39,268,485	37,596,704
Consolidated VIEs without recourse to iKang Healthcare Group, Inc.	'	'
Accounts payable	14,599	8,370
Accrued expenses and other current liabilities	17,126	9,885
Income tax payable	5,299	2,085
Amount due to related parties	8,049	12,379
Deferred revenues	22,234	19,183
Deferred government subsidy - current	47	63
Short term borrowings	17,717	5,482
Convertible loan	0	0
Deferred government subsidy - non-current	63	125
Long term borrowings	1,865	0
Deferred tax liabilities - non-current	2,929	483
Series A convertible redeemable participating preferred shares	'	'
Convertible redeemable participating preferred shares, par value (in dollars per share)	$0.01	$0.01
Convertible redeemable participating preferred shares, authorized	1,094,668	1,391,044
Convertible redeemable participating preferred shares, issued	1,094,668	1,094,668
Convertible redeemable participating preferred shares, outstanding	1,094,668	1,094,668
Convertible redeemable participating preferred shares, liquidation value	1,970	1,970
Series B convertible redeemable participating preferred shares	'	'
Convertible redeemable participating preferred shares, par value (in dollars per share)	$0.01	$0.01
Convertible redeemable participating preferred shares, authorized	686,368	1,059,735
Convertible redeemable participating preferred shares, issued	686,368	686,368
Convertible redeemable participating preferred shares, outstanding	686,368	686,368
Convertible redeemable participating preferred shares, liquidation value	2,162	2,162
Series C1 convertible redeemable participating preferred shares	'	'
Convertible redeemable participating preferred shares, par value (in dollars per share)	$0.01	$0.01
Convertible redeemable participating preferred shares, authorized	794,250	794,250
Convertible redeemable participating preferred shares, issued	794,250	794,250
Convertible redeemable participating preferred shares, outstanding	794,250	794,250
Convertible redeemable participating preferred shares, liquidation value	1,893	1,893
Series C2 convertible redeemable participating preferred shares	'	'
Convertible redeemable participating preferred shares, par value (in dollars per share)	$0.01	$0.01
Convertible redeemable participating preferred shares, authorized	126,286	252,572
Convertible redeemable participating preferred shares, issued	126,286	126,286
Convertible redeemable participating preferred shares, outstanding	126,286	126,286
Convertible redeemable participating preferred shares, liquidation value	568	568
Series C3 convertible redeemable participating preferred shares	'	'
Convertible redeemable participating preferred shares, par value (in dollars per share)	$0.01	$0.01
Convertible redeemable participating preferred shares, authorized	1,024,318	1,024,318
Convertible redeemable participating preferred shares, issued	1,024,318	1,024,318
Convertible redeemable participating preferred shares, outstanding	1,024,318	1,024,318
Convertible redeemable participating preferred shares, liquidation value	1,382	1,382
Series D1 convertible redeemable participating preferred shares	'	'
Convertible redeemable participating preferred shares, par value (in dollars per share)	$0.01	$0.01
Convertible redeemable participating preferred shares, authorized	3,488,864	3,655,151
Convertible redeemable participating preferred shares, issued	3,538,864	3,538,864
Convertible redeemable participating preferred shares, outstanding	3,488,864	3,538,864
Convertible redeemable participating preferred shares, liquidation value	10,083	10,227
Series D2 convertible redeemable participating preferred shares	'	'
Convertible redeemable participating preferred shares, par value (in dollars per share)	$0.01	$0.01
Convertible redeemable participating preferred shares, authorized	2,072,624	2,436,769
Convertible redeemable participating preferred shares, issued	2,307,536	2,307,536
Convertible redeemable participating preferred shares, outstanding	2,072,624	2,307,536
Convertible redeemable participating preferred shares, liquidation value	2,798	3,115
Series E convertible redeemable participating preferred shares	'	'
Convertible redeemable participating preferred shares, par value (in dollars per share)	$0.01	$0.01
Convertible redeemable participating preferred shares, authorized	4,289,457	4,289,457
Convertible redeemable participating preferred shares, issued	4,289,457	4,289,457
Convertible redeemable participating preferred shares, outstanding	4,289,457	4,289,457
Convertible redeemable participating preferred shares, liquidation value	22,056	22,056
Series F convertible redeemable participating preferred shares	'	'
Convertible redeemable participating preferred shares, par value (in dollars per share)	$0.01	$0.01
Convertible redeemable participating preferred shares, authorized	7,204,680	7,500,000
Convertible redeemable participating preferred shares, issued	4,654,697	4,654,697
Convertible redeemable participating preferred shares, outstanding	7,204,680	4,654,697
Convertible redeemable participating preferred shares, liquidation value	$93,639	$60,000
Class A common shares	'	'
Common shares, par value (in dollars per share)	$0.01	$0.01
Common shares, authorized	37,698,485	36,026,704
Common shares, issued	4,911,245	4,911,245
Common shares, outstanding	4,599,674	4,599,674
Class B common shares	'	'
Common shares, par value (in dollars per share)	$0.01	$0.01
Common shares, authorized	1,570,000	1,570,000
Common shares, issued	1,570,000	1,570,000
Common shares, outstanding	1,570,000	1,570,000

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
CONSOLIDATED STATEMENTS OF OPERATIONS	'	'	'
Net revenues	$202,304	$133,871	$93,713
Cost of revenues	106,405	71,079	49,506
Gross profit	95,899	62,792	44,207
Operating expenses:	'	'	'
Selling and marketing	28,879	18,486	14,005
General and administrative (including share-based compensation of $216, $2,273 and $930 in 2012, 2013 and 2014, respectively)	32,053	23,447	14,756
Research and development	1,603	1,270	748
Write-off of leasehold improvement	'	'	309
Total operating expenses	62,535	43,203	29,818
Income from operations	33,364	19,589	14,389
Gain from forward contracts	57	'	'
Interest expense	-1,331	-1,106	-159
Interest income	93	100	101
Income before provision for income taxes and loss from equity method investment	32,183	18,583	14,331
Income tax expenses	10,101	6,134	3,939
Income before loss from equity method investment	22,082	12,449	10,392
Loss from equity method investment	156	'	'
Net income	21,926	12,449	10,392
Less: Net income attributable to non-controlling interest	319	338	690
Net income attributable to iKang Healthcare Group, Inc.	21,607	12,111	9,702
Deemed dividend to preferred shareholders	20,436	84,306	2,312
Undistributed earnings allocated to preferred shareholders	7,310	2,818	2,770
Net income (loss) attributable to common and preferred shareholders of iKang Healthcare Group, Inc.	($6,139)	($75,013)	$4,620
Net income (loss) per share attributable to common shareholders of iKang Healthcare Group, Inc.	'	'	'
Basic (in dollars per share)	($0.97)	($11.22)	$0.22
Diluted (in dollars per share)	($0.97)	($11.22)	$0.21
Weighted average shares used in calculating net (loss) income per common share	'	'	'
Basic (in shares)	6,340,005	6,683,678	6,599,009
Diluted (in shares)	6,340,005	6,683,678	6,768,074

CONSOLIDATED_STATEMENTS_OF_OPE1

CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
CONSOLIDATED STATEMENTS OF OPERATIONS	'	'	'
Share-based compensation	$930	$2,273	$216

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME	'	'	'
Net income	$21,926	$12,449	$10,392
Other comprehensive income (loss):	'	'	'
Other comprehensive income (loss), foreign currency translation adjustment	-779	568	1,541
Comprehensive income	21,147	13,017	11,933
Less: Comprehensive income attributable to non-controlling interest	298	322	706
Comprehensive income attributable iKang Healthcare Group, Inc.	$20,849	$12,695	$11,227

CONSOLIDATED_STATEMENTS_OF_CHA

CONSOLIDATED STATEMENTS OF CHANGE IN EQUITY (DEFICIT) (USD $)

Total

Shenzhen Hospital Management

iKang Shanghai Guobin Blue Cross Clinic Co. Ltd

Shanghai Guobin Medical Center Co., Ltd

Shanghai iKang Jianwei Health Management Co., Ltd

Jiandatong Health Technology (Beijing) Co., Ltd

Changzhou iKang Guobin Clinic Co., Ltd

Fujian iKang Guobin Health Management Co., Ltd.

Shanghai Wangzu Guobin Medical Center Co., Ltd.

Shenzhen iKang Guobin Hospital Management Inc.

MediFast (Hong Kong) Limited

iKang's shareholder's equity (deficit)

iKang's shareholder's equity (deficit)

iKang's shareholder's equity (deficit)

iKang's shareholder's equity (deficit)

iKang's shareholder's equity (deficit)

Common stock

Additional paid-in capital

Additional paid-in capital

Additional paid-in capital

Additional paid-in capital

Statutory reserve

Accumulated equity/(deficit)

Accumulated equity/(deficit)

Accumulated other comprehensive income

Non-controlling Interest

Non-controlling Interest

Non-controlling Interest

Non-controlling Interest

Non-controlling Interest

Non-controlling Interest

Non-controlling Interest

Non-controlling Interest

Non-controlling Interest

Non-controlling Interest

In Thousands, except Share data, unless otherwise specified

iKang Shanghai Guobin Blue Cross Clinic Co. Ltd

Shanghai Guobin Medical Center Co., Ltd

Shanghai iKang Jianwei Health Management Co., Ltd

Shenzhen iKang Guobin Hospital Management Inc.

iKang Shanghai Guobin Blue Cross Clinic Co. Ltd

Shanghai Guobin Medical Center Co., Ltd

Shenzhen iKang Guobin Hospital Management Inc.

Shanghai iKang Jianwei Health Management Co., Ltd

iKang Shanghai Guobin Blue Cross Clinic Co. Ltd

Shanghai Guobin Medical Center Co., Ltd

Shanghai iKang Jianwei Health Management Co., Ltd

Jiandatong Health Technology (Beijing) Co., Ltd

Changzhou iKang Guobin Clinic Co., Ltd

Fujian iKang Guobin Health Management Co., Ltd.

Shanghai Wangzu Guobin Medical Center Co., Ltd.

Shenzhen iKang Guobin Hospital Management Inc.

MediFast (Hong Kong) Limited

Balance at Mar. 31, 2011

($46,676)

'

'

'

'

'

'

'

'

'

'

($48,245)

'

'

'

'

$65

$16,103

'

'

'

$501

($67,327)

'

$2,413

$1,569

'

'

'

'

'

'

'

'

'

Balance (in shares) at Mar. 31, 2011

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,476,645

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increase (Decrease) in Stockholders' Equity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Provision for statutory reserve

470

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

470

-470

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation

216

'

'

'

'

'

'

'

'

'

'

216

'

'

'

'

'

216

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of share options

136

'

'

'

'

'

'

'

'

'

'

136

'

'

'

'

1

135

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of share options (in shares)

75,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

75,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of share option to shareholders

271

'

'

'

'

'

'

'

'

'

'

271

'

'

'

'

1

1,762

'

'

'

'

-1,492

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of share option to shareholders (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

134,845

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Change in effective ownership of iKang Zhejiang, Inc.

95

'

'

'

'

'

'

'

'

'

'

-95

'

'

'

'

'

-95

'

'

'

'

'

'

'

95

'

'

'

'

'

'

'

'

'

Capital contribution of non-controlling interest holder of iKang Zhejiang, Inc.

164

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

164

'

'

'

'

'

'

'

'

'

Addition of non-controlling interest in connection with acquisition

'

'

'

'

'

'

'

305

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

305

'

'

'

Dividend distribution to non-controlling interest holder of Shanghai Guobin Medical Center Co., Ltd.

'

'

'

-420

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-420

'

'

'

'

'

'

'

Deemed dividend on convertible redeemable preferred shares - accretion of redemption premium

-2,312

'

'

'

'

'

'

'

'

'

'

-2,312

'

'

'

'

'

'

'

'

'

'

-2,312

'

'

'

'

'

'

'

'

'

'

'

'

Purchase of non-controlling interest

-1,711

29

-191

-14,721

'

'

'

'

'

-209

'

'

-15

-13,157

'

-238

'

'

-15

-13,157

-238

'

'

'

'

'

176

-1,564

'

'

'

'

'

29

'

Net income

10,392

'

'

'

'

'

'

'

'

'

'

9,702

'

'

'

'

'

'

'

'

'

'

9,702

'

'

690

'

'

'

'

'

'

'

'

'

Foreign currency translation adjustment

1,541

'

'

'

'

'

'

'

'

'

'

1,525

'

'

'

'

'

'

'

'

'

'

'

'

1,525

16

'

'

'

'

'

'

'

'

'

Balance at Mar. 31, 2012

-51,504

'

'

'

'

'

'

'

'

'

'

-52,212

'

'

'

'

67

4,711

'

'

'

971

-61,899

'

3,938

708

'

'

'

'

'

'

'

'

'

Balance (in shares) at Mar. 31, 2012

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,686,490

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increase (Decrease) in Stockholders' Equity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Provision for statutory reserve

1,296

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,296

-1,296

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation

2,273

'

'

'

'

'

'

'

'

'

'

2,273

'

'

'

'

'

2,273

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deemed dividend on convertible redeemable preferred shares - accretion of redemption premium

-84,306

'

'

'

'

'

'

'

'

'

'

-84,306

'

'

'

'

'

'

'

'

'

'

-84,306

'

'

'

'

'

'

'

'

'

'

'

'

Net income

12,449

'

'

'

'

'

'

'

'

'

'

12,111

'

'

'

'

'

'

'

'

'

'

12,111

'

'

338

'

'

'

'

'

'

'

'

'

Foreign currency translation adjustment

568

'

'

'

'

'

'

'

'

'

'

584

'

'

'

'

'

'

'

'

'

'

'

'

584

-16

'

'

'

'

'

'

'

'

'

Redesignation to Series F convertible redeemable preferred shares

-2,645

'

'

'

'

'

'

'

'

'

'

-2,645

'

'

'

'

-2

-2,643

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Redesignation to Series F convertible redeemable preferred shares (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-205,245

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Mar. 31, 2013

-123,165

'

'

'

'

'

'

'

'

'

'

-124,195

'

'

'

'

65

4,341

'

'

'

2,267

-135,390

'

4,522

1,030

'

'

'

'

'

'

'

'

'

Balance (in shares) at Mar. 31, 2013

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,481,245

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increase (Decrease) in Stockholders' Equity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Provision for statutory reserve

2,738

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,738

-2,738

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation

930

'

'

'

'

'

'

'

'

'

'

930

'

'

'

'

'

930

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Addition of non-controlling interest in connection with acquisition

'

'

'

'

-172

82

732

'

'

'

1,690

'

'

'

-172

'

'

'

'

'

'

'

'

-172

'

'

'

'

172

82

732

'

'

'

1,690

Dividend distribution to non-controlling interest holder of Shanghai Guobin Medical Center Co., Ltd.

'

'

'

'

'

'

'

'

-44

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

44

'

'

Deemed dividend on convertible redeemable preferred shares - accretion of redemption premium

-20,436

'

'

'

'

'

'

'

'

'

'

-20,436

'

'

'

'

'

'

'

'

'

'

-20,436

'

'

'

'

'

'

'

'

'

'

'

'

Purchase of non-controlling interest

-142

'

-326

'

'

'

'

'

'

'

'

'

-184

'

'

'

'

'

-184

'

'

'

'

'

'

'

-142

'

'

'

'

'

'

'

'

Net income

21,926

'

'

'

'

'

'

'

'

'

'

21,607

'

'

'

'

'

'

'

'

'

'

21,607

'

'

319

'

'

'

'

'

'

'

'

'

Foreign currency translation adjustment

-779

'

'

'

'

'

'

'

'

'

'

-758

'

'

'

'

'

'

'

'

'

'

'

'

-758

-21

'

'

'

'

'

'

'

'

'

iKang Healthcare Group, Inc. one common share of US$0.01 entered into a share swap agreement (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Redesignation to Series F convertible redeemable preferred shares

-3,749

'

'

'

'

'

'

'

'

'

'

-3,749

'

'

'

'

-4

-3,745

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Redesignation to Series F convertible redeemable preferred shares (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-311,572

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Mar. 31, 2014

($123,139)

'

'

'

'

'

'

'

'

'

'

($126,957)

'

'

'

'

$61

$1,342

'

'

'

$5,005

($137,129)

'

$3,764

$3,818

'

'

'

'

'

'

'

'

'

Balance (in shares) at Mar. 31, 2014

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,169,674

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

CONSOLIDATED_STATEMENTS_OF_CHA1

CONSOLIDATED STATEMENTS OF CHANGE IN EQUITY (DEFICIT) (Parenthetical) (USD $)	Mar. 31, 2014	Mar. 31, 2013
CONSOLIDATED STATEMENTS OF CHANGE IN EQUITY (DEFICIT)	'	'
Common shares, par value (in dollars per share)	$0.01	$0.01

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES	'	'	'
Net income	$21,926	$12,449	$10,392
Adjustments to reconcile net (loss) income to net cash provided by operating activities	'	'	'
Depreciation and amortization	10,759	7,710	6,285
Write-off of leasehold improvement	'	'	309
Share-based compensation	930	2,273	216
Loss on disposal of property and equipment	163	475	122
Provision for doubtful account	1,100	1,800	481
Inventory written-down	0	0	25
Amortization of discount on payable purchase of non-controlling interest of Shanghai Guobin Medical Center Co., Ltd	504	629	155
Loss from equity method investment	156	'	'
Changes in assets and liabilities	'	'	'
Accounts receivable	-3,802	-12,986	-6,421
Inventories	-459	-97	-253
Prepaid expenses and other current assets	-1,193	176	45
Amount due from related parties	'	-477	49
Deferred tax assets	-1,232	-1,081	64
Rental deposit and other long-term assets	-1,485	-1,429	-1,244
Accounts payable	-955	1,864	991
Accrued expenses and other current liabilities	2,884	3,071	2,235
Income tax payable	3,824	528	1,332
Amount due to related parties	'	'	-198
Deferred revenues	1,774	1,589	-442
Deferred government subsidy	-79	-62	-62
Deferred tax liabilities	-512	-118	-76
Net cash generated from operating activities	34,303	16,314	14,005
CASH FLOWS FROM INVESTING ACTIVITIES	'	'	'
Purchase of property and equipment	-35,838	-9,979	-12,205
Proceeds from disposal of property and equipment	13	94	3
Restricted cash	-18,429	'	65
Payment for business acquisitions (net of cash acquired of $50, $4 and $2,749 for years ended March 31, 2012, 2013 and 2014, respectively)	-41,311	-6,038	-2,966
Loan provided to related parties	-4,306	'	'
Repayment of loan provided to a related party	3,483	'	'
Net cash used in investing activities	-96,714	-16,058	-15,706
CASH FLOW FROM FINANCING ACTIVITIES	'	'	'
Proceeds from issuance of convertible redeemable preferred shares	25,181	45,000	'
Proceeds from redesignation of convertible redeemable preferred shares	669	'	'
Proceeds from redesignation of Common A	612	'	'
Proceeds from exercise of share options	'	'	136
Proceeds from exercise of share option to shareholders	'	'	269
Payment for business acquisitions	-3,010	'	'
Dividend distribution to non-controlling interest shareholder of Shanghai Guobin Medical Center Co., Ltd	-44	'	-428
Payment for professional fees in connection of issuance of series F convertible preferred shares	-2,847	'	'
Proceeds from convertible loan	'	2,000	'
Repayment of convertible loan	-2,000	'	'
Repayment short-term borrowing	-7,383	-3,976	'
Proceeds from short-term borrowings	20,298	7,800	1,563
Proceeds from long term borrowings	1,901	'	'
Net cash (used in)/ provided by financing activities	29,342	50,824	-1,161
Effect of exchange rate changes	136	199	595
Net increase in cash and cash equivalent	-32,933	51,279	-2,267
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR	63,154	11,875	14,142
CASH AND CASH EQUIVALENTS AT END OF THE YEAR	30,221	63,154	11,875
Supplemental cash flow information	'	'	'
Income tax paid	8,224	6,850	2,756
Interest paid	1,068	308	'
Supplemental non-cash financing and investing activities	'	'	'
Payable purchase of non-controlling interest of iKang Shanghai Xikang Road	-8,049	-12,379	-11,572
Acquisition payable of business acquisitions	-3,628	-505	-1,383
Payable of purchase of assets	'	-32	'
Change in payable for purchase of property and equipment	4,927	1,802	1,022
iKang Zhejiang BVI	'	'	'
CASH FLOW FROM FINANCING ACTIVITIES	'	'	'
Capital contribution from non-controlling interest holder	'	'	477
iKang Shanghai Guobin Blue Cross Clinic Co. Ltd	'	'	'
CASH FLOWS FROM INVESTING ACTIVITIES	'	'	'
Purchase of non-controlling interest	-326	'	-199
Shenzhen iKang Guobin Hospital Management Inc.	'	'	'
CASH FLOWS FROM INVESTING ACTIVITIES	'	'	'
Purchase of non-controlling interest	'	'	-205
Shenzhen Kefa Clinic	'	'	'
CASH FLOWS FROM INVESTING ACTIVITIES	'	'	'
Purchase of assets	'	-135	'
Nanjing iKang Guobin Clinic Co., Ltd	'	'	'
CASH FLOWS FROM INVESTING ACTIVITIES	'	'	'
Purchase of assets	'	'	-16
Shenzhen Xinglin Clinic Co., Ltd.	'	'	'
CASH FLOWS FROM INVESTING ACTIVITIES	'	'	'
Purchase of assets	'	'	-183
iKang Changzhou	'	'	'
CASH FLOW FROM FINANCING ACTIVITIES	'	'	'
Capital contribution from non-controlling interest holder	732	'	'
Shanghai Guobin Medical Center Co., Ltd	'	'	'
CASH FLOW FROM FINANCING ACTIVITIES	'	'	'
Purchase of non-controlling interest of Shanghai Guobin Medical Center Co., Ltd.	($4,767)	'	($3,178)

CONSOLIDATED_STATEMENTS_OF_CAS1

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
CONSOLIDATED STATEMENTS OF CASH FLOWS	'	'	'
Cash acquired	$2,749	$4	$50

ORGANIZATION_AND_PRINCIPAL_ACT

ORGANIZATION AND PRINCIPAL ACTIVITIES	12 Months Ended
	Mar. 31, 2014
ORGANIZATION AND PRINCIPAL ACTIVITIES	'
ORGANIZATION AND PRINCIPAL ACTIVITIES	'
	1.                                      ORGANIZATION AND PRINCIPAL ACTIVITIES
	iKang Healthcare Group, Inc. (the “Company”), was incorporated on May 25, 2011 as a limited liability company in the Cayman Islands. The Company has no operations and has been created for the initial public offering (“IPO”) purpose. On March 1, 2014, the Company entered into a share swap agreement and became the ultimate holding company of iKang Guobin Healthcare Group, Inc. with the completion of the one to one share exchange to the existing shareholders of iKang Guobin Healthcare Group, Inc. for all shares of equivalent classes.
	The Company, its subsidiaries, its variable interest entities (“VIEs”) and its VIEs’ subsidiaries (collectively the “Group”) are primarily engaged in providing medical examination, disease screening services, and other healthcare related services in the People’s Republic of China (the “PRC”).
	As of March 31, 2014, details of the Group’s subsidiaries, VIEs and the VIEs’ subsidiaries were as follows:
						Percentage of
		Later date of				beneficial interest
		incorporation/		Place of		by iKang
	Names	acquisition		incorporation		Healthcare Group, Inc.		Principal activities
	Subsidiaries:
	iKang Guobin Healthcare Group, Inc.(“iKang Guobin”)	24-Dec-03		BVI		100	%	Holding company
	ShanghaiMed iKang, Inc. (“Beijing iKang”)	27-Feb-04		PRC		100	%	Sales of healthcare service
	Shanghai iKang Co., Ltd. (“Shanghai iKang”)	27-Dec-04		PRC		100	%	Sales of healthcare service
	iKang Zhejiang, Inc. (“iKang Zhejiang BVI”)	5-Apr-06		BVI		73	%	Holding company
	iKang HealthManagement (Zhejiang) Co., Ltd. (“Zhejiang iKang”)	11-Jul-06		PRC		73	%	Sales of healthcare service
	Bayley & Jackson (China) Medical Services Limited (“Bayley & Jackson (Hong Kong)”)	10-Oct-06		Hong Kong		100	%	Holding company
	Beijing Bayley & Jackson Clinic Co., Ltd. (“iKang Beijing Ritan”)	10-Oct-06		PRC		100	%	Medical examination & clinical
	Yuanhua Healthcare Limited (HongKong) (“Yuanhua HK”)	31-Jul-13		BVI		100	%	Holding company
	MediFast (Hong Kong) Limited (“MediFast”)	16-Mar-95		Hong Kong		80	%	Medical examination & clinical
	Yuanhua Medical Consultancy Services (Shanghai) Co., Ltd. (“Yuanhua WFOE”)	31-Jul-13		PRC		100	%	Sales of healthcare service
	VIEs:
	Shanghai iKang Guobin Holding Co., Ltd. (“iKang Holding”)	27-Apr-07		PRC		100	%	Holding company
	Hangzhou iKang Guobin Clinic, Co., Ltd. (“iKang Hangzhou Xixi”)	26-Sep-10		PRC		73	%	Medical examination
	Shanghai Yuanhua Information Technology Co., Ltd. (“Yuanhua Information”)	31-Jul-13		PRC		100	%	Holding company
	Jiandatong Health Technology (Beijing) Co., Ltd. (“Beijing Jiandatong”)	1-Apr-13		PRC		80	%	Sales of healthcare service
	VIEs’ subsidiaries:
	iKang Guobin Healthcare Management Group Co., Ltd. (“iKang Online”)	13-Sep-04		PRC		100	%	Sales of healthcare service
	Beijing iKang Guobin Health Technology Co., Ltd. (“iKang Technology”)	3-Feb-05		PRC		100	%	Sales of healthcare service
	Shenzhen iKang Co., Ltd. (“Shenzhen iKang”)	12-Jul-06		PRC		100	%	Sales of healthcare service
	Shanghai Yalong Daoyi Services Co., Ltd. (“Yalong Daoyi”)	20-Dec-06		PRC		100	%	Sales of healthcare service
	Guangzhou iKang Guobin Health Checkup Co., Ltd. (“iKang Guangzhou Huanshi East/Tianhe”)	27-Apr-07		PRC		100	%	Medical examination
	Shanghai Guobin Medical Center Co., Ltd. (“iKang Shanghai Xikang Road”)	27-Apr-07		PRC		100	%	Medical examination & clinical
	Shanghai Wangzu Guobin Medical Center Co., Ltd. (“iKang Shanghai Gubei”)	27-Apr-07		PRC		70	%	Medical examination
	Shanghai iKang Guobin Mingmen Clinic Co., Ltd. (“iKang Shanghai Pudong Avenue”)	27-Apr-07		PRC		100	%	Medical examination
	Shenzhen iKang Guobin Hospital Management, Inc. (“Shenzhen Hospital Management”)	10-Sep-07		PRC		66	%	Holding company
	Shenzhen Puji Clinic Co., Inc. (“iKang Shenzhen Nanshan”)	10-Sep-07		PRC		66	%	Medical examination
	Beijing iKang Guobin Lidu Clinic, Co., Ltd. (“iKang Beijing Lidu”)	3-Dec-07		PRC		100	%	Medical examination
	Chengdu iKang Guobin Blue Coast Health Management Co., Ltd. (“Chengdu Blue Coast”)	7-Dec-07		PRC		100	%	Relaxation and recreation
	Nanjing Joycome Clinic, Co., Ltd (“iKang Nanjing Xinjiekou”)	10-Jan-08		PRC		100	%	Medical examination
	Shenzhen iKang Guobin Clinic Co., Ltd. (“iKang Shenzhen Luohu”)	25-Mar-08		PRC		100	%	Medical examination
						Percentage of
		Later date of				beneficial interest
		incorporation/		Place of		by iKang Guobin
	Names	acquisition		incorporation		Healthcare Group, Inc.		Principal activities
	VIEs’ subsidiaries:
	Beijing iKang Guobin Jianwai Clinic, Co., Ltd. (“iKang Beijing Jianguomen”)	9-Sep-08		PRC		100	%	Medical examination
	Beijing iKang Guobin Zhongguan Clinic, Co., Ltd. (“iKang Beijing Zhongguancun”)	19-Sep-08		PRC		100	%	Medical examination
	Beijing iKang Guobin Zhengqingyuan Clinic, Co., Ltd. (“iKang Beijing Kunming Lake”)	1-Dec-08		PRC		100	%	Medical examination
	Beijing iKang Guobin Jiuxianqiao Clinic, Co., Ltd. (“iKang Beijing Yansha East”)	1-Dec-08		PRC		100	%	Medical examination
	Shanghai iKang Guobin Renren Clinic, Co., Ltd. (“iKang Shanghai Yangpu”)	9-Dec-08		PRC		100	%	Medical examination
	Chengdu iKang Guobin Health Examination Hospital Co., Ltd. (“iKang Chengdu Waishuangnan”)	15-Jan-09		PRC		100	%	Medical examination
	Shanghai iKang Guobin Blue Cross Clinic, Co., Ltd. (“iKang Shanghai Lujiazui”)	28-Jan-10		PRC		100	%	Medical examination
	Shanghai Wenzhong Clinic, Co., Ltd. (“Shanghai Wenzhong”)	12-Feb-10		PRC		71	%	Medical examination
	Beijing iKang Guobin Clinic, Co., Ltd. (“iKang Beijing Xuanwumen”)	5-Aug-10		PRC		100	%	Medical examination
	Nanjing iKang Guobin Clinic Co., Ltd. (“iKang Nanjing Gulou”)	19-Jan-11		PRC		100	%	Medical examination
	Shenzhen Xinglin Clinic Co., Ltd. (“iKang Shenzhen Futian”)	25-Jan-11		PRC		100	%	Medical examination
	Fujian iKang Guobin Health Management Co., Ltd. (“Fujian iKang”)	1-Apr-11		PRC		71	%	Sales of healthcare service
	Fuzhou iKang Guobin General Clinic, Co., Ltd. (“iKang Fuzhou Gulou”)	14-Nov-11		PRC		71	%	Medical examination
	Beijing iKang Guobin Xinei Clinic, Co., Ltd. (“iKang Beijing Xinei”)	30-Jan-12		PRC		100	%	Medical examination
	Shanghai iKang Guobin Fukang Clinic, Co., Ltd. (“Yan’an West Road”)	18-Jan-12		PRC		100	%	Medical examination
	Shanghai Zhonghuan Yipin Clinic, Co., Ltd. (“iKang Shanghai Zhonghuan”)	21-Jan-12		PRC		100	%	Medical examination
	Shanghai Yipin Clinic, Co., Ltd. (“iKang Shanghai Jing’an”)	21-Jan-12		PRC		100	%	Medical examination
	Shanghai iKang Guobin Waizhitan Clinic, Co., Ltd. (“iKang Shanghai Yan’an East Road”)	29-May-12		PRC		100	%	Medical examination
	Shanghai Jianwei Clinic, Co., Ltd. (“iKang Shanghai Jianwei”)	17-Aug-12		PRC		100	%	Medical examination
Hangzhou iKang Guobin Wenhui Clinic, Co., Ltd. (“iKang Hangzhou Wenhui”)	3-Sep-12		PRC		100	%	Medical examination
Tianjin Heping Aibin Clinic, Co., Ltd. (“iKang Tianjin Heping”)	15-Oct-12		PRC		100	%	Medical examination
Suzhou Aibin Clinic, Co., Ltd. (“iKang Suzhou”)	13-Nov-12		PRC		100	%	Medical examination
Changchun iKang Guobin Jiachang General Clinic, Co., Ltd. (“iKang Changchun”)	5-Nov-12		PRC		100	%	Medical examination
Chengdu Jinjiang iKang Guobin Hongzhaobi Health Examination General Clinic, Co., Ltd. (“iKang Chengdu Jinjiang”)	21-Dec-12		PRC		100	%	Medical examination
Chongqing Aibin Clinic, Co., Ltd. (“iKang Chongqing”)	18-Dec-12		PRC		100	%	Medical examination
Guangzhou Wokang Clinic (“iKang Guangzhou Wokang”)	3-Dec-12		PRC		100	%	Medical examination
Shenzhen Kefa Clinic (“Shenzhen Kefa”)	26-Mar-13		PRC		100	%	Medical examination
Shanghai iKang Jianwei Health Management Co., Ltd (“Shanghai Jianwei Management”)	6-Sep-13		PRC		65	%	Sales of healthcare service
Shanghai Yuanhua Clinic Co., Ltd. (“Yuanhua Clinic”)	31-Jul-13		PRC		100	%	Medical examination
Nanjing Aoyang TCM Clinic Co., Ltd., (“Nanjing Aoyang Clinic”)	1-Sep-13		PRC		100	%	Medical examination
Nanjing Aoyang Shunkang Health Information Consultancy Co., Ltd. (“Nanjing Aoyang Shunkang”)	1-Sep-13		PRC		100	%	Sales of healthcare service
Jiangyin iKang Guobin Clinic Co., Ltd. (“iKang Jiangyin”)	16-Dec-13		PRC		100	%	Medical examination
Zhejiang Huzhou Ailikang Investment Management Co., Ltd. (“Zhejiang Ailikang”)	31-Dec-13		PRC		100	%	Sales of healthcare service
Hangzhou Aibo Huagang Clinic Co. Ltd. (“Hangzhou Aibo”)	31-Dec-13		PRC		100	%	Medical examination
Beijing iKang Jun’an Clinic Co., Ltd. (“iKang Beijing Jun’an”)	28-Nov-13		PRC		100	%	Medical examination
Beijing iKang Guobin Yayun Clinic Co., Ltd. (“iKang Beijing Yayun”)	5-Dec-13		PRC		100	%	Medical examination
Changzhou iKang Guobin Clinic Co., Ltd. (“iKang Changzhou”)	14-Mar-14		PRC		62.5	%	Medical examination
The VIE arrangements
Before January 31, 2012, PRC regulations limited business entities with direct foreign ownership of more than 70% to provide certain healthcare services in the PRC. To comply with related PRC regulations, the Company conducted the majority of its businesses through Beijing iKang and Zhejiang iKang, subsidiaries of the Group, and iKang Holding, iKang Holding’s subsidiaries and iKang Hangzhou Xixi, which are VIE entities of the Company. Beijing iKang and Zhejiang iKang entered into a series of contractual arrangements with the VIE entities and their shareholders, and through those contractual arrangements, as described below, the Company obtained the control and the right to substantially all of economic benefits of the VIE entities.
In July 2013, iKang acquired 100% Yuanhua, including Yuanhua BVI, Yuanhua WFOE, a variable interest entity Yuanhua Information and Yuanhua Clinic, which provide medical examination related services in China. Yuanhua WFOE entered into a series of contractual arrangements with Yuanhua Information and Mr. Haiqing Hu and Mr. Lei Zhao through which Yuanhua WFOE gained effective control over the operation of Yuanhua Information and is able to receive substantially all the economic benefits of Yuanhua Information.
In December 2013, Beijing iKang entered into a series of contractual arrangements with Beijing Jiandatong and Mr. Haiqing Hu through which Beijing iKang gained effective control over the operation of Beijing Jiandatong and is able to receive substantially all the economic benefits of Beijing Jiandatong.
Starting from January 31, 2012, foreign-invested enterprises incorporated in the PRC are not expressly prohibited from providing healthcare services in the PRC; however, in order to operate under foreign-invested enterprise, the Group needs to reapply for the licenses or permits required for conducting such business from the Ministry of Health and Ministry of Commerce, because currently most licenses of the Group to conduct healthcare services are held by PRC entities. As of March 31, 2014, the Group has not yet applied for such licenses or permits.  Therefore the Group still operates through its VIE entities.
The VIE arrangements - continued
Beijing iKang, Zhejiang iKang and Yuanhua WFOE have entered into the following contractual arrangements with iKang Holding, iKang Hangzhou Xixi, Beijing Jiandatong, Yuanhua Information and the shareholders of iKang Holding , iKang Hangzhou Xixi, Beijing Jiandatong and Yuanhua Information that enable the Company to (1) have power to direct the activities that most significantly affects the economic performance of the VIE entities, and (2) receive the economic benefits of the VIE entities that could be significant to the VIE entities. Accordingly, the Company is considered the primary beneficiary of the VIE entities and has consolidated the VIE entities’ financial results of operations, assets and liabilities in the Company’s consolidated financial statements. In making the conclusion that the Company is the primary beneficiary of the VIE entities, the Company believes the Company’s rights under the terms of the Exclusive Equity Option agreement provide it with a substantive kick out right. More specifically, the Company believes the terms of the Exclusive Equity Option agreement are valid, binding and enforceable under PRC laws and regulations currently in effect. The Company also believes that the minimum amount of consideration permitted by the applicable PRC law to exercise the option does not represent a financial barrier or disincentive for the Company to currently exercise its rights under the exclusive equity option agreement. The Company’s rights under the Exclusive Equity Option agreement give the Company the power to control the shareholders of iKang Holding, iKang Hangzhou Xixi, Beijing Jiandatong and Yuanhua Information and thus the power to direct the activities that most significantly impact the VIE entities economic performance. In addition, the Company’s rights under the Power of Attorney also reinforce the Company’s abilities to direct the activities that most significantly impact the VIE entities’ economic performance. The Company also believes that this ability to exercise control ensures that the VIE entities will continue to execute and renew the Exclusive Service agreement and pay service fees to the Company. By charging service fees in whatever amounts the Company deems fit, and by ensuring that the Exclusive Service agreements are executed and renewed indefinitely, the Company has the rights to receive substantially all of the economic benefits from the VIE entities.
Agreements that provide the Company effective control over the VIE entities
(1)     Power of Attorney: Each registered shareholder of iKang Holding, iKang Hangzhou Xixi, Beijing Jiandatong and Yuanhua Information has executed a power of attorney agreement appointing Beijing iKang, Zhejiang iKang or Yuanhua WFOE to be the only and exclusive attorney, and irrevocably authorizing it to vote on each registered shareholder’s behalf on all of the matters concerning the VIE entities, that may require shareholders’ approval.  The term of the power of attorney is perpetual and the contract can be terminated at the discretion of the wholly foreign owned enterprises (“WFOEs”).
(2)     Exclusive Equity Option Agreement: Beijing iKang, Zhejiang iKang and Yuanhua WFOE have the exclusive right to purchase the equity interests of the VIE entities from the registered legal equity owners at the lowest consideration allowed by PRC regulations as far as PRC regulations permit a transfer of legal ownership to foreign ownership.  The term of the exclusive purchase right agreement is ten years and will be renewed on the expiration date by WFOEs and can be terminated at the discretion of the WFOEs.
(3)     Spousal Consent Under the Spousal Consent letters, the spouse of each married registered shareholder of iKang Holding and Beijing Jiandatong has signed a spousal consent letter, whereby the spouse agrees that (i) the equity interests of iKang Holding and Beijing Jiandatong owned by such shareholder will be disposed of only in accordance with the applicable Exclusive Equity Option Agreement, Equity Interest Pledge Agreement, and other related agreements executed by the shareholder, (ii) such equity interests do not constitute communal property with such shareholder and (iii) the spouse irrevocably and unconditionally waives all rights and benefits with respect to such equity interests, including the right to sue in any court and under all applicable laws.
Agreements that transfer economic benefits to the Company
(1)     Exclusive Services Agreement: Beijing iKang, Zhejiang iKang, Yuanhua WFOE and registered shareholders irrevocably agree that Beijing iKang, Zhejiang iKang and Yuanhua WFOE shall be the exclusive technology and consulting service provider to the VIE entities in return for a service fee as determined by Beijing iKang, Zhejiang iKang and Yuanhua WFOE up to the entire net profit of the VIE entities.  The terms of the services agreement are ten years, respectively, and this agreement will be automatically renewed on applicable expiration dates, and the agreement can be terminated at the discretion of the WFOEs.
(2)     Equity Interest Pledge Agreement: Shareholders of iKang Holding, iKang Hangzhou Xixi, Beijing Jiandatong and Yuanhua Information have pledged all of their equity interests in VIE entities with Beijing iKang, Zhejiang iKang and Yuanhua WFOE and Beijing iKang, Zhejiang iKang and Yuanhua WFOE are entitled to the rights to sell the pledged equity interests if the VIE entities or the shareholders default in their obligations.  The term of the pledge agreement is as long as service agreement; and it can be terminated when the service agreement is terminated.
Through these contractual agreements, the Company has the ability to effectively control the VIE entities and is also able to receive substantially all the economic benefits of the VIE entities.
Risk in relation to the VIE structure
The Company believes that WFOE’s contractual arrangements with the VIE entities are in compliance with PRC law and are legally enforceable.  The shareholders of iKang Holding are also shareholders of the Company and therefore have no current interest in seeking to act contrary to the contractual arrangements. However, uncertainties in the PRC legal system could limit the Company’s ability to enforce these contractual arrangements and if the shareholders of the VIE entities were to reduce their interest in the Company, their interests may diverge from that of the Company and that may potentially increase the risk that they would seek to act contrary to the contractual terms, for example by influencing the VIE entities not to pay the service fees when required to do so.
The Company’s ability to control the VIE entities also depends on the power of attorney Beijing iKang, Zhejiang iKang and Yuanhua WFOE have to vote on all matters requiring shareholder approval in the VIE entities. As noted above, the Company believes this power of attorney is legally enforceable but may not be as effective as direct equity ownership.
In addition, if the legal structure and contractual arrangements were found to be in violation of any existing PRC laws and regulations, the PRC government could:
·         revoke the Group’s business and operating licenses;
·         require the Group to discontinue or restrict operations;
·         restrict the Group’s right to collect revenues;
·         block the Group’s websites;
·         require the Group to restructure the operations in such a way as to compel the Group to establish a new enterprise, re-apply for the necessary licenses or relocate our businesses, staff and assets;
·         impose additional conditions or requirements with which the Group may not be able to comply; or
·         take other regulatory or enforcement actions against the Group that could be harmful to the Group’s business.
The imposition of any of these penalties may result in a material and adverse effect on the Group’s ability to conduct the Group’s business.  In addition, if the imposition of any of these penalties causes the Group to lose the rights to direct the activities of the VIE entities or the right to receive their economic benefits, the Group would no longer be able to consolidate the VIE entities.  The Group does not believe that any penalties imposed or actions taken by the PRC Government would result in the liquidation of the Company, Beijing iKang, Zhejiang iKang, Yuanhua WFOE or the VIE entities.
The shareholders of the VIEs and the Company are as the following:
(1)     iKang Holding’s shareholders are Mr. Ligang Zhang and Mr. Boquan He, each of whom holds 50% of the equity interest in iKang Holding.
(2)     iKang Hangzhou Xixi’s shareholders are iKang Holding and Yalong Daoyi, which hold 80% and 20% of the equity interest in iKang Hangzhou Xixi, respectively. Yalong Daoyi is wholly-owned by iKang Holding. Therefore, iKang Holding owns the 100% equity interest in iKang Hangzhou Xixi.
(3)     Beijing Jiandatong’s shareholders is Mr. Haiqing Hu, who holds 80% of the equity interest in Beijing Jiandatong.
(4)     Yuanhua Information’s shareholders are Mr. Haiqing Hu and Mr. Lei Zhao, who hold 80% and 20% of the equity interest in Yuanhua Information, respectively.
(5)     Mr. Ligang Zhang and Mr. Boquan He are shareholders of the Company, who held 25.6% and 14.8% voting interest of the Company as of March 31, 2014, respectively. They own the equity interests in iKang Holding and iKang Hangzhou Xixi. Other than Mr. Ligang Zhang and Mr. Boquan He, none of the Company’s shareholders owns equity interests in iKang Holding and iKang Hangzhou Xixi.
The two shareholders of iKang holding are directors and shareholders of the Company.  One of them is the Company’s CEO, and the managing director of the VIEs.  Therefore they have no current interest in seeking to act contrary to the contractual arrangements.  The interests of the VIE’s shareholders may differ from the interests of the Company as a whole.  The Company cannot assure that when conflicts of interest arise, the shareholders will act in the best interests of the Company or that conflicts of interests will be resolved in the Company’s favor.  Currently, the Company does not have existing arrangements to address potential conflicts of interest the shareholders of the VIE’s may encounter in their capacity as the beneficial owners and director of the VIE entities, on the one hand, and as beneficial owners and directors or officer of the Company, on the other hand.  The Company believes the shareholders of the VIE entities will not act contrary to any of the contractual arrangements and the exclusive equity option agreement provides the Company with a mechanism to remove the shareholders as the beneficial shareholders of the VIE should they act to the detriment of the Company.  The Company relies on the VIE’ shareholders, as directors and officer of the Company, to fulfill their fiduciary duties and abide by laws of the PRC and BVI and act in the best interest of the Company.  If the Company cannot resolve any conflicts of interest or disputes between the Company and the VIE’ shareholders, the Company would have to rely on legal proceedings, which could result in disruption of its business, and there is substantial uncertainty as to the outcome of any such legal proceedings.
The following financial statements amounts and balances of the VIE entities were included in the accompanying consolidated financial statements as of and for the years ended March 31(after inter-company elimination):
	As of March 31,
	2013			2014
Cash and cash equivalents	$	13,308		$	11,326
Account receivable and other current assets	34,789			54,508
Total current assets	48,097			65,834
Property and equipment, net	31,511			60,325
Acquired intangible assets, net	4,475			14,070
Other noncurrent assets	7,069			38,466
Total non-current assets	43,055			112,861
Total assets	91,152			178,695
Deferred revenues	19,183			22,234
Account payable and other current liabilities	38,264			62,837
Total current liabilities	57,447			85,071
Total non-current liabilities	608			4,857
Total liabilities	$	58,055		$	89,928
	For the year ended March 31,
	2012			2013			2014
Net revenues	$	80,563		$	113,506		$	170,226
Net income	$	9,772		$	11,728		$	20,948
	For the year ended March 31,
	2012			2013			2014
Net cash provided by operating activities	$	13,310		$	14,978		$	18,327
Net cash used in investing activities	(12,867		)	(15,944		)	(29,304		)
Net cash (used in)/ provided by financing activities	$	(2,043	)	$	3,824		$	8,995
The VIE entities contributed an aggregate of 86.0%, 84.8% and 84.1% of the consolidated net revenues for the years ended March 31, 2012, 2013 and 2014, respectively. The Company’s operations not conducted through contractual arrangements with the VIE primarily consist of its high end health check services. As of the fiscal years ended March 31, 2013 and 2014, the VIE entities accounted for an aggregate of 55.1% and 71.4%, respectively, of the consolidated total assets, and 77.9% and 82.6%, respectively, of the consolidated total liabilities. The assets that were not associated with the VIE entities primarily consist of cash and cash equivalents, account receivable and prepaid expenses and other current assets.
There are no terms in any arrangements, considering both explicit arrangements and implicit variable interests, that require the Company or its subsidiaries to provide financial support to the VIE entities. However, if the VIE entities ever needs financial support, the Company or its subsidiaries may, at its option and subject to statutory limits and restrictions, provide financial support to its VIE entities through loans to the shareholders of the VIE or entrustment loans to the VIE entities. Relevant PRC laws and regulations restrict the VIE entities from transferring a portion of its net assets, equivalent to the balance of its statutory reserve and its share capital, to the Company in the form of loans and advances or cash dividends. Please refer to Note 24 for disclosure of restricted net assets.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Mar. 31, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	2.                                      SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Basis of presentation
	The consolidated financial statements of the Group have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”).
	Basis of consolidation
	The consolidated financial statements of the Group include the financial statements of iKang Healthcare Group Inc., its subsidiaries, its VIEs and its VIEs’ subsidiaries.  All inter-company transactions and balances have been eliminated upon consolidation.
	Use of estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and revenues, costs and expenses in the financial statements and accompanying notes. Significant accounting estimates reflected in the Group’s consolidated financial statements include revenue recognition, allowance for doubtful accounts, the useful lives and impairment of property and equipment, the useful lives and impairment of intangible assets, impairment of goodwill, write off of leasehold improvement, valuation allowance for deferred tax assets, share-based compensation and fair value of the common shares, convertible redeemable preferred shares and forward contracts.
	Cash and cash equivalents
	Cash and cash equivalents consist of cash on hand, and demand deposits, which are unrestricted as to withdrawal and use, and which have maturities of three months or less when purchased.
	Accounts receivable and allowance for doubtful accounts
	Accounts receivable represents those receivables derived in the ordinary course of business.  A general allowance for doubtful accounts is provided based on aging analyses of accounts receivable balances, historical bad debt rates, in addition to specific provisions established based on customers’ repayment patterns and customer credit worthiness.
	Financial instruments
	Financial instruments of the Group primarily consist of cash and cash equivalent, restricted cash, accounts receivable, forward contract, equity method investment, cost method investment, amount due from related parties, accounts payable, amount due to related parties, short-term borrowing and long-term borrowing.
	The carrying values of cash, and cash equivalent, restricted cash, accounts receivable, accounts payable, and amounts due from related parties, short-term borrowing approximate their fair values due to short-term maturities.  It is not practical to estimate the fair value of the Group’s cost method investment because of the lack of quoted market price and the inability to estimate fair value without incurring excessive costs.
	The fair value of long-term borrowings is based on the amount of future cash flows associated with each debt instrument discounted at the Company’s current borrowing rate for similar debt instruments of comparable terms. The carrying values of the long-term borrowings approximate their fair values as all the long-term debt carry variable interest rates which approximate rates currently offered by the Company’s bankers for similar debt instruments of comparable maturities.
	For amounts due to related parties, they are carried at amortized cost using effective interest method.
	Effective interest method
	The effective interest method is a method of calculating the amortized cost of a financial liability and of allocating interest expense over the relevant period.  The effective interest rate is the rate that exactly discounts estimated future cash payments (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial liability, or, where appropriate, a shorter period, to the net carrying amount on initial recognition.
	Interest expense is recognized on an effective interest basis.
	Fair value
	Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Group considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.
	Authoritative literature provides a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.  An asset or liability categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement as follows:
	Level 1
	Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.
	Level 2
	Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.
	Fair value of foreign currency forward contract is discussed in Note 18.
	Level 3
	Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.
	Significant risks and uncertainties
	The Group operates in an industry with rapid changes in regulations, customer demand and competition and believes that changes in any of the following areas could have a material adverse effect on the Group’s future financial position, results of operations, or cash flows: advances and trends in healthcare industry standards, changes in certain strategic relationships or customer relationships, regulatory or other PRC related factors, risks associated with the Group’s ability to keep and increase the customer base, and risks surrounding pending litigations.
	Foreign currency risk
	The Renminbi (“RMB”) is not a freely convertible currency.  The State Administration for Foreign Exchange, under the authority of the People’s Bank of China, controls the conversion of RMB into foreign currencies.  The value of the RMB is subject to changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange Trading System market.  Cash and cash equivalent of the Group included aggregate amounts of $15,830 and $15,853 at March 31, 2013 and 2014, respectively, which were denominated in RMB.
	Concentration of credit risk
	Financial instruments that potentially expose the Group to concentration of credit risk consist primarily of cash and cash equivalents, and accounts receivable.  The Group places their cash with financial institutions with high-credit ratings and quality.  The Group conducts credit evaluations of customers and generally do not require collateral or other security from their customers.
	No customer accounted for 10% or more of total revenues for the years ended March 31, 2012, 2013 and 2014.  No customer accounted for 10% or more of accounts receivable as of March 31, 2013 and 2014.
	Inventories
	Inventories are medical consumables and are stated at the lower of cost or market value.  Inventories are written down for obsolescence to net realizable value based upon estimates of future demand and expiration date of inventories.  The Group reflected the write-down of inventories of $25, nil and nil for the year ended March 31, 2012, 2013 and 2014, respectively in cost of revenues.
	Equity method investment
	The investee company over which the Group has the ability to exercise significant influence, but does not have a controlling interest are accounted for using the equity method. Significant influence is generally considered to exist when the Group has an ownership interest in the voting stock of the investee between 20% and 50%, and other factors, such as representation in the investee’s Board of Directors, voting rights and the impact of commercial arrangements, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the affiliated company’s accounts are not reflected within the Group’s consolidated balance sheets and statements of operations; however, the Group’s share of the earnings or losses of the affiliated company is reflected in the caption “loss from equity method investment” in the consolidated statements of operations.
	An impairment charge is recorded if the carrying amount of the investment exceeds its fair value and this condition is determined to be other-than temporary. The Group estimated the fair value of the investee company based on comparable quoted price for similar investment in active market, if applicable, or discounted cash flow approach which requires significant judgments, including the estimation of future cash flows, which is dependent on internal forecasts, the estimation of long term growth rate of a company’s business, the estimation of the useful life over which cash flows will occur, and the determination of the weighted average cost of capital. The Company did not record impairment losses on its equity method investment during the year ended March 31, 2012, 2013 and 2014.
	Property and equipment, net
	Property and equipment are carried at cost less accumulated depreciation and amortization.  Depreciation and amortization are calculated on a straight-line basis over the following estimated useful lives:
	Computer equipment and application software	5 years
	Furniture and fixture	5 years
	Medical equipment	10 years
	Motor vehicles	5 years
	Leasehold improvement	Shorter of useful life of the asset or the lease term
	Construction in progress represents unfinished leasehold improvement and installment of equipment for new clinics.  Construction in progress will be transferred to leasehold improvement or property and equipment when it is finished.  Depreciation is recorded at the time when assets are ready for the intended use.
	Intangible assets, net
	Intangible assets, other than goodwill, resulting from the acquisitions of entities accounted for using the purchase method of accounting are estimated by management based on the fair value of assets acquired.  Identifiable intangible assets are carried at cost less accumulated amortization.  Amortization of customer relationship is computed using the estimated attrition pattern of the acquired customers, and amortization of other finite-lived intangible assets is computed using the straight-line method over the following estimated average useful lives, which are as follows:
		Weighted average (years)	range (years)
	Customer relationship	6.8	2.1~10.0
	Non-compete agreement	3	2.0~3.0
	Contract backlog	0.7	0.4~0.9
	Operating license	3.2	0.3~4.8
	Favorable lease contract	8.8	5.1~9.8
	The weighted average estimated average useful life of the intangible assets with determinable lives is 6.4 years.
	Intangible assets-indefinite lives
	If an intangible asset is determined to have an indefinite life, it should not be amortized until its useful life is determined to be no longer indefinite.  An intangible asset that is not subject to amortization is tested for impairment at least annually or if events or changes in circumstances indicate that the asset might be impaired.  Such impairment test consists of the fair values of assets with their carrying value amounts and an impairment loss is recognized if and when the carrying amounts exceed the fair values.  The estimates of fair values of intangible assets not subject to amortization are determined using various discounted cash flow valuation methodologies.  Significant assumptions are inherent in this process, including estimates of discount rates.
	Impairment of long-lived assets and intangible assets with definite life
	Long-lived assets, such as property and equipment and definite-lived intangible assets are stated at cost less accumulated depreciation or amortization.  Depreciation and amortization is computed principally using the straight-line method.
	The Group evaluates the recoverability of long-lived assets, including identifiable intangible assets, with determinable useful lives whenever events or changes in circumstances indicate that an intangible asset’s carrying amount may not be recoverable.  The Group measures the carrying amount of long-lived asset against the estimated undiscounted future cash flows associated with it.  Impairment exists when the sum of the expected future net cash flows is less than the carrying value of the asset being evaluated.  Impairment loss is calculated as the amount by which the carrying value of the asset exceeds its fair value.  Fair value is estimated based on various valuation techniques, including the discounted value of estimated future cash flows.  The evaluation of asset impairment requires the Group to make assumptions about future cash flows over the life of the asset being evaluated.  These assumptions require significant judgment and actual results may differ from assumed and estimated amounts.
Goodwill
Goodwill represents the excess of the fair value of consideration paid over the fair value of identifiable net assets acquired in business combinations. Goodwill and intangible assets deemed to have indefinite useful lives are not amortized, but tested for impairment annually or more frequently if event and circumstances indicate that they might be impaired.
Goodwill is tested for impairment at the reporting unit level on an annual basis (March 31 for the Group) and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. These events or circumstances could include a significant change in the stock prices, business climate, legal factors, operating performance indicators, competition, or sale or disposition of a significant portion of a reporting unit.
In the evaluation of the goodwill for impairment, the Group may first assess qualitative factors to determine whether it is “more likely than not” that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. If it is more likely than not that the fair value of a reporting unit is less than its carrying amount, goodwill is then tested following a two-step process.
The first step compares the fair value of each reporting unit to its carrying amount, including goodwill. If the fair value of each reporting unit exceeds its carrying amount, goodwill is not considered to be impaired and the second step will not be required. If the carrying amount of a reporting unit exceeds its fair value, the second step compares the implied fair value of goodwill to the carrying value of a reporting unit’s goodwill. The implied fair value of goodwill is determined in a manner similar to accounting for a business combination with the allocation of the assessed fair value determined in the first step to the assets and liabilities of the reporting unit. The excess of the fair value of the reporting unit over the amounts assigned to the assets and liabilities is the implied fair value of goodwill. An impairment loss is recognized for any excess in the carrying value of goodwill over the implied fair value of goodwill.
Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities to reporting units, assignment of goodwill to reporting units, and determination of the fair value of each reporting unit. The estimation of fair value of each reporting unit using a discounted cash flow methodology also requires significant judgments, including estimation of future cash flows, which is dependent on internal forecasts, estimation of the long-term rate of growth for the Group’s business, estimation of the useful life over which cash flows will occur, and determination of the Group’s weighted average cost of capital. The estimates used to calculate the fair value of a reporting unit change from year to year based on operating results and market conditions. Changes in these estimates and assumptions could materially affect the determination of fair value and goodwill impairment for the reporting unit.
The Group did not incur any impairment loss on goodwill for the years ended March 31, 2012, 2013 and 2014.
Cost method investment
For investment over which the Group does not have significant influence, the Group carries the investments at cost.  The Group reviews the cost method investment for impairment whenever events or circumstances indicate that an other-than-temporary decline has occurred.  The Group considers available quantitative and qualitative evidence in evaluating potential impairment of its cost method investment.  If the cost of an investment exceeds the investment’s fair value, the Group considers, among other factors, general market conditions, government economic plans, the duration and the extent to which the fair value of the investment is less than the cost, and the Group’s intent and ability to hold the investment.
Revenue recognition
Revenue is stated net of business tax.  The Group’s PRC subsidiaries and VIE entities are subject to a 5% business tax and related surcharges on the revenues earned from providing services and selling products in the PRC.  Certain contracts under specific formalities are exempted from business tax in accordance with the PRC tax laws.  The Group recognized $1,098, $1,576, and $2,084 business tax for the years ended March 31, 2012, 2013 and 2014, respectively.
The Group recognizes revenues when persuasive evidence of an arrangement exists, service has been provided, the sales price is fixed or determinable, and collectability is reasonably assured.
The Group offers medical examination and disease screening services and renders such services at the request of its customers.  The Group recognizes revenues when the examination reports are issued and passed to the local couriers if hard copy reports are required by its customers, or when the examination reports are uploaded on line and can be viewed by the customers on line if hard copy reports are not required.  The Group notifies its customers when their examination reports are delivered to the local couriers or ready to be viewed and downloaded on line.
For individual customers, fees are collected before the performance of the services while corporate customers prepay a portion of service fees upon signing of the master contract, which is recognized as deferred revenue by the Group.  All fees for services rendered are first charged against the corporate customer’s deferred revenues until it is entirely exhausted before the Group starts to invoice the corporate customers.  The Group records accounts receivables from its corporate customers when the examination reports of the employees of corporate customers have been delivered or uploaded on line but the Group has not received remaining payments from the corporate customers.
Sometimes the Group engages third-party providers to provide medical examination and disease screening services on behalf of the Group.  The Group evaluates the services provided by third parties on behalf of the Group to determine whether to recognize the revenues on a gross or net basis.  The determination is based upon an assessment as to whether the Group acts as a principal or agent when providing the services.  All of the revenues involving third-party providers providing medical examination or disease screening services on behalf of the Group are currently accounted for on a gross basis since the Group is the primary obligor, has the latitude in establishing prices, discretion in third-party provider selection and the credit risks.
The Group has also historically provided medical concierge services.  The value included in the medical concierge card prepaid by the Group’s customers is initially recorded as deferred revenues, and a predetermined amount which is based on the number of appointments actually made is deducted and recognized as revenue when a customer schedules an appointment with a hospital because the Group has no further service obligation after such appointment is made.  There is no right of return if a card expires, which is on average one to two year from the date of purchase.  Any remaining balance of deferred revenue is recognized upon expiry of the card.
The Group also provides packages of bundled services principally comprising combinations of the above to its corporate customers.  Components normally expire within one year from the date of purchase and does not include right of return.  The Group allocates revenues from the sale of bundled services to each component using the relative selling price of each component based on the Group’s best estimate.  Revenue recognition criteria for components included in the bundled services is identical to as if the components are sold on a standalone basis.
Value added tax (“VAT”)
In July 2012, the Ministry of Finance and the State Administration of Taxation jointly issued a circular regarding the pilot collection of VAT in lieu of business tax in certain areas and industries in the PRC. Such VAT pilot program is to be phased in Beijing, Jiangsu, Anhui, Fujian, Guangdong, Tianjin, Zhejiang, and Hubei between September and December 2012. Starting from September 1, 2012, certain subsidiaries became subject to VAT at the rate of 3% on certain service revenues which were previously subject to business tax.
Non-monetary exchange
The Group occasionally exchanges medical examination service with advertising agencies for advertising credits. The amount of deferred revenues and prepaid expenses is based on the fair value of the medical examination services surrendered which approximates the price the Group offers to the individual customers and is more readily determinable. The amounts of revenues recognized for non-monetary transactions were $1,291, $972 and $706 for the years ended March 31, 2012, 2013 and 2014, respectively. No direct costs are attributable to the revenues.
Cost of revenues
Cost of revenues consist of expenditures incurred in the generation of the Group’s revenues, includes but not limited to salaries and welfare paid to physicians, nurses, purchase of medical consumables, depreciation and amortization, rental, and fees paid to third-party service providers.
Research and development costs
Research and development expenses primarily consist of (i) salaries and benefits for research and development personnel, and (ii) office rental, general expenses and depreciation and amortization expenses associated with the research and development activities.  The Group’s research and development activities primarily consist of the research and development of its information technology platform and technical support for its customer services.
Income taxes
Current income taxes are provided for in accordance with the laws of the relevant tax authorities.  Deferred income taxes are recognized when temporary differences exist between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements.  Net operating loss carry forwards and credits are applied using enacted statutory tax rates applicable to future years.  Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more-likely-than-not that a portion of or all of the deferred tax assets will not be realized.  The components of the deferred tax assets and liabilities are individually classified as current and non-current based on their characteristics.
The impact of an uncertain income tax position on the income tax return is recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant tax authority.  An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.  Interest and penalties on income taxes will be classified as a component of the provisions for income taxes.  The Group did not recognize any income tax due to uncertain tax position or incur any interest and penalties related to potential underpaid income tax expenses for the years ended March 31, 2012, 2013 or 2014, respectively.
Share-based compensation
Share-based payment transactions with employees, such as share options are measured based on the grant date fair value of the equity instrument.  The Group recognizes the compensation costs net of an estimated forfeiture rate using the graded vesting attribution method over the requisite service period of the award, which is generally the vesting period of the award.  The estimate of forfeitures will be adjusted over the requisite service period to the extent that actual forfeitures differ, or are expected to differ, from such estimates.  Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of share compensation expense to be recognized in future periods.
Share awards issued to non-employees, such as advisors, are measured at fair value at the earlier of the commitment date or the date the service is completed and recognized over the period the service is provided.
Earnings (loss) per share
Basic earnings (loss) per common share is computed by dividing net income (loss) attributable to common shareholders by the weighted average number of common shares outstanding during the period.
The Group’s convertible redeemable preferred shares are participating securities as they participate in undistributed earnings on an as-if-converted basis.  Accordingly, the Group uses the two-class method whereby undistributed net income is allocated on a pro rata basis to the common shares and preferred shares to the extent that each class may share in income for the period; whereas the undistributed net loss for the period is allocated to common shares only because preferred shares are not contractually obligated to share the loss.
Diluted earnings (loss) per common share reflect the potential dilution that could occur if securities were exercised or converted into common shares.  The Group had convertible redeemable preferred shares, and stock options, which could potentially dilute basic earnings per share in the future.  To calculate the number of shares for diluted income per share, the effect of the convertible redeemable preferred shares is computed using the as-if-converted method; the effect of the stock options is computed using the treasury stock method.
Foreign currency translation
The functional and reporting currency of the Company is the United States dollar (“U.S. dollar”).  The financial records of the Group’s subsidiaries and VIE entities located in the PRC are maintained in their local currencies, the RMB, which are also the functional currencies of these entities.
Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency at the rates of exchange ruling at the balance sheet date.  Transactions in currencies other than the functional currency during the year are converted into functional currency at the applicable rates of exchange prevailing when the transactions occurred.  Transaction gains and losses are recognized in the statement of operations.
The Group’s entities with functional currency of RMB, translate their operating results and financial positions into the U.S. dollar, the Group’s reporting currency.  Assets and liabilities are translated using the exchange rates in effect on the balance sheet date.  Revenues, expenses, gains and losses are translated using the average rate for the year.  Translation adjustments are report as cumulative translation adjustments and are shown as a separate component of other comprehensive income.
Comprehensive income
Comprehensive income includes net income and cumulative foreign currency translation adjustments and is reported in the statement of shareholder’s equity (deficit).
Operating leases
Leases where the rewards and risks of ownership of assets primarily remain with the lessor are accounted for as operating leases.  Payments made under operating leases are charged to the consolidated statements of operations on a straight-line basis over the lease periods.
Newly adopted accounting pronouncements
In July 2012, the FASB has issued an authoritative pronouncement related to testing indefinite-lived intangible assets, other than goodwill, for impairment. Under the pronouncement, entities testing indefinite-lived intangible assets for impairment would have the option of performing a qualitative assessment before calculating the fair value of the asset. If an entity determines, on the basis of qualitative factors, that the indefinite-lived intangible asset is not more likely than not impaired, a quantitative fair value calculation would not be needed. The guidance is effective for annual and interim indefinite-lived intangible assets impairment tests performed for fiscal years beginning after September 15, 2012. Early adoption is permitted. The Group has adopted this guidance on April 1, 2013. The adoption of this guidance did not have a material effect on the Group’s consolidated financial statements.
Recently issued accounting pronouncements not yet adopted
In January 2014, the FASB issued a pronouncement which provides guidance on the accounting for service concession arrangements. This ASU specifies that an operating entity should not account for a service concession arrangement, within the scope of this ASU, as a lease in accordance with Topic 840, Leases. Service concession arrangements may become more prevalent in the United States as public-sector entities seek alternative ways to provide public services on a more efficient and cost-effective basis.
An operating entity should refer to other Codification Topics as applicable to account for various aspects of a service concession arrangement. The amendments also specify that the infrastructure used in a service concession arrangement should not be recognized as property, plant, and equipment of the operating entity.
The amendments in this ASU should be applied on a modified retrospective basis to service concession arrangements that exist at the beginning of an entity’s fiscal year of adoption. The modified retrospective approach requires the cumulative effect of applying this ASU to arrangements existing at the beginning of the period of adoption to be recognized as an adjustment to the opening retained earnings balance for the annual period of adoption. The amendments are effective for a public business entity for annual periods, and interim periods within those annual periods, beginning after December 15, 2014. The Group does not expect the adoption of this guidance will have a material effect on its consolidated financial statements.
In April 2014, the FASB issued a new pronouncement which amends to change the criteria for reporting discontinued operations while enhancing disclosures in this area. It also addresses sources of confusion and inconsistent application related to financial reporting of discontinued operations guidance in U.S. GAAP.
Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment.
In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations.
The new guidance also requires disclosure of the pre-tax income attributable to a disposal of a significant part of an organization that does not qualify for discontinued operations reporting. This disclosure will provide users with information about the ongoing trends in a reporting organization’s results from continuing operations. The amendments in the ASU are effective in the first quarter of 2015 for public organizations with calendar year ends. Early adoption is permitted. The Group does not expect the adoption of this guidance will have a material effect on its consolidated financial statements.
In May 2014, the FASB issued a new pronouncement which affects any entity using U.S. GAAP that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). This ASU will supersede the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance. This ASU also supersedes some cost guidance included in Subtopic 605-35, Revenue Recognition—Construction-Type and Production-Type Contracts. In addition, the existing requirements for the recognition of a gain or loss on the transfer of nonfinancial assets that are not in a contract with a customer (e.g., assets within the scope of Topic 360, Property, Plant, and Equipment, and intangible assets within the scope of Topic 350, Intangibles—Goodwill and Other) are amended to be consistent with the guidance on recognition and measurement (including the constraint on revenue) in this ASU.
The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps:
·         Step 1: Identify the contract(s) with a customer.
·         Step 2: Identify the performance obligations in the contract.
·         Step 3: Determine the transaction price.
·         Step 4: Allocate the transaction price to the performance obligations in the contract.
·         Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.
For a public entity, the amendments in this ASU are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted.
An entity should apply the amendments in this ASU using one of the following two methods:
1. Retrospectively to each prior reporting period presented and the entity may elect any of the following practical expedients:
·         For completed contracts, an entity need not restate contracts that begin and end within the same annual reporting period.
·         For completed contracts that have variable consideration, an entity may use the transaction price at the date the contract was completed rather than estimating variable consideration amounts in the comparative reporting periods.
·         For all reporting periods presented before the date of initial application, an entity need not disclose the amount of the transaction price allocated to remaining performance obligations and an explanation of when the entity expects to recognize that amount as revenue.
2. Retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application. If an entity elects this transition method it also should provide the additional disclosures in reporting periods that include the date of initial application of:
·         The amount by which each financial statement line item is affected in the current reporting period by the application of this ASU as compared to the guidance that was in effect before the change.
·         An explanation of the reasons for significant changes.
The Group is in processing to adopt this pronouncement.
In June 2014, the FASB issued a new pronouncement which requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Topic 718, Compensation — Stock Compensation, as it relates to awards with performance conditions that affect vesting to account for such awards. The performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved.
The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted.
Entities may apply the amendments in this ASU either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. If retrospective transition is adopted, the cumulative effect of applying this ASU as of the beginning of the earliest annual period presented in the financial statements should be recognized as an adjustment to the opening retained earnings balance at that date. In addition, if retrospective transition is adopted, an entity may use hindsight in measuring and recognizing the compensation cost. The Group does not expect the adoption of this guidance will have a material effect on its consolidated financial statements.

ACQUISITION

ACQUISITION	12 Months Ended
	Mar. 31, 2014
ACQUISITION	'
ACQUISITION	'
	3.                                      ACQUISITION
	(1)                                 Acquisition of iKang Shanghai Jianwei
	On August 17, 2012, the Group acquired 100% equity interest of iKang Shanghai Jianwei, which provides medical examination services with cash consideration of $1,249. Acquisition-related costs were nil.
	The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows:
					Estimated
					useful life
	Net tangible assets:
	Current assets	$	39
	Non-current assets	463
	Deferred tax assets	274
	Total	776
	Intangible assets acquired:
	Customer relationship	71			5.3 years
	Operating license	32			1.4 years
	Goodwill	396
	Deferred tax liability	(26		)
	Total	473
	Total consideration	$	1,249
	The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition.  The acquired goodwill is not deductible for tax purpose.
	The operating results of the acquired business of iKang Shanghai Jianwei have been included in the Group’s consolidated financial statements since the date of acquisition.  iKang Shanghai Jianwei contributed net revenue of $300 and $1,122, and net loss of $647 and $773 to the Group’s consolidated statements of operations in the years ended March 31, 2013 and 2014, respectively.
	(2)                                 Acquisition of iKang Changchun
	On November 5, 2012, the Group acquired 100% equity interest of iKang Changchun, which provides medical examination services with cash consideration of $915. Acquisition-related costs were nil.
	The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows:
					Estimated
					useful life
	Net tangible assets:
	Current assets	$	5
	Non-current assets	307
	Total	312
	Intangible assets acquired:
	Customer relationship	165			6.1 years
	Favorable lease contract	21			5.1 years
	Operating license	48			2.5 years
	Goodwill	427
	Deferred tax liability	(58		)
	Total	603
	Total consideration	$	915
	The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition.  The acquired goodwill is not deductible for tax purpose.
	The operating results of the acquired business of iKang Changchun have been included in the Group’s consolidated financial statements since the date of acquisition. iKang Changchun contributed net revenue of $25 and $593, and net loss of $301 and $832 to the Group’s consolidated statements of operations in the years ended March 31, 2013 and 2014, respectively.
	(3)                                 Acquisition of iKang Guangzhou Wokang
	On December 3, 2012, the Group acquired 100% equity interest of iKang Guangzhou Wokang, which provides medical examination services with cash consideration of $2,986. Acquisition-related costs were nil.
	The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows:
					Estimated
					useful life
	Net tangible assets:
	Current assets	$	117
	Non-current assets	550
	Total	667
	Net tangible liabilities:
	Current liabilities	$	(44	)
	Total	(44		)
	Intangible assets acquired:
	Customer relationship	175			6.0 years
	Favorable lease contract	1,074			9.8 years
	Operating license	48			3.1 years
	Goodwill	1,390
	Deferred tax liability	(324		)
	Total	2,363
	Total consideration	$	2,986
	The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition.  The acquired goodwill is not deductible for tax purpose.
	The operating results of the acquired business of iKang Guangzhou Wokang have been included in the Group’s consolidated financial statements since the date of acquisition.  iKang Guangzhou Wokang contributed net revenue of $7 and $2,737, and net loss of $273 and net income of $964 to the Group’s consolidated statements of operations in the years ended March 31, 2013 and 2014, respectively.
	(4)                                 Acquisition of Yuanhua BVI, Yuanhua WFOE, Yuanhua information and Yuanhua Clinic (collectively, “Yuanhua”)
	On July 31, 2013, the Group acquired 100% equity interest of Yuanhua, which provides medical examination related services with cash consideration of $27,600. Acquisition-related costs were nil.
The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows:
				Estimated
				useful life
Net tangible assets:
Current assets	$	8,059
Non-current assets	1,150
Deferred tax assets	371
Total	9,580
Net tangible liabilities:
Current liabilities	$	(6,060	)
Total	(6,060		)
Intangible assets acquired:
Trade name	4,830
Customer relationship	6,307			5.0-7.4 years
Operating license	49			2.3 years
Contract backlog	49			0.9 years
Goodwill	15,654
Deferred tax liability	(2,809		)
Total	24,080
Total consideration	$	27,600
The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose.
The operating results of the acquired business of Yuanhua have been included in the Group’s consolidated financial statements since the date of acquisition. Yuanhua contributed net revenue of $10,091, and net loss of $1,023 to the Group’s consolidated statements of operations in the year ended March 31, 2014.
(5)                                 Acquisition of Nanjing Aoyang TCM Clinic Co., Ltd. and Nanjing Aoyang Shunkang Health Information Consultancy Co., Ltd. (collectively, “Nanjing Aoyang”)
On September 1, 2013, the Group acquired 100% equity interest of Nanjing Aoyang, which provides medical examination services with cash consideration of $4,085. Acquisition-related costs were nil.
The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows:
				Estimated
				useful life
Net tangible assets:
Current assets	$	15
Non-current assets	3,314
Total	3,329
Intangible assets acquired:
Operating license	33			1.3 years
Goodwill	731
Deferred tax liability	(8		)
Total	756
Total consideration	$	4,085
The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose.
The operating results of the acquired business of Nanjing Aoyang have been included in the Group’s consolidated financial statements since the date of acquisition. Nanjing Aoyang contributed net revenue of $218, and net loss of $1,145 to the Group’s consolidated statements of operations in the year ended March 31, 2014.
(6)                                 Acquisition of Zhejiang Huzhou Ailikang Investment Management Co. Ltd. (“Zhejiang Ailikang”)
On December 31, 2013, the Company acquired 100% equity interest of Zhejiang Ailikang, which holds 100% equity of Hangzhou Aibo Huagang Clinic Co. Ltd., a company providing medical examination service, for cash consideration of $1,663. Acquisition-related costs were nil.
The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows:
				Estimated
				useful life
Net tangible assets:
Current assets	$	2
Non-current assets	576
Total	578
Net tangible liabilities:
Current liabilities	$	(818	)
Total	(818		)
Intangible assets acquired:
Favorable lease contract	283			5.3 years
Operating license	83			2.7 years
Goodwill	1,628
Deferred tax liability	(91		)
Total	1,903
Total consideration	$	1,663
The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose.
The operating results of the acquired business of Zhejiang Ailikang have been included in the Group’s consolidated financial statements since the date of acquisition. Zhejiang Ailikang contributed net revenue of nil, and net loss of $158 to the Group’s consolidated statements of operations in the year ended March 31, 2014.
(7)                                 Acquisition of MediFast
On January 14, 2014, the Group acquired 80% equity interest of MediFast, which provides medical examination, health management and medical services, with cash consideration of $8,113.  Acquisition-related costs were nil.
The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows:
				Estimated
				useful life
Net tangible assets:
Current assets	$	1,944
Non-current assets	927
Total	2,871
Net tangible liabilities:
Current liabilities	$	(1,431	)
Total	(1,431		)
Intangible assets acquired:
Customer relationship	2,825			5.0-10.0 years
Non-compete agreement	451			3.0 years
Trade-name	374			Indefinite
Goodwill	5,332
Deferred tax liability	(619		)
Total	8,363
Non-controlling interest	$	(1,690	)
Total consideration	$	8,113
The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose.
The operating results of the acquired business of MediFast have been included in the Group’s consolidated financial statements since the date of acquisition.  MediFast contributed net revenue of $2,570, and net income of $328 to the Group’s consolidated statements of operations in the year ended March 31, 2014.
(8)                                Pro forma information
The following unaudited pro forma information summarizes the results of operations of the Group for the years ended March 31, 2012 and 2013 assuming that the acquisitions of iKang Shanghai Jianwei, iKang Changchun and iKang Guangzhou Wokang occurred as of April 1, 2011. The following pro forma financial information is not necessarily indicative of the results that would have occurred had the acquisitions been completed at the beginning of the periods indicated, nor is it indicative of future operating results:
	Year ended March 31,
	2012			2013
	(Unaudited)			(Unaudited)
Pro forma net revenue	$	98,177		$	137,269
Pro forma net income attributable to common shareholders of iKang Healthcare Group, Inc.	$	8,657		$	12,334
The following unaudited pro forma information summarizes the results of operations of the Group for the years ended March 31, 2013 and 2014 assuming that the acquisitions of Yuanhua, Nanjing Aoyang, Shanghai Jianwei Management, Zhejiang Ailikang and MediFast occurred as of April 1, 2012, the acquisition of iKang Shanghai Jianwei, iKang Changchun and iKang Guangzhou Wokang occurred as of April 1, 2011. The following pro forma financial information is not necessarily indicative of the results that would have occurred had the acquisitions been completed at the beginning of the periods indicated, nor is it indicative of future operating results:
	Year ended March 31,
	2013			2014
	(Unaudited)			(Unaudited)
Pro forma net revenue	$	161,447		$	215,104
Pro forma net income attributable to common shareholders of iKang Healthcare Group, Inc.	$	12,818		$	21,110
(9)                                 Acquisition of Assets
On March 26, 2013, the Company acquired the operating license of iKang Shenzhen Kefa with a cash consideration of $167.

ACCOUNTS_RECEIVABLE_NET

ACCOUNTS RECEIVABLE, NET	12 Months Ended
	Mar. 31, 2014
ACCOUNTS RECEIVABLE, NET	'
ACCOUNTS RECEIVABLE, NET	'
	4.                                      ACCOUNTS RECEIVABLE, NET
	Accounts receivable consists of the following:
		As of March 31,
		2013			2014
	Accounts receivable	$	33,461		$	41,949
	Less: allowance for doubtful accounts	3,272			4,330
	Accounts receivable, net	$	30,189		$	37,619
	Movement of allowance for doubtful accounts is as follows:
		As of March 31,
		2013			2014
	Balance at beginning of year	$	1,561		$	3,272
	Charge to expenses	1,800			1,100
	Write off	(132		)	(97		)
	Exchange difference	43			55
	Balance at end of year	$	3,272		$	4,330
	The Group decides to write off a receivable and the corresponding provision when it determines that certain events indicate that there is no chance that an account receivable can be collected, such as liquidation of a customer or termination of cooperation.  The Group can also claim deduction on a current tax return for a bad debt expense when sufficient evidence is submitted to the tax authority and approved by the tax authority to support the uncollectibility of the bad debt.

INVENTORIES

INVENTORIES	12 Months Ended
	Mar. 31, 2014
INVENTORIES	'
INVENTORIES	'
	5.                                     INVENTORIES
	Inventories consist of the following:
		As of March 31,
		2013		2014
	Medical consumable	$	1,162	$	1,693

PREPAID_EXPENSES_AND_OTHER_CUR

PREPAID EXPENSES AND OTHER CURRENT ASSETS	12 Months Ended
	Mar. 31, 2014
PREPAID EXPENSES AND OTHER CURRENT ASSETS	'
PREPAID EXPENSES AND OTHER CURRENT ASSETS	'
	6.                                      PREPAID EXPENSES AND OTHER CURRENT ASSETS
	Prepaid expenses and other current assets consist of the following:
		As of March 31,
		2013		2014
	Advance to suppliers(1)	$	2,191	$	9,022
	Deferred IPO cost	—		3,482
	Prepaid rental expense	1,511		2,226
	Staff advance	939		2,141
	Prepaid acquisition fees(2)	—		1,705
	Prepaid expenses(3)	1,269		792
	Fair value of the forward contracts(4)	—		57
	Other receivable	706		587
		$	6,616	$	20,012
	(1)                 Advance to suppliers represents advance payment to suppliers to purchase medical equipment and consumables.
	(2)                 Prepaid acquisition fees represent advance payments for acquisitions.
	(3)                 Prepaid expenses mainly consist of amounts paid for professional fee and advertisement fees for which relating services have not been provided.
	(4)                 The Bayley & Jackson (Hong Kong) entered into two foreign currency exchange forward contracts with Bank of East Asia (“BEA”) in June and July 2013, respectively. Pursuant to those contracts, Bayley & Jackson (Hong Kong) bought two buy RMB20,000, sell USD foreign exchange forward contracts using the quoted exchange rates at 6.2825 and 6.2620, respectively. The Group carries the forward contracts at fair value in its balance sheet and the changes in the exchange forward contract fair value during the each period end are recorded in the statement of the operations. The Group carries the forward contract as asset at fair value at March 31, 2014. The Group measures the fair value of the forward contract on a recurring basis based on a level 2 measure, i.e. the Group uses the market exchange rate to assess the fair value of the forward contract and recognizes the changes in fair value attributable to the difference between the market exchange rate and contractual exchange rate in change in fair value of the forward contracts. For the year ended March 31, 2014, the Group recorded a gain of $57 in change in fair value of the forward contracts. The forward contracts was settled in June 2014.

PROPERTY_AND_EQUIPMENT_NET

PROPERTY AND EQUIPMENT, NET	12 Months Ended
	Mar. 31, 2014
PROPERTY AND EQUIPMENT, NET	'
PROPERTY AND EQUIPMENT, NET	'
	7.                                      PROPERTY AND EQUIPMENT, NET
	Property and equipment, net consists of the following:
		As of March 31,
		2013		2014
	Medical equipment	$	30,805	$	46,275
	Leasehold improvements	22,310		33,807
	Computer equipment and application software	5,569		7,815
	Furniture and fixtures	3,718		5,329
	Motor vehicles	440		732
	Construction in progress	385		8,560
	Less: accumulated depreciation and amortization	30,655		38,874
		$	32,572	$	63,644
	Depreciation expenses charged to the consolidated statement of operations for the years ended March 31, 2012, 2013 and 2014 were $5,722, $7,112 and $8,874, respectively.

ACQUIRED_INTANGIBLE_ASSETS_NET

ACQUIRED INTANGIBLE ASSETS, NET	12 Months Ended
	Mar. 31, 2014
ACQUIRED INTANGIBLE ASSETS, NET	'
ACQUIRED INTANGIBLE ASSETS, NET	'
	8.                                      ACQUIRED INTANGIBLE ASSETS, NET
	The gross carrying amount, accumulated amortization and net carrying amount of the intangible assets are as follows:
		As of March 31,
		2013		2014
	Acquired intangible assets not subject to amortization
	Trade-name	$	2,078	$	7,212
	Acquired intangible assets subject to amortization
	Customer relationship	3,265		12,303
	Operating license	2,002		2,161
	Favorable lease contract	1,098		1,372
	Contract backlog	39		88
	Non-compete agreement	2		454
	Less: accumulated amortization
	Customer relationship	2,484		4,059
	Operating license	1,024		1,289
	Favorable lease contract	29		169
	Contract backlog	39		80
	Non-compete agreement	1		37
	Less: impairment	427		426
	Intangible assets, net	$	4,480	$	17,530
	Amortization expenses for the years ended March 31, 2012, 2013 and 2014 were $563, $598 and $1,885, respectively.  Amortization expenses for the years ended March 31, 2015, 2016, 2017, 2018, 2019 and thereafter would be $2,865, $2,292, $1,785, $1,264, $838 and $1,274, respectively. No impairment loss was recognized on acquired intangible assets during the years ended March 31, 2012, 2013 and 2014.

GOODWILL

GOODWILL	12 Months Ended
	Mar. 31, 2014
GOODWILL.	'
GOODWILL	'
	9.                                      GOODWILL
	The changes in carrying amounts of goodwill for the years ended March 31, 2012 and 2013 were as follows:
		As of March 31,
		2013		2014
	Gross amount:
	Beginning balance	$	41,103	$	43,503
	Addition for the year by acquisition of
	iKang Shanghai Jianwei	396		—
	iKang Changchun	427		—
	iKang Guangzhou Wokang	1,390		—
	Nanjing Aoyang	—		731
	Yuanhua	—		15,654
	Shanghai Jianwei Management	—		572
	Zhejiang Ailikang	—		1,628
	MediFast	—		5,332
	Exchange difference	187		(484		)
	Ending balance	43,503		66,936
	Accumulated impairment loss:
	Beginning balance	25,665		25,712
	Exchange difference	47		(188		)
	Ending balance	$	25,712	$	25,524
	Goodwill	$	17,791	$	41,412

ACCRUED_EXPENSES_AND_OTHER_CUR

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	12 Months Ended
	Mar. 31, 2014
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	'
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	'
	10.                               ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
	Accrued expenses and other current liabilities consist of the following:
		As of March 31,
		2013		2014
	Accrued rental expense	$	2,554	$	4,944
	Accrued payroll and welfare	2,434		4,231
	Acquisitions consideration payable (1)	537		3,628
	Accrued social insurance	2,248		2,368
	Accrued IPO expenses	—		2,268
	Other taxes payable	1,610		2,254
	Accrued outsourcing cost	1,121		1,909
	Accrued professional fees (2)	2,738		55
	Interest expense payable	169		27
	Other payable to shareholders (3)	2,256		—
	Other payables	1,524		2,591
		$	17,191	$	24,275
	(1)     Acquisitions consideration payable consists of remaining payables to sellers of the acquired entities. As of March 31, 2013, the acquisitions consideration payable consisted payable for the acquisition of iKang Shanghai Zhonghuan and iKang Shanghai Jing’an, iKang Shanghai Jianwei, and iKang Changchun amounted $137, $322 and $78, respectively. As of March 31, 2014, the acquisitions consideration payable consisted payable for the acquisition of iKang Shanghai Jianwei, Nanjing Aoyang, Yuanhua, Zhejiang Ailikang, MediFast and Shanghai Huajian Clinic Ltd. amounted $129, $402, $540, $62, $839 and $1,656, respectively.
	(2)     As of March 31, 2013, the balance represents the professional fees for the issuance of Series F convertible redeemable participating preferred shares (“Series F shares”), which was paid in June 2013.
	(3)     In March 2013, pursuant to the share purchase agreement and various agreements among the Company, some existing shareholders and the Series F shares investors, certain existing shareholders sold some of their shares to some series F shares investors. Part of the consideration amounted $2,256 was received by the Company on behalf of the selling shareholders, which was paid back to those selling shareholders in May 2013.

BANK_BORROWINGS

BANK BORROWINGS	12 Months Ended
	Mar. 31, 2014
BANK BORROWINGS	'
BANK BORROWINGS	'
	11.                              BANK BORROWINGS
		As of March 31,
		2013		2014
	Short term borrowings(1)	$	5,482	$	18,201
	Long term borrowings(2)	—		1,865
		$	5,482	$	20,066
	(1)                On June 25, June 28, July 10, September 17 and December 19, 2013, iKang Holding borrowed five one-year loans of $1,627, $1,304, $1,630, $1,606 and $4,941 respectively from BEA, to purchase the property and equipment capital and meet temporary working capital needs of the Group. The annual interest rates are the benchmark interest rate announced by the People’s Bank of China plus 10% of the benchmark interest rate. The loans were guaranteed by Beijing iKang and collateralized by restricted cash. As of March 31, 2013 and 2014, the outstanding short term borrowings were nil and $10,910, respectively.
	In September 2013, iKang Online signed a ten-year loan framework agreement with an amount no more than $2,451 with BEA, to repay the loans from China Merchants Bank which was due in September 2013. On September 17, 2013, iKang Online borrowed a one-year loan of $2,410 according to the framework agreement. The annual interest rate was equal to the benchmark interest rate announced by the People’s Bank of China plus 10% of the benchmark interest rate. The loan was guaranteed by Beijing iKang and collateralized by restricted cash. As of March 31, 2013 and 2014, the outstanding short-term borrowings were nil and $2,372, respectively.
	In March 2014, seven clinics in Beijing signed seven one-year loan framework agreements with an amount no more than $8,896 with Bank of Beijing, to meet temporary working capital needs of the Group. Clinics borrowed total $4,919 in March, 2014. The annual interest rate is the benchmark interest rate announced by the People’s Bank of China plus 15% of the benchmark interest rate. The loans were guaranteed by iKang Online and iKang Holdings. As of March 31, 2013 and 2014, the outstanding short term borrowing were nil and $4,919, respectively.
	(2)                In June 2013, iKang Holding signed a ten-year loan framework agreement with total loan amounts no more than $3,268 with BEA, to meet the Group’s needs to purchase the property and equipment . On June 28, 2013, iKang Holding borrowed a two-year loan of $1,897 according to the framework agreement. The annual interest rate is the benchmark interest rate announced by the People’s Bank of China plus 10% of the benchmark interest rate. The loan was guaranteed by Beijing iKang and collateralized by restricted cash. As of March 31, 2013 and 2014, the outstanding long term borrowings were nil and $1,865, respectively.
	Interest expenses incurred for the year ended March 31, 2012, 2013 and 2014 were $5 and $477, $827, respectively. The weighted average effective interest rate for the year ended March 31, 2012, 2013 and 2014 was 8.2%, 7.8% and 7.0%, respectively.

CONVERTIBLE_LOAN

CONVERTIBLE LOAN	12 Months Ended
	Mar. 31, 2014
CONVERTIBLE LOAN	'
CONVERTIBLE LOAN	'
	12.                               CONVERTIBLE LOAN
	In May 2012, the Company signed a convertible loan agreement with amount of $2,000 with an unrelated third party, with annual interest rate of 8% and the maturity date of December 31, 2012. On or prior to the maturity date, the lender has the option to extend the maturity date of the convertible loan to June 30, 2013, and also has the option but not the obligation to convert the loan into common shares of the Company. As of March 31, 2013, the loan has not been repaid or converted because no notice from the lender was received by the Company. In June 2013, the Group repaid the convertible loan and accrued interests amounted to $2,300 in full pursuant to an agreement with the lender.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Mar. 31, 2014
INCOME TAXES	'
INCOME TAXES	'
	13.                               INCOME TAXES
	Cayman Islands
	The Company was tax-exempted companies incorporated in the Cayman Islands and is not subject to tax on income or capital gains.
	British Virgin Islands (“BVI”)
	The iKang Guobin and iKang Zhejiang BVI are exempted from income tax in BVI where were incorporated.
	Hong Kong
	Bayley & Jackson (Hong Kong), Yuanhua HK and MediFast are subject to Hong Kong Profits Tax at 16.5% on its activities conducted in Hong Kong.
	PRC
	Since January 1, 2008, the Company’s PRC subsidiaries, iKang holding and its subsidiaries are subject to the 25% standard enterprise income tax except for those accepted as deemed profit method enterprises, or qualified for small-scale enterprises, or granted preferential tax treatment.
	Shanghai iKang and iKang Holding were established in “Shanghai Pudong Economic Open Zones”, which entitled them to a preferential tax rate of 15% prior to January 1, 2008.  Based on the transition rules of the EIT Law, iKang Holdings and Shanghai iKang continued to enjoy preferential tax rates of 18%, 20%, 22%, 24%, from January 1, 2008 through December 31, 2011, respectively, due to the preferential tax qualification obtained prior to January 1, 2008.
	iKang Shenzhen Nanshan, iKang Shenzhen Luohu, iKang Shenzhen Futian and Shenzhen Kefa are subject to PRC individual income tax rate of 35% due to regulations set by local governments.
	Under the EIT Law and its implementation rules which became effective on January 1, 2008, dividends generated after January 1, 2008 and payable by a foreign-invested enterprise in PRC to its foreign investors who are non-resident enterprises are subject to a 10% withholding tax, unless any such foreign investor’s jurisdiction of incorporation has a tax treaty with PRC that provides for a different withholding arrangement.  Under the taxation arrangement between the PRC and Hong Kong, a qualified Hong Kong tax resident which is the “beneficial owner” and directly holds 25% or more of the equity interest in a PRC-resident enterprise is entitled to a reduced withholding tax rate of 5%. The BVI, where the Company is incorporated, does not have a tax treaty with PRC.
	Since January 1, 2008, the relevant tax authorities of the Group’s subsidiaries have not conducted a tax examination on the Group’s PRC entities.  In accordance with relevant PRC tax administration laws, tax years from 2009 to 2013 of the Group’s PRC subsidiaries and VIE entities, remain subject to tax audits as of March 31, 2014, at the tax authority’s discretion.
	Aggregate undistributed earnings of the Company’s subsidiaries located in the PRC that are available for distribution to the Company are approximately $6,309 as of March 31, 2014.  The undistributed earnings of the Company’s subsidiaries located in the PRC are considered to be indefinitely reinvested, because the Group does not have any present plan to pay any cash dividends on its common shares in the foreseeable future and intends to retain most of its available funds and any future earnings for use in the operation and expansion of its business.  Accordingly, no deferred tax liability has been accrued for the Chinese dividend withholding taxes that would be payable upon the distribution of those amounts to the Company as of March 31, 2014.
	Aggregate undistributed earnings of the Company’s VIEs and its VIEs’ subsidiaries located in the PRC that are available for distribution to the Company were approximately $52,786 as of March 31, 2014. A deferred tax liability should be recorded for taxable temporary differences attributable to the excess of financial reporting amounts over tax basis amount in domestic subsidiaries However, recognition is not required in situations where the tax law provides a means by which the reported amount of that investment can be recovered tax-free and the enterprise expects that it will ultimately use that means. The Company has not recorded any such deferred tax liability attributable to the undistributed earnings of its financial interest in VIEs because it believes such excess earnings can be distributed in a manner that would not be subject to income tax.
	Uncertainties exist with respect to how the current income tax law in the PRC applies to the Group’s overall operations, and more specifically, with regard to tax residency status.  The EIT Law includes a provision specifying that legal entities organized outside of the PRC will be considered residents for Chinese Income tax purposes if the place of effective management or control is within the PRC.  The implementation rules to the EIT Law provide that non-resident legal entities will be considered China residents if substantial and overall management and control over the manufacturing and business operations, personnel, accounting, properties, etc., occurs within the PRC.  Despite the present uncertainties resulting from the limited PRC tax guidance on the issue, the Group does not believe that the legal entities organized outside of the PRC within the Group should be treated as residents for EIT law purposes.  If the PRC tax authorities subsequently determine that the Company and its subsidiaries registered outside the PRC should be deemed resident enterprises, the Company and its subsidiaries registered outside the PRC will be subject to the PRC income taxes, at a rate of 25%.
	The current and deferred portions of income tax expenses included in the consolidated statements of operations, which were all attributable to the Group’s PRC subsidiaries and VIE entities, are as follows:
		Years ended March 31,
		2012			2013			2014
	Current tax expense	$	3,987		$	7,311		$	12,048
	Deferred tax benefits	(48		)	(1,177		)	(1,947		)
	Income tax expenses	$	3,939		$	6,134		$	10,101
	The principal components of the deferred income tax assets and liabilities are as follows:
		As of March 31,
		2013			2014
	Current deferred tax assets:
	Accrued expenses	$	1,410		$	2,185
	Deferred revenue	158			125
	Accrued payroll	656			1,056
	Bad debt provision	791			995
	Less: Valuation allowance	(141		)	(370		)
	Current deferred tax assets	$	2,874		$	3,991
	Non-current deferred tax assets:
	Depreciation and amortization	$	358		212
	Due to impairment of long-lived assets	102			88
	Net operating tax loss carry-forwards	1,724			3,748
	Less: Valuation allowance	(728		)	(2,041		)
	Non-current deferred tax assets	$	1,456		$	2,007
		As of March 31,
		2013			2014
	Non-current deferred tax liabilities:
	Intangible assets	$	499		$	3,478
	Non-current deferred tax liabilities	$	499		$	3,478
	The Group considers the following factors, among other matters, when determining whether some portion or all of the deferred tax assets will more likely than not be realized: the nature, frequency and severity of recent losses, forecasts of future profitability, the duration of statutory carryforward periods, the Group’s experience with tax attributes expiring unused and tax planning alternatives.  The Group’s ability to realize deferred tax assets depends on its ability to generate sufficient taxable income within the carryforward periods provided for in the tax law.
	As of March 31, 2014, the Group’s PRC subsidiaries, VIE and VIE’s subsidiaries had a tax loss carry-forward amounted to $14,993 and would expire on various dates between March 31, 2015 and March 31, 2019.  The Group does not file combined or consolidated tax returns, therefore, losses from individual subsidiaries or the VIE entities may not be used to offset other subsidiaries’ or VIE entities’ earnings within the Group.  Valuation allowance is considered on each individual subsidiary and legal entity basis.  Valuation allowances have been established in respect of certain deferred tax assets as it is considered more likely than not that the relevant deferred tax assets will not be realized in the foreseeable future.
	Reconciliation between the expense (benefit) of income taxes computed by applying the PRC tax rate to income (loss) before income taxes and the actual provision for income taxes is as follows:
		For the year ended March 31,
		2012			2013			2014
	Net income before provision	$	14,331		$	18,583		$	32,183
	PRC statutory tax rate	25		%	25		%	25		%
	Income tax at statutory tax rate	$	3,583		$	4,646		$	8,046
	Change in valuation allowance	(16		)	126			704
	Expenses not deductible for tax purposes	258			631			440
	Effect of income tax rate difference for entities under individual income tax rate of 35%	67			129			390
	Loss utilized for entities under individual income tax rate of 35%	(235		)	(153		)	(99		)
	Effect of income tax rate differences in other jurisdictions	282			755			620
	Income tax expense	$	3,939		$	6,134		$	10,101
	The Group did not identify significant unrecognized tax benefits for the years ended March 31, 2012, 2013 and 2014.  The Group did not incur any interest and penalties related to potential underpaid income tax expenses and also believed that uncertainty in income taxes did not have a significant impact on the unrecognized tax benefits within next twelve months.

COMMON_SHARE

COMMON SHARE	12 Months Ended
	Mar. 31, 2014
COMMON SHARE	'
COMMON SHARE	'
	14.                               COMMON SHARE
	As of March 31, 2014, the Company was authorized to issue a maximum of 39,268,485 shares with a par value of $0.01 per share, comprised 37,698,485 Class A common shares and 1,570,000 Class B common shares.
	As of March 31, 2013, the Company was authorized to issue a maximum of 37,596,704 shares with a par value of $0.01 per share, comprised 36,026,704 Class A common shares and 1,570,000 Class B common shares.

CONVERTIBLE_REDEEMABLE_PREFERR

CONVERTIBLE REDEEMABLE PREFERRED SHARES	12 Months Ended
	Mar. 31, 2014
CONVERTIBLE REDEEMABLE PREFERRED SHARES	'
CONVERTIBLE REDEEMABLE PREFERRED SHARES	'
	15.                              CONVERTIBLE REDEEMABLE PREFERRED SHARES
	On March 31, 2013, there were 1,094,668 Series A convertible redeemable participating preferred shares (“Series A shares”), 686,368 Series B convertible redeemable participating preferred shares (“Series B shares”), 794,250 Series C1 convertible redeemable participating preferred shares (“Series C1 shares”), 126,286 convertible redeemable participating preferred shares (“Series C2 shares”), 1,024,318 Series C3 convertible redeemable participating preferred shares (“Series C3 shares”) (Series C1 shares, Series C2 shares and Series C3 shares are collectively referred to as “Series C shares”), 3,538,864 Series D1 convertible redeemable participating preferred shares (“Series D1 shares”), 2,307,536 Series D2 convertible redeemable participating preferred shares (“Series D2 shares”) (Series D1 shares and Series D2 shares are collectively referred to as “Series D shares”), 4,289,457 Series E convertible redeemable participating preferred shares (“Series E shares”) and 4,654,697 Series F shares outstanding.
	On August 28, 2013, the Company issued 1,953,499 Series F shares, which are under the same terms of Series F shares issued on March 28, 2013 to a group of investors for a consideration of $25,181.
	On October 16, 2013, a total number of 596,484 Class A common shares and Series D1 and D2 preferred shares held by certain existing shareholders were sold to a third party investor pursuant to the share purchase agreements dated September 12, 2013. The existing shares were sold for $12.0309 per share, which was the same as the selling price of existing shares to new investors in March 2013. The 596,484 sold shares were redesignated as 596,484 Series F shares immediately after the completion of the sale and purchase of the shares. The price agreed and paid by the purchaser of Series F shares was $14.1792 per share, which was determined by the Company and agreed by the purchaser based on the estimated equity value of the Company on the date of the share purchase agreement. Total sold price of $7,176 was paid by the purchaser to the sellers in October 2013. The difference of selling price and purchase price of the shares totaling $1,281 was paid by the purchaser to the Company in October 2013. The Company credited for the $1,281 to the series F shares.
	As of March 31, 2014, there were 1,094,668 Series A shares, 686,368 Series B shares, 794,250 Series C1 shares, 126,286 Series C2 shares, 1,024,318 Series C3 shares, 3,488,864 Series D1 shares, 2,072,624 Series D2 shares, 4,289,457 Series E shares and 7,204,680 Series F shares preferred shares outstanding.
	The Series A, B, C, D, E and F shares are collectively referred to as the preferred shares.
	Key terms of the preferred shares are summarized as follows:
	Redemption
	The original redemption price of the Series A, B, C, D and E shares equaled the sum of (i) the preferred share original issue price, and (ii) interest calculated at 10% per year compounded annually from the original preferred share issue date until original maturity on April 22, 2012.  The Company recognized entire changes in the redemption value and adjusted the carrying value of the preferred shares to equal the redemption value immediately when the preferred shares were issued. As a result, $26,353 of redemption premium of the preferred shares was recorded as a deemed dividend upon issuance of those preferred shares.
	Series E shares which were originally redeemable upon or at any time after (i) November 28, 2011, if no qualified IPO or a company sale had occurred by such date, or (ii) February 28, 2011, in the event that any shareholder refused to participate in a company sale.
	Pursuant to a supplemental agreement entered into between the Company and the holders of Series E shares dated on July 14, 2011, Series E shares would be redeemable after April 22, 2012.  hence additional redemption premium of $2,312 related to the period from the original redemption due date of July 14, 2011 to April 22, 2012 was charged as deemed dividend for the year ended March 31, 2012.
	After issuance of Series F shares and at the election of Series F shareholders, each Series F share shall be eligible to be redeemed if any of the following events occurs:
	(1)                 by March 28, 2017, the Restructuring has been completed but a Qualified IPO has not been consummated;
	“Restructuring” means the transfer of all interests in the medical centers, clients, employees, contractors and all other assets held by the PRC Entities (other than direct or indirect wholly-owned subsidiaries of the Company) as of Series F shares issuance date and any such additional interests in medical centers, clients, employees, contractors and other acquired by the PRC Entities thereafter to a direct or indirect wholly owned subsidiary of the Company.
	(2)                 Other than as approved by the Company’s board of directors (including the affirmative votes of Series F share directors), the loss of control or the inability to consolidate over any subsidiaries or VIE entities of the Group that account for three percent (3%) or more of the then consolidated revenues or hold three percent (3%) or more of the then consolidated assets;
	(3)                 the Restructuring is not completed by the expiry of 18 months from the earlier of (i) the effective date of a Change of Law or (ii) the date of such announcement or promulgation of a Change of Law;
	“Change of Law” means any change of applicable Laws that would have a material adverse effect on the validity of, or on the rights (as a whole) granted under, the VIE arrangements.
	(4)                 the Restructuring is not completed within two years from the date of a Restricted Venue Resolution, or
	“Restricted Venue Resolution” means the resolution passed by the majority of the Company’s board of directors to proceed with an IPO upon the occurrence of Change of Law;
	(5)                 by March 28, 2017, the Restructuring has not been completed and a Qualified IPO has not been consummated.
	In the case of (1) to (4) above, the redemption price of the Series F shares equals to the sum of (i) the preferred share original issue price, and (ii) interest calculated at 10% per year compounded annually from the original preferred share issue date.
	In the case of (5) above,  the redemption price of the Series F shares equals to the sum of (i) the preferred share original issue price, and (ii) interest calculated at 12% per year compounded annually from the original preferred share issue date.
	Upon the issuance of Series F shares, redemption of preferred shares other than Series F and E shares, shall require no less than five affirmative votes out of nine votes of the board directors, including the both affirmative votes of Series F shares directors.
	Series E shares can only be redeemed at the election of Series E preferred shareholders for cash at their redemption price when Series F shares are redeemed.
	Series B, C1, C2 and D1 shares are redeemable upon the second anniversary of the Series F issuance date and thereafter.
	Series A shares are redeemable at the election of the relevant classes of preferred shareholders for cash at their redemption price when Series F, E, B, C1, C2 and D1 shares are redeemed.
	Series C3 and D2 shares can only be redeemed when series F, E, B, C1, C2, D1 and A shares are redeemed at the election of the preferred shareholders.
	Upon the issuance of Series F shares, the redemption price of the Series A, B, C, D and E shares equals to the sum of (i) the preferred share original issue price, and (ii) interest calculated at 10% per year compounded annually from the original preferred share issue date until March 28, 2017.
	The Company recognized changes in the redemption value and adjusted the carrying value of the preferred shares to equal the entire redemption value immediately when the preferred shares were issued, as a result, $74,075 and $17,763 of redemption premium of the preferred shares was recorded as a deemed dividend for the years ended March 31, 2013 and 2014, respectively.
	Voting rights
	Preferred shareholders are entitled to the number of votes equal to the number of common shares into which such preferred shares could be converted at the record date.
	Dividends
	Whenever a dividend is declared by the board of directors of the Company, the preferred shares holders shall receive, in preference to any dividend on any common shares a non-cumulative dividend in an amount equal to 6% annually of the preferred shares’ original purchase price, as adjusted for stock splits, stock dividends, etc., and shall also participate on an as converted basis with respect to any dividends payable to the common shares.  The sequence of dividend participating right of all series of preferred shares was as follows:
	(1)                 Series F
	(2)                 Series E
	(3)                 Series B, C1, C2 and D1
	(4)                 Series A
	(5)                 Series C3 and D2
	Conversion
	Each preferred share shall be convertible, at the option of the holder thereof, at any time after the preferred shares’ original date of issuance, into such number common shares as determined by dividing the preferred share original issue price by preferred share conversion price.
	The initial conversion ratio was one for one.  The conversion price has a standard anti-dilution adjustment term for items such as stock splits and recapitalization.  It also has a down-round provision, under which when the Company issues any additional shares at a price per share that is lower than the conversion price per share then in effect, the conversion price per share is adjusted down.  There have been no such adjustments to the conversion price.
	The Company has recorded beneficial conversion feature amounted nil, nil, $328, nil, nil and nil attributable to the Series A, B, C, D, E and F shares, respectively.
	Each preferred share would automatically be converted into common shares at the then effective preferred share conversion price upon the closing of a qualified IPO, which was consummated in April 2014.
	Liquidation preference
	Upon occurrence of a liquidation event, an amount shall be paid with respect to each preferred share equal to 100% of the original purchase price, plus any declared but unpaid dividends, adjusted for any share dividends, combinations, splits, recapitalizations and the like. If, after liquidation, distribution, or winding up, the assets of the Company are insufficient to make payment in full to all preferred shareholders, then such assets shall be distributed among the preferred shareholders ratably in proportion to the full amounts to which they would otherwise be respectively entitled thereon. The sequence of liquidation right of all series of preferred shares is as follows:
	(1)                 Series F shares
	(2)                 Series E shares
	(3)                 Series B, C1, C2 and D1 shares
	(4)                 Series A shares
	(5)                 Series C3 and D2 shares
	The preferred shares were accounted for as mezzanine equity.

NET_INCOME_LOSS_PER_SHARE

NET INCOME (LOSS) PER SHARE	12 Months Ended
	Mar. 31, 2014
NET INCOME (LOSS) PER SHARE	'
NET INCOME (LOSS) PER SHARE	'
	16.                               NET INCOME (LOSS) PER SHARE
	The Group has determined that its convertible redeemable preferred shares are participating securities as the preferred shares participate in undistributed earnings on an as-if-converted basis.  The holders of the preferred shares are entitled to receive dividends on a pro rata basis, as if their shares had been converted into common shares. Accordingly, the Group uses the two-class method of computing net income per share, for common and preferred shares according to participation rights in undistributed earnings.
	The calculation of net income (loss) per share is as follows:
		For the year ended March 31,
		2012		2013			2014
	Net income attributable to iKang Healthcare Group, Inc.	$	9,702	$	12,111		$	21,607
	Deemed dividend to Series A shares	—		5,112			—
	Deemed dividend to Series B shares	—		5,204			—
	Deemed dividend to Series C shares	—		4,366			—
	Deemed dividend to Series D shares	—		14,875			1,945
	Deemed dividend to Series E shares	2,312		20,308			—
	Deemed dividend to Series F shares	—		34,441			18,491
	Undistributed earnings allocated to Series A shares	150		150			118
	Undistributed earnings allocated to Series B shares	200		200			130
	Undistributed earnings allocated to Series C shares	265		265			231
	Undistributed earnings allocated to Series D shares	831		831			789
	Undistributed earnings allocated to Series E shares	1,324		1,324			1,323
	Undistributed earnings allocated to Series F shares	—		48			4,719
	Net (loss) income attributed to common and preferred shareholders for computing net income per common share- basic and diluted (1)	4,620		(75,013		)	(6,139		)
	Numerator:
	Series A shares-
	Deemed dividend	—		5,112			—
	Undistributed earnings allocation	150		150			118
	Net income attribution	299		—			—
		449		5,262			118
	Series B shares-
	Deemed dividend	—		5,204			—
	Undistributed earnings allocation	200		200			130
	Net income attribution	228		—			—
		428		5,404			130
	Series C shares-
	Deemed dividend	—		4,366			—
	Undistributed earnings allocation	265		265			231
	Net income attribution	445		—			—
		710		4,631			231
		For the year ended March 31,
		2012		2013			2014
	Series D shares-
	Deemed dividend	—		14,875			1,945
	Undistributed earnings allocation	831		831			789
	Net income attribution	1,309		—			—
		2,140		15,706			2,734
	Series E shares-
	Deemed dividend	2,312		20,308			—
	Undistributed earnings allocation	1,324		1,324			1,323
	Net income attribution	921		—			—
		4,557		21,632			1,323
	Series F shares-
	Deemed dividend	—		34,441			18,491
	Undistributed earnings allocation	—		48			4,719
	Net income attribution	—		—			—
		—		34,489			23,210
	Net (loss) income attributed to common shareholders for computing net income per common share- basic and diluted(1)	1,418		(75,013		)	(6,139		)
	Denominator:
	Weighted average common shares outstanding used in computing diluted net income per common share-basic(2)	6,599,009		6,683,678			6,340,005
	Weighted average shares outstanding used in computing net income per common shares-diluted (2)	6,768,074		6,683,678			6,340,005
	Weighted average shares used in computing basic net income per shares
	Series A shares	1,391,044		1,386,984			1,094,668
	Series B shares	1,059,735		1,054,620			686,368
	Series C shares	2,071,140		2,069,410			1,944,854
	Series D shares	6,091,920		6,088,557			5,717,326
	Series E shares	4,289,457		4,289,457			4,289,457
	Series F shares			63,763			6,075,702
Net (loss) income per common share attributable to iKang Healthcare Group, Inc.-basic	$	0.22	$	(11.22	)	$	(0.97	)
Net (loss) income per common share attributable to iKang Healthcare Group, Inc.-diluted	$	0.21	$	(11.22	)	$	(0.97	)
Net income per Series A shares	$	0.32	$	3.79		$	0.11
Net income per Series B shares	$	0.4	$	5.13		$	0.19
Net income per Series C shares	$	0.34	$	2.24		$	0.12
Net income per Series D shares	$	0.35	$	2.58		$	0.48
Net income per Series E shares	$	1.06	$	5.04		$	0.31
Net income per Series F shares	$	—	$	540.89		$	3.82
Notes:
(1)     The Class A and Class B common shares enjoy the same dividend participating right, therefore earnings per share of each class was not separately presented.
(2)     The calculation of the weighted average number of common shares for the purpose of diluted net income (loss) per share has considered the effect of certain potentially dilutive securities.
The weighted average common shares outstanding used in computing basic and diluted net income per common share was adjusted retroactively for all periods presented to reflect the stock dividend of 251,079 Class A common shares distributed to shareholders in October 2010.
For the year ended March 31, 2012, an incremental weighted average number of 169,065 common shares from the assumed exercise of share options using the treasury stock method were included.  1,391,044, 1,059,735, 2,071,140, 6,091,920 and 4,289,457 common shares resulting from the assumed conversion of the preferred shares Series A shares, Series B shares, Series C shares, Series D shares, and Series E shares were excluded as they were anti-dilutive as their effect was anti-dilutive.
For the year ended March 31, 2013, 1,386,984, 1,054,620, 2,069,410, 6,088,557, 4,289,457, 63,763 and 355,410 common shares resulting from the assumed conversion of the Series A shares, Series B shares, Series C shares, Series D shares, Series E shares, Series F shares and options, respectively, were excluded as their effect was anti-dilutive.
For the year ended March 31, 2014, 1,094,668, 686,368, 1,944,954, 5,717,326, 4,289,457, 6,075,702 and 988,507 common shares resulting from the assumed conversion of the Series A shares, Series B shares, Series C shares, Series D shares, Series E shares, Series F shares and options, respectively, were excluded as their effect was anti-dilutive.

SHAREBASED_COMPENSATION

SHARE-BASED COMPENSATION	12 Months Ended
	Mar. 31, 2014
SHARE-BASED COMPENSATION.	'
SHARE-BASED COMPENSATION	'
	17.                               SHARE-BASED COMPENSATION
	The Company’s Board of Directors has approved and the Company has granted various tranches of options to its management and consultants as follows:
	From 2007 to 2010, the Company granted 240,000 share options to its management with various exercise prices per share with different service period from 3 to 4 years.
	From 2004 to 2011, the Company granted 302,855 options with various exercise prices per share to its executives and consultants, which can be exercised only when the Company’s common stocks become publicly traded or the Company is acquired by other parties (“Company Sale”).
	On June 8, 2011, the Company granted 41,843 options with exercise prices of $ 0.01 per share to its management, which can be exercised only when the Company’s common stocks become public traded or upon a liquidation of the Company.
	On February 17, 2012, the Company modified the 60,000 options granted to one of its employees on December 31, 2010 with exercise price of $ 5.13 per share for 80,000 options with the same exercise price which are fully vest but can be exercised only when all of the following conditions are met:
	(1)                 The Company’s common stocks become public traded or a Company Sale occurs;
	(2)                 The former employee should not engage with any entity or business of healthcare management and consulting business in the PRC (the “Competitive Business”) in the next two years.
	(3)                 The former employee should not disclose any confidential information to third parties without authorization.
	On March 18, 2013, the Company granted 330,000 options with exercise price of $5.13 per share to certain directors and employees, which can be exercised immediately upon the issuance of the options. The Group recorded share-based compensation expenses of $2,273 during the years ended March 31, 2013.
	On March 18, 2013, The Company granted additional 440,000 options with exercise price of $5.13 per share and 80,000 options with exercise price of $6.00 to its certain directors and employees, which can be exercised only when the Company’s common stocks become public traded or upon a liquidation of the Company.
	On September 12, 2013, the Company granted 200,000 options with exercise price of $6.00 to its director, which has a vesting period of 3.55 years and can be exercised only when the Company’s common stocks become publicly traded or upon a Company Sale.
	On February 27, 2014, the Company granted additional 356,300 options with exercise price of $5.13 per share and 72,700 options with exercise price of $6.00 to its certain directors and employees, which have vesting periods of 1.35 and 1.91 years respectively and can be exercised only when the Company’s common stocks become publicly traded or upon a Company Sale.
	For these options which can only be excised when the Company’s common stock becomes public traded or a Company Sale, no compensation expenses would be recognized until the Company’s common stocks become public traded or a Company Sale occurs, after which the Company will immediately recognize compensation cost of $5,966 related to these options.
	The following table summarizes information regarding options granted:
		For the years ended March 31,
		2012								2013								2014
				Weighted			Weighted					Weighted			Weighted					Weighted		Weighted
				average			average					average			average					average		average
				exercise			fair value					exercise			fair value					exercise		fair value
		Number of		price per			per option			Number of		price per			per option			Number of		price per		per option
		options		option			at grant date			options		option			at grant date			options		option		at grant date
	Outstanding on April 1 of year	497,855		$	2.34		$	3.25		434,698		$	2.02		$	3.94		1,284,698		$	4.13	$	6.08
	Granted	61,843		1.67			10.88			850,000		5.21			7.17			629,000		5.51		15.61
	Exercised	(75,000	)	1.8			1.59			—		—			—			—		—		—
	Forfeited	(50,000	)	5.13			9.2			—		—			—			(25,000	)	6		7.13
	Outstanding on March 31 year	434,698		$	2.02		$	3.94		1,284,698		$	4.13		$	6.08		1,888,698		$	4.56	$	9.24
	There were 390,000 vested options, and 1,498,698 options expected to vest as of March 31, 2014.  For options expected to vest, the weighted-average exercise price is $4.42 and aggregate intrinsic value is $34,355 as of March 31, 2014.
	Total intrinsic value of options exercised were $458, nil and nil for the years ended March 31, 2012, 2013, 2014, respectively.
	The following table summarizes information with respect to share options outstanding as of March 31, 2014:
		Option outstanding									Option exercisable
				Weighted	Weighted			Aggregate					Weighted			Aggregate
				average	average			intrinsic					average			intrinsic
				remaining	Exercise			values as of					Exercise			values as of
		Number		contractual	price per			March 31,			Number		price per			March 31,
	Range of exercise price	outstanding		life in years	option			2014			exercisable		option			2014
	$ 0.01	221,843		1.13	$	0.01		$	6,063		—		$	—		$	—
	$ 1.00-$2.00	62,855		2.94	$	1.68		1,613			—		$	—		—
	$ 5.13	1,276,300		8.88	$	5.13		28,348			390,000		$	5.13		8,662
	$ 6.00	327,700		9.48	$	6		6,993			—		$	—		—
		1,888,698						$	43,017		390,000					$	8,662
	The fair value of each option granted was estimated on the date of grant using the binomial tree pricing model with the following assumptions used for grants during the applicable periods:
		Risk-free interest
		rate of return		Contractual term	Volatility		Dividend yield		Exercise price
	December 31, 2010	4.67	%	10 years	40.9	%	—		5.13
	June 8, 2011	1.11	%	2.39 years	42	%	—		0.01
	February 17, 2012	2.99	%	10 years	41	%	—		5.13
	March 18, 2013	2.15	%	10 years	40	%	—		5.13~6.00
	September 12, 2013	3.22		10 years	38.2	%	—		6
	February 27, 2014	3.24	%	10 years	38.09	%	—		5.13~6.00
	(1)                 Risk-free interest rate
	Risk-free interest rate was estimated based on the yield to maturity of China international government bonds with a maturity period close to the expected term of the options.
	(2)                 Contractual term
	The Company used the original contractual term.
	(3)                 Volatility
	The volatility of the underlying common shares during the life of the options was estimated based on the historical stock price volatility of comparable listed companies over a period comparable to the expected term of the options.
	(4)                 Dividend yield
	The dividend yield was estimated by the Group based on its expected dividend policy over the expected term of the options.
	(5)                 Exercise price
	The exercise price of the options was determined by the Group’s board of directors.
	(6)                 Fair value of underlying common shares
	The estimated fair value of the common shares underlying the options as of the respective grant dates was determined based on a retrospective valuation, which used management’s best estimate for projected cash flows as of each valuation date.
	The Group recorded share-based compensation of $216, $2,273 and $930 during the years ended March 31, 2012, 2013 and 2014, respectively, based on the fair value on the grant dates over the requisite service period of award according to the vesting schedule for employee share option.
As of March 31, 2014, total unrecognized compensation expense relating to unvested share options was $7,383, which will be recognized over 3 years.  The weighted-average remaining contractual term of options outstanding is 7.88 years.

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Mar. 31, 2014
FAIR VALUE MEASUREMENTS	'
FAIR VALUE MEASUREMENTS	'
	18.                               FAIR VALUE MEASUREMENTS
	(a)                                 Measured on recurring basis
	Foreign currency forward contracts
	The Group purchased foreign currency forward contracts to protect against the adverse effect that exchange rate fluctuation may have on foreign currency denominated sales activities. Foreign currency forward contracts are marked to market based on the prevailing forward exchange rate quoted by the contracted bank (Level 2 inputs). Assets and liabilities resulted from foreign currency forward contracts are recorded at its fair value.
	As of March 31, 2013 and 2014, the fair value of foreign currency forward contracts, which amounted to nil and $57, respectively, is recorded in prepaid expenses and other current assets. During the year ended on March 31, 2014, gains on the foreign currency forward contracts are recognized in the consolidated statements of operations.
	Details of the outstanding foreign currency forward contracts as of March 31, 2013 and 2014 were as follows:
		As of March 31,
		2013		2014
	Settlement currency in:
	U.S. dollar of entity with functional currency in RMB
	Notional contract amount (U.S. dollar)	$	—	$	6,377
	(b)           Measured at fair value on a non-recurring basis
	The Group measured the fair value of the purchased intangible assets using the “cost”, “income approach excess earnings” and “with & without” valuation methods. These acquired intangible assets are considered Level 3 assets and liabilities because the Group used unobservable inputs, such as forecasted financial performance of the acquired business and discount rates, to determine the fair value of these purchased assets and liabilities.
	The fair value was determined using models with significant unobservable inputs, Level 3 inputs, primarily the discounted future cash flow.
	The fair value measurements of the intangible assets encompass the following significant unobservable inputs:
		Range
	Discount rate	20.5%-22%
	Timing of cash flows	0.4-10 years
	The Group measured the goodwill and intangible assets at fair value on a nonrecurring basis when it is annually evaluated or whenever events or changes in circumstances indicate that carrying amount of a reporting unit exceeds its fair value as a result of the impairment assessments. The Group did not recognize any impairment loss related to goodwill and acquired intangible assets for the year ended March 31, 2013 and 2014. The fair value was determined using models with significant unobservable inputs (Level 3 inputs), primarily the management projection of discounted future cash flow and the discount rate.

RELATED_PARTY_BALANCES_AND_TRA

RELATED PARTY BALANCES AND TRANSACTIONS	12 Months Ended
	Mar. 31, 2014
RELATED PARTY BALANCES AND TRANSACTIONS	'
RELATED PARTY BALANCES AND TRANSACTIONS	'
	19.                              RELATED PARTY BALANCES AND TRANSACTIONS
	Amounts due from related parties of the Group:
		As of March 31,
		2013		2014
	Amounts due from related parties - current:
	Amounts due from
	Shanghai Huajian Clinic Ltd. (1)	$	—	$	1,287
	Amounts due from shareholder	483		—
		$	483	$	1,287
	Amounts due to related parties of the Group:
		As of March 31,
		2013		2014
	Amounts due to related parties - current:
	Amounts due to a former non-controlling interest holder(2)	$	12,379	$	8,049
		$	12,379	$	8,049
	(1)                 Amount represents loan provided by the Group to its equity method investee Shanghai Huajian Clinic Ltd. for daily operating use and the loan is schedule to be repaid in September 2014.
	(2)                 On August 1, 2011, iKang Holding signed an agreement with the non-controlling interest holder of iKang Shanghai Xikang Road to purchase the remaining 35% of the equity interest in iKang Shanghai Xikang Road held by the non-controlling interest holders, with consideration of $15,894.  The transaction was closed on December 31, 2011. The group paid first installment of $1,589 in August 2011 within five days after the agreement was signed.  The second installment of $1,589 was paid in February 2012.  In December 2013, $3,941 was repaid and in March 2014, $991 was paid by the Group for individual income tax on behalf of the former non-controlling interest holder. The remaining balance was settled in June 2014.
	The amounts due to non-controlling interest holder represents amortized cost of the principal amount.
	The group recognized $155, $629 and $504 imputed interest expense for the years ended March 31, 2012, 2013 and 2014, respectively. The effective interest rate of the amount due from non-controlling interest holder is 5.5%.

NONCONTROLLING_INTEREST

NONCONTROLLING INTEREST	12 Months Ended
	Mar. 31, 2014
NONCONTROLLING INTEREST	'
NONCONTROLLING INTEREST	'
	20.                               NONCONTROLLING INTEREST
		iKang			iKang			iKang			iKang						Shenzhen			Shanghai
		Zhejiang			Shanghai			Shanghai			Shanghai			Fujian			Hospital			Jianwei			Beijing						iKang
		BVI			Xikang Road			Gubei			Lujiazui			iKang			Management			Management			Jiandatong			MediFast			Changzhou			Total
	Balance at April 1, 2011	$	(383	)	$	1,516		$	414		$	254		$	—		$	(232	)	$	—		$	—		$	—		$	—		$	1,569
	Change in effective ownership of iKang Zhejiang BVI	95			—			—			—			—			—			—			—			—			—			95
	Capital contribution of non-controlling interest holder of iKang Zhejiang BVI	164			—			—			—			—			—			—			—			—			—			164
	Addition of non-controlling interest in connection with establishment of Fujian iKang	—			—			—			—			305			—			—			—			—			—			305
	Dividend distribution to non-controlling interest holder of iKang Shanghai Xikang Road	—			(420		)	—			—			—			—			—			—			—			—			(420		)
	Share of profit (loss)	164			414			53			29			(107		)	137			—			—			—			—			690
	Purchase of non-controlling interest	—			(1,564		)	—			(176		)	—			29			—			—			—			—			(1,711		)
	Other comprehensive income	(65		)	54			17			8			10			(8		)	—			—			—			—			16
	Balance at March 31, 2012	(25		)	—			484			115			208			(74		)	—			—			—			—			708
	Share of profit	59			—			146			(1		)	39			95			—			—			—			—			338
	Other comprehensive income	(30		)	—			9			2			3			—			—			—			—			—			(16		)
	Balance at March 31, 2013	4			—			639			116			250			21			—			—			—			—			1,030
	Addition of non-controlling interest in connection with establishment of Beijing Jiandatong	—			—			—			—			—			—			—			82			—			—			82
	Addition of non-controlling interest in connection with acquisition of Shanghai iKang Jianwei Health Management Co., Ltd.	—			—			—			—			—			—			172			—			—			—			172
	Addition of non-controlling interest in connection with acquisition of MediFast	—			—			—			—			—			—			—			—			1,690			—			1,690
	Addition of non-controlling interest in connection with establishment of iKang Changzhou	—			—			—			—			—			—			—			—			—			732			732
	Dividend distribution to non-controlling interest holder of Shanghai Wangzu Guobin Medical Center Co., Ltd.	—			—			(44		)	—			—			—			—			—			—			—			(44		)
	Share of profit (loss)	104			—			236			25			143			33			(9		)	(36		)	48			(225		)	319
	Purchase of non-controlling interest	—			—			—			(142		)	—			—			—			—			—			—			(142		)
	Other comprehensive income	(2		)	—			(7		)	1			(4		)	(1		)	(2		)	(1		)	(1		)	(4		)	(21		)
	Balance at March 31, 2014	$	106		$	—		$	824		$	—		$	389		$	53		$	161		$	45		$	1,737		$	503		$	3,818

SEGMENT_INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Mar. 31, 2014
SEGMENT INFORMATION	'
SEGMENT INFORMATION	'
	21.                              SEGMENT INFORMATION
	The Group’s chief operating decision maker has been identified as the Chief Executive Officer, who reviews consolidated results when making decisions about allocating resources and assessing performance of the Group.  The Group has one operating segment.
	Components of net revenues are presented in the following table:
		Years ended March 31,
		2012		2013		2014
	Medical examinations	$	78,997	$	116,449	$	173,903
	Disease screening	5,162		9,240		15,017
	Other services	9,554		8,182		13,384
	Total	$	93,713	$	133,871	$	202,304
	Substantially all of the Company’s revenues for the years ended March 31, 2012, 2013 and 2014 were generated from the PRC entities.
	Substantially all of long-lived assets of the Group are located in the PRC as of March 31, 2012, 2013 and 2014.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Mar. 31, 2014
COMMITMENTS AND CONTINGENCIES	'
COMMITMENTS AND CONTINGENCIES	'
	22.                              COMMITMENTS AND CONTINGENCIES
	Commitments
	The Group leases its clinics, hospitals and offices under non-cancelable operating lease agreements.  These leases expire through 2025 and are renewable upon negotiation.  Rental expenses under operating leases for the year ended March 31, 2012, 2013 and 2014 were $11,051, $16,436 and $28,129, respectively.
	Future minimum lease payments under such leases as of March 31, 2014 were as follows:
	2015	$	27,870
	2016	25,397
	2017	23,450
	2018	21,131
	2019	16,072
	After 2019	34,608
		$	148,528
	Contingent liabilities
	Pursuant to PRC individual income tax laws, when a corporation purchases equity interest from individuals, the individuals are obligated to pay individual income tax based on 20% of the capital gain from the transaction. The Group has purchased equity interests of certain entities from individual sellers. There is a possibility that if individual sellers fail to meet their income tax obligations, the tax authority may require the Group to pay the taxes for the sellers. Based on the information currently available, the Group was unable to make a reasonable estimate of the related liability due to the uncertainty related to the outcome and amount of payment and relating penalty and interest. Accordingly, the Company did not accrue any provision for this contingency as of March 31, 2014.
	The Group is subject to governmental supervision and regulations by the relevant PRC regulatory authorities including the Ministry of Health, the Ministry of Industry and Information Technology, and other relevant government authorities.  Each of the Group’s medical centers is required to obtain a business license, a medical institution establishment approval, a medical institution practicing license and a radiation-related diagnosis and treatment license.  If the Group fails to obtain such licenses or to amend the medical institution practicing licenses for the forgoing medical centers or other competent PRC regulatory authorities consider that the Group is operating the relevant businesses in an illegal manner, the Group may be ordered to shut down the relevant medical centers or cease the relevant services or suffer fines or penalties.

EMPLOYEE_BENEFIT_PLAN

EMPLOYEE BENEFIT PLAN	12 Months Ended
	Mar. 31, 2014
EMPLOYEE BENEFIT PLAN	'
EMPLOYEE BENEFIT PLAN	'
	23.                              EMPLOYEE BENEFIT PLAN
	Full time employees of the Group in the PRC participate in a government-mandated defined contribution plan pursuant to which certain pension benefits, medical care, unemployment insurance, employee housing fund and other welfare benefits are provided to employees.  The Group accrues for these benefits based on certain percentages of the employees’ salaries.  The total provisions for such employee benefits were $3,365, $4,908 and $7,249 for the years ended March 31, 2012, 2013 and 2014, respectively.

STATUTORY_RESERVE_AND_RESTRICT

STATUTORY RESERVE AND RESTRICTED NET ASSETS	12 Months Ended
	Mar. 31, 2014
STATUTORY RESERVE AND RESTRICTED NET ASSETS	'
STATUTORY RESERVE AND RESTRICTED NET ASSETS	'
	24.                              STATUTORY RESERVE AND RESTRICTED NET ASSETS
	In accordance with the Regulations on Enterprises with Foreign Investment of China and their articles of association, the Group’s subsidiaries and VIE entities located in the PRC, being foreign invested enterprises established in the PRC, are required to provide for certain statutory reserves.  These statutory reserve funds include one or more of the following: (i) a general reserve, (ii) an enterprise expansion fund or discretionary reserve fund, and (iii) a staff bonus and welfare fund.  Subject to certain cumulative limits, the general reserve fund requires a minimum annual appropriation of 10% of after-tax profit (as determined under accounting principles generally accepted in China at each year-end); the other fund appropriations are at the subsidiaries’ or the affiliated PRC entities’ discretion.  These statutory reserve funds can only be used for specific purposes of enterprise expansion, staff bonus and welfare, and are not distributable as cash dividends except in the event of liquidation of our subsidiaries, our affiliated PRC entities and their respective subsidiaries.  The Group’s subsidiaries and VIE entities are required to allocate at least 10% of their after-tax profits to the general reserve until such reserve has reached 50% of their respective registered capital.  As of March 31, 2014, none of the Group’s PRC subsidiaries and VIE entities had a general reserve that reached the 50% of their registered capital threshold except iKang Nanjing Gulou, therefore they will continue to allocate at least 10% of their after tax profits to the general reserve fund.
	Appropriations to the enterprise expansion reserve and the staff welfare and bonus reserve are to be made at the discretion of the board of directors of each of the Group’s subsidiaries.
	The appropriation to these reserves by the Group’s PRC subsidiaries was $470, $1,296 and $2,738 for the years ended March 31, 2012, 2013 and 2014, respectively.
	As a result of these PRC laws and regulations and the requirement that distributions by PRC entities can only be paid out of distributable profits computed in accordance with PRC GAAP, the PRC entities are restricted from transferring a portion of their net assets to the Group. Amounts restricted include paid-in capital and the statutory reserves of the Group’s PRC subsidiaries and VIE entities. The aggregate amounts of capital and statutory reserves restricted which represented the amount of net assets of the relevant subsidiaries and VIE entities in the Group not available for distribution was $103,355 as of March 31, 2014.
	As a result of the above restrictions, parent-only financials are presented in Schedule I.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Mar. 31, 2014
SUBSEQUENT EVENTS	'
SUBSEQUENT EVENTS	'
	25.                              SUBSEQUENT EVENTS
	On April 9, 2014, the Company completed its IPO in NASDAQ by offering 10,904,846 American Depositary Shares (“ADS”), representing 5,452,423 Class A Common Shares, and received net proceeds of $87,900. On the same date, Best Investment Corporation, a limited liability company incorporated in the PRC, which is a wholly-owned subsidiary of CIC International Co., Ltd., purchased from the Company 1,428,571 common shares for a total purchase price of $40,000 in the concurrent private placement. Net proceeds to the Company were $37,200. On May 9, 2014, the Company issued an additional 1,029,112 ADS, representing 514,556 Class A Common Shares to the investment bankers for excising the green shoe option at price of $14.00 per ADS and received net proceeds of $13,400.
	In May and June 2014, the Group entered into two share purchase agreements to acquire 37% and 30% of equity interest of Shanghai Huajian Clinic Ltd. (“Huajian”) from Shanghai GaoTong Supporting Services Management Ltd. and Shanghai Huajian Investment Management Ltd., for cash considerations are $7,121 and $5,373, respectively. Besides cash considerations, an option award arrangement agreement with the ex-shareholder, in connection with her continuous employment with Huajian following the Company’s acquisitions of remaining 30% of equity interests in Huajian. Pursuant to this option award arrangement agreement, the Company will grant an option to purchase its 300,000 Class A common shares when the Company acquires 63% equity interest of Huajian, including 33% equity interest from this shareholder and a 30% equity interest from another shareholder. The exercise price for the option will be US$16.18 per share. The acquisition was closed in July 2014. The Group is currently undertaking the purchase price allocation of the acquisition with the assistance of a third party appraiser.
	The Group acquired the above businesses for the purpose of expanding its medical examination related services in multiple cities and is in the process of assessing the purchase price allocation of the above acquisitions with the assistance of an independent valuation firm.
	On April 9, 2014, iKang Beijing Ritan and iKang Beijing Xuanwumen borrowed short term loans of $657 and $692 with Bank of Beijing, respectively according to the framework agreement signed in March 2014. The annual interest rate is the benchmark interest rate announced by the People’s Bank of China plus 15% of the benchmark interest rate. The loan was guaranteed by iKang Online and iKang Holding.
	In May 2014, iKang Holding signed two one-year credit loan agreement with amount $1,234 and $4,275; in June, 2014 signed a one-year loan with amount $1,432 with China Merchants Bank, to meet both its equipment capital needs and temporary working capital needs and the property of the Group. The annual interest rate was equal to the benchmark interest rate announced by the People’s Bank of China plus 20% of the benchmark interest rate.
	On May 5, 2014, iKang Online borrowed two one-year loan of $2,252 and $2,245, respectively with BEA, to meet its equipment capital needs and temporary working capital needs of the Group. The annual interest rate was equal to the benchmark interest rate announced by the People’s Bank of China plus 10% of the benchmark interest rate. The loan was collateralized by restricted cash.
	In June 2014, iKang Online borrowed a one-year loan of $14,523 with Xiamen International Bank, to repay the loans from BEA which was due in June 2014 and paid remaining balance of purchase 35% of equity interest in iKang Shanghai Xikang Road. The loan was collateralized by restricted cash.

FINANCIAL_STATEMENT_SCHEDULE_I

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY	12 Months Ended
	Mar. 31, 2014
ADDITIONAL INFORMATION-FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY	'
ADDITIONAL INFORMATION-FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY	'
	IKANG HEALTHCARE GROUP, INC.
	ADDITIONAL INFORMATION-FINANCIAL STATEMENT SCHEDULE I
	CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY
	CONDENSED BALANCE SHEETS
	(In thousands of U.S. dollars, except share and per share data and unless otherwise stated)
		Year ended March 31,
		2013			2014
	ASSETS
	Current assets:
	Cash and cash equivalents	$	47,290		$	13,937
	Amounts due from related parties	9,780			27,622
	Prepaid expenses and other current assets	—			334
	Total current assets	57,070			41,893
	Property and equipment, net	1			1
	Investment in subsidiaries and VIE entities	40,908			99,584
	TOTAL ASSETS	$	97,979		$	141,478
	LIABILITIES, MEZZANINE EQUITY AND EQUITY (DEFICIT):
	Current liabilities:
	Convertible loan	2,000			—
	Accrued expenses and other current liabilities	5,180			2,767
	Amount due to related companies	1,016			1,151
	Total current liabilities	8,196			3,918
	Mezzanine Equity:
	Series A convertible redeemable participating preferred shares ($0.01 par value; 1,391,044 and 1,094,668 shares authorized as of March 31, 2013 and 2014, respectively, 1,094,668 shares issued and outstanding as of March 31, 2013 and 2014, liquidation value of $1,970 as of March 31, 2013 and 2014)	$	6,496		$	6,496
	Series B convertible redeemable participating preferred shares ($0.01 par value; 1,059,735 and 686,368 shares authorized as of March 31, 2013 and 2014, respectively, 686,368 shares issued and outstanding as of March 31, 2013 and 2014, liquidation value of $2,162 as of March 31, 2013 and 2014)	6,512			6,512
	Series C1 convertible redeemable participating preferred shares ($0.01 par value; 794,250 shares authorized, issued and outstanding as of March 31, 2013 and 2014, liquidation value of $1,893 as of March 31, 2013 and 2014)	5,700			5,700
	Series C2 convertible redeemable participating preferred shares ($0.01 par value; 252,572 and 126,286 shares authorized as of March 31, 2013 and 2014, respectively, 126,286 shares issued and outstanding as of March 31, 2013 and 2014, liquidation value of $568 as of March 31, 2013 and 2014)	1,709			1,709
	Series C3 convertible redeemable participating preferred shares ($0.01 par value; 1,024,318 shares authorized, issued and outstanding as of March 31, 2013 and 2014, liquidation value of and $1,382 as of March 31, 2013 and 2014)	4,157			4,157
	Series D1 convertible redeemable participating preferred shares ($0.01 par value; 3,655,151 and 3,488,864 shares authorized as of March 31, 2013 and 2014, respectively, 3,538,864 and 3,488,864 shares issued and outstanding as of March 31, 2013 and 2014, respectively, liquidation value of $10,227 and $10,083 as of March 31, 2013 and 2014, respectively)	30,176			29,750
	Series D2 convertible redeemable participating preferred shares ($0.01 par value; 2,436,769 and 2,072,624 shares authorized as of March 31, 2013 and 2014, respectively, 2,307,536 and 2,072,624 shares issued and outstanding as of March 31, 2013 and 2014, respectively, liquidation value of $3,115 and $2,798 as of March 31, 2013 and 2014, respectively)	12,356			11,300
	Series E convertible redeemable participating preferred shares ($0.01 par value; 4,289,457 shares authorized, issued and outstanding as of March 31, 2013 and 2014, liquidation value of $22,056 as of March 31, 2013 and 2014)	54,098			54,098
	Series F convertible redeemable participating preferred shares ($0.01 par value; 7,500,000 and 7,204,680 shares authorized as of March 31, 2013 and 2014, respectively, 4,654,697 and 7,204,680 shares issued and outstanding as of March 31, 2013 and 2014 respectively, liquidation value of $60,000 and $93,639 as of March 31, 2013 and 2014, respectively)	92,774			144,795
		Year ended March 31,
		2013			2014
	Equity:
	Class A common shares ($0.01 par value; 36,026,704 and 37,648,485 shares authorized as of March 31, 2013 and 2014, respectively, 4,911,245 and 4,599,673 issued and outstanding as of March 31, 2013 and 2014, respectively)	$	49		$	45
	Class B common shares ($0.01 par value; 1,570,000 shares authorized, issued and outstanding as of March 31, 2013 and 2014, respectively)	16			16
	Additional paid-in capital	4,341			1,342
	Accumulated deficit	(133,123		)	(132,124		)
	Accumulated other comprehensive income	4,522			3,764
	Total iKang Healthcare Group, Inc.’s deficit	(124,195		)	(126,957		)
	TOTAL LIABILITIES, MEZZANINE EQUITY AND EQUITY	$	97,979		$	141,478
		Year ended March 31
		2012			2013			2014
	Operating expenses:
	Selling and marketing	$	6		$	—		$	—
	General and administrative	668			2,849			2,457
	Total operating expenses	674			2,849			2,457
	Loss from operations	(674		)	(2,849		)	(2,457		)
	Interest income	—			—			11
	Interest expense	—			(169		)	(18		)
	Equity in earnings of subsidiaries and VIE entities	10,376			15,129			24,071
	Income before provision for income taxes	9,702			12,111			21,607
	Net income	$	9,702		$	12,111		$	21,607
		For the year ended March 31,
		2012			2013			2014
	Net income	$	9,702		$	12,111		$	21,607
	Other comprehensive income:
	Other comprehensive income, foreign currency translation adjustment	$	1,525		$	584		$	(758	)
	Comprehensive income attributable iKang Healthcare Group, Inc.	$	11,227		$	12,695		$	20,849
		Common											Accumulated other			Total
		Comprehensive					Additional			Accumulated			comprehensive			shareholders’
		Shares		Amount			paid-in capital			deficit			income			equity/(deficit)
Balance at April 1, 2011	6,476,645		$	65		$	16,103		$	(66,826	)	$	2,413		$	(48,245	)
Share-based compensation	—		—			216			—			—			216
Exercise of share options	75,000		1			135			—			—			136
Exercise of share option to shareholders	134,845		1			1,762			(1,492		)	—			271
Change in effective ownership of iKang Zhejiang BVI	—		—			(95		)	—			—			(95		)
Purchase of non-controlling interest of iKang Shanghai Lujiazui	—		—			(15		)	—			—			(15		)
Purchase of non-controlling interest of iKang Shanghai Xikang Road	—		—			(13,157		)	—			—			(13,157		)
Purchase of non-controlling interest of Shenzhen Hospital Management	—		—			(238		)	—			—			(238		)
Deemed dividend on convertible redeemable preferred shares - accretion of redemption premium	—		—			—			(2,312		)	—			(2,312		)
Exercise of share options	—		—			—			—			—			—
Net income	—		—			—			9,702			—			9,702
Foreign currency translation adjustment	—		—			—			—			1,525			1,525
Balance at March 31, 2012	6,686,490		$	67		$	4,711		$	(60,928	)	$	3,938		$	(52,212	)
Share-based compensation	—		—			2,273			—			—			2,273
Redesignation to Series F Series F convertible redeemable participating preferred shares	(205,245	)	(2		)	(2,643		)	—			—			(2,645		)
Deemed dividend on convertible redeemable preferred shares - accretion of redemption premium	—		—			—			(84,306		)	—			(84,306		)
Net income	—		—			—			12,111			—			12,111
Foreign currency translation adjustment	—		—			—			—			584			584
Balance at March 31, 2013	6,481,245		$	65		$	4,341		$	(133,123	)	$	4,522		$	(124,195	)
Share-based compensation	—		—			930			—			—			930
iKang Healthcare Group, Inc. one common share of US$0.01 entered into a share swap agreement	1		—			—			—			—			—
Redesignation to Series F Series F convertible redeemable participating preferred shares	(311,572	)	(4		)	(3,745		)	—			—			(3,749		)
Addition of non-controlling interest in connection with acquisition of Shanghai iKang Jianwei Health Management Co., Ltd.	—		—			—			(172		)	—			(172		)
Purchase of non-controlling interest of Shanghai iKang Guobin Blue Cross Clinic, Co. Ltd.	—		—			(184		)	—			—			(184		)
Deemed dividend on convertible redeemable preferred shares - accretion of redemption premium	—		—			—			(20,436		)	—			(20,436		)
Net income	—		—			—			21,607			—			21,607
Foreign currency translation adjustment	—		—			—			—			(758		)	(758		)
Balance at March 31, 2014	6,169,674		$	61		$	1,342		$	(132,124	)	$	3,764		$	(126,957	)
	For the year ended March 31,
	2012			2013			2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	9,702		$	12,111		$	21,607
Adjustments to reconcile net income to net cash provided by operating activities:
Investment income from subsidiaries	(10,376		)	(15,129		)	(24,071		)
Stock-based compensation	216			2,273			930
Changes in assets and liabilities:
Prepaid expenses and other current assets	(980		)	2,754			(316		)
Amount due from related party	1,576			(1,502		)	(17,732		)
Accrued expenses and other current liabilities	(108		)	(297		)	(2,409		)
Amount due to related parties	(564		)	—			—
Net cash (used in) generated from operating activities	(534		)	210			(21,991		)
CASH FLOW FROM FINANCING ACTIVITIES:
Loan provided to a related party	—			—			(3,000		)
Repayment of loan provided to a related party	—			—			3,000
Payment for business acquisitions	—			—			(31,710		)
Net cash (used in) generated from investing activities	—			—			(31,710		)
CASH FLOW FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible redeemable preferred shares	—			45,000			—
Proceeds from convertible loan	—			2,000			—
Repayment of convertible loan	—			—			(2,000		)
Proceeds from exercise of share options	135			—			—
Proceeds from exercise of share option to shareholders	269			—			—
Proceeds from issuance of convertible redeemable preferred shares	—			—			25,181
Proceeds from redesignation of Common A	—			—			669
Proceeds from redesignation of convertible redeemable preferred shares	—			—			612
Payment for convertible preferred shares transaction professional fees	—			—			(2,847		)
Payment for business acquisitions	—			—			(1,267		)
Net cash (used in) provided by financing activities	404			47,000			20,348
Effect of exchange rate changes	—			—			—
Net (decrease)/ increase in cash	(130		)	47,210			(33,353		)
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR	210			80			47,290
CASH AND CASH EQUIVALENTS AT END OF THE YEAR	$	80		$	47,290		$	13,937
1.                                      BASIS FOR PREPARATION
The condensed financial information of the Parent Company has been prepared using the same accounting policies as set out in the Group’s consolidated financial statement except that the Parent Company used the equity method to account for investments in its subsidiaries, VIE entities.
The condensed financial information is provided since the restricted net assets of the Group’s subsidiaries VIE entities were over the 25% of the consolidated net assets of the Group as of March 31, 2014.
2.                                      INVESTMENTS IN SUBSIDIARIES
The Parent Company and its subsidiaries, VIE entities were included in the consolidated financial statements where inter-company balances and transactions were eliminated upon consolidation.  For purpose of the Parent Company’s stand-alone financial statements, its investments in subsidiaries, VIE entities were reported using the equity method of accounting.  The Parent Company’s share of income (loss) from its subsidiaries, VIE entities were reported as share of income (loss) of subsidiaries and subsidiaries entities in the accompanying parent company financial statements.
For the purpose of the Parent Company’s stand-alone financial information, its investments in subsidiaries, VIEs and the VIEs’ subsidiaries are reported using the equity method of accounting.  The Parent Company’s share of income (loss) from its VIEs and the VIEs’ subsidiaries were reported as share of income (loss) of subsidiaries and VIEs in the accompanying parent company financial information.
3.                                      CONVERTIBLE LOAN
In May 2012, the Company signed a convertible loan agreement with amount of $2,000 with an unrelated third party, with annual interest rate of 8% and the maturity date of December 31, 2012. On or prior to the maturity date, the lender has the option to extend the maturity date of the convertible loan to June 30, 2013, and also has the option but not the obligation to convert the loan into common shares of the Company. As of March 31, 2013, the loan has not been repaid or converted because no notice from the lender was received by the Company. In June 2013, the Group repaid the convertible loan and accrued interests amounted $2,300 in full pursuant to an agreement with the lender.
4.                                      SUBSEQUENT EVENTS
On April 8, 2014, the Company completed its IPO in NASDAQ by offering 10,904,846 American Depositary Shares (“ADS”), representing 5,452,423 Class A Common Shares, and received net proceeds of $87,900. On the same date, Best Investment Corporation, a limited liability company incorporated in the PRC, which is a wholly-owned subsidiary of CIC International Co., Ltd., purchased from the Company 1,428,571 common shares for a total purchase price of $40,000 in the concurrent private placement. Net proceeds to the Company were $37,200. On May 9, 2014, the Company issued an additional 1,029,112 ADS, representing 514,556 Class A Common Shares to the investment bankers for excising the green shoe option at price of $14.00 per ADS and received net proceeds of $13,400.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Mar. 31, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
Basis of presentation	'
	Basis of presentation
	The consolidated financial statements of the Group have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”).
Basis of consolidation	'
	Basis of consolidation
	The consolidated financial statements of the Group include the financial statements of iKang Healthcare Group Inc., its subsidiaries, its VIEs and its VIEs’ subsidiaries.  All inter-company transactions and balances have been eliminated upon consolidation.
Use of estimates	'
	Use of estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and revenues, costs and expenses in the financial statements and accompanying notes. Significant accounting estimates reflected in the Group’s consolidated financial statements include revenue recognition, allowance for doubtful accounts, the useful lives and impairment of property and equipment, the useful lives and impairment of intangible assets, impairment of goodwill, write off of leasehold improvement, valuation allowance for deferred tax assets, share-based compensation and fair value of the common shares, convertible redeemable preferred shares and forward contracts.
Cash and cash equivalents	'
	Cash and cash equivalents
	Cash and cash equivalents consist of cash on hand, and demand deposits, which are unrestricted as to withdrawal and use, and which have maturities of three months or less when purchased.
Accounts receivable and allowance for doubtful accounts	'
	Accounts receivable and allowance for doubtful accounts
	Accounts receivable represents those receivables derived in the ordinary course of business.  A general allowance for doubtful accounts is provided based on aging analyses of accounts receivable balances, historical bad debt rates, in addition to specific provisions established based on customers’ repayment patterns and customer credit worthiness.
Financial instruments	'
	Financial instruments
	Financial instruments of the Group primarily consist of cash and cash equivalent, restricted cash, accounts receivable, forward contract, equity method investment, cost method investment, amount due from related parties, accounts payable, amount due to related parties, short-term borrowing and long-term borrowing.
	The carrying values of cash, and cash equivalent, restricted cash, accounts receivable, accounts payable, and amounts due from related parties, short-term borrowing approximate their fair values due to short-term maturities.  It is not practical to estimate the fair value of the Group’s cost method investment because of the lack of quoted market price and the inability to estimate fair value without incurring excessive costs.
	The fair value of long-term borrowings is based on the amount of future cash flows associated with each debt instrument discounted at the Company’s current borrowing rate for similar debt instruments of comparable terms. The carrying values of the long-term borrowings approximate their fair values as all the long-term debt carry variable interest rates which approximate rates currently offered by the Company’s bankers for similar debt instruments of comparable maturities.
	For amounts due to related parties, they are carried at amortized cost using effective interest method.
Effective interest method	'
	Effective interest method
	The effective interest method is a method of calculating the amortized cost of a financial liability and of allocating interest expense over the relevant period.  The effective interest rate is the rate that exactly discounts estimated future cash payments (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial liability, or, where appropriate, a shorter period, to the net carrying amount on initial recognition.
	Interest expense is recognized on an effective interest basis.
Fair value	'
	Fair value
	Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Group considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.
	Authoritative literature provides a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.  An asset or liability categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement as follows:
	Level 1
	Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.
	Level 2
	Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.
	Fair value of foreign currency forward contract is discussed in Note 18.
	Level 3
	Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.
Significant risks and uncertainties	'
	Significant risks and uncertainties
	The Group operates in an industry with rapid changes in regulations, customer demand and competition and believes that changes in any of the following areas could have a material adverse effect on the Group’s future financial position, results of operations, or cash flows: advances and trends in healthcare industry standards, changes in certain strategic relationships or customer relationships, regulatory or other PRC related factors, risks associated with the Group’s ability to keep and increase the customer base, and risks surrounding pending litigations.
Foreign currency risk	'
	Foreign currency risk
	The Renminbi (“RMB”) is not a freely convertible currency.  The State Administration for Foreign Exchange, under the authority of the People’s Bank of China, controls the conversion of RMB into foreign currencies.  The value of the RMB is subject to changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange Trading System market.  Cash and cash equivalent of the Group included aggregate amounts of $15,830 and $15,853 at March 31, 2013 and 2014, respectively, which were denominated in RMB.
Concentration of credit risk	'
	Concentration of credit risk
	Financial instruments that potentially expose the Group to concentration of credit risk consist primarily of cash and cash equivalents, and accounts receivable.  The Group places their cash with financial institutions with high-credit ratings and quality.  The Group conducts credit evaluations of customers and generally do not require collateral or other security from their customers.
	No customer accounted for 10% or more of total revenues for the years ended March 31, 2012, 2013 and 2014.  No customer accounted for 10% or more of accounts receivable as of March 31, 2013 and 2014.
Inventories	'
	Inventories
	Inventories are medical consumables and are stated at the lower of cost or market value.  Inventories are written down for obsolescence to net realizable value based upon estimates of future demand and expiration date of inventories.  The Group reflected the write-down of inventories of $25, nil and nil for the year ended March 31, 2012, 2013 and 2014, respectively in cost of revenues.
Equity method investment	'
	Equity method investment
	The investee company over which the Group has the ability to exercise significant influence, but does not have a controlling interest are accounted for using the equity method. Significant influence is generally considered to exist when the Group has an ownership interest in the voting stock of the investee between 20% and 50%, and other factors, such as representation in the investee’s Board of Directors, voting rights and the impact of commercial arrangements, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the affiliated company’s accounts are not reflected within the Group’s consolidated balance sheets and statements of operations; however, the Group’s share of the earnings or losses of the affiliated company is reflected in the caption “loss from equity method investment” in the consolidated statements of operations.
	An impairment charge is recorded if the carrying amount of the investment exceeds its fair value and this condition is determined to be other-than temporary. The Group estimated the fair value of the investee company based on comparable quoted price for similar investment in active market, if applicable, or discounted cash flow approach which requires significant judgments, including the estimation of future cash flows, which is dependent on internal forecasts, the estimation of long term growth rate of a company’s business, the estimation of the useful life over which cash flows will occur, and the determination of the weighted average cost of capital. The Company did not record impairment losses on its equity method investment during the year ended March 31, 2012, 2013 and 2014.
Property and equipment, net	'
	Property and equipment, net
	Property and equipment are carried at cost less accumulated depreciation and amortization.  Depreciation and amortization are calculated on a straight-line basis over the following estimated useful lives:
	Computer equipment and application software	5 years
	Furniture and fixture	5 years
	Medical equipment	10 years
	Motor vehicles	5 years
	Leasehold improvement	Shorter of useful life of the asset or the lease term
	Construction in progress represents unfinished leasehold improvement and installment of equipment for new clinics.  Construction in progress will be transferred to leasehold improvement or property and equipment when it is finished.  Depreciation is recorded at the time when assets are ready for the intended use.
Intangible assets, net	'
	Intangible assets, net
	Intangible assets, other than goodwill, resulting from the acquisitions of entities accounted for using the purchase method of accounting are estimated by management based on the fair value of assets acquired.  Identifiable intangible assets are carried at cost less accumulated amortization.  Amortization of customer relationship is computed using the estimated attrition pattern of the acquired customers, and amortization of other finite-lived intangible assets is computed using the straight-line method over the following estimated average useful lives, which are as follows:
		Weighted average (years)	range (years)
	Customer relationship	6.8	2.1~10.0
	Non-compete agreement	3	2.0~3.0
	Contract backlog	0.7	0.4~0.9
	Operating license	3.2	0.3~4.8
	Favorable lease contract	8.8	5.1~9.8
	The weighted average estimated average useful life of the intangible assets with determinable lives is 6.4 years.
Intangible assets-indefinite lives	'
	Intangible assets-indefinite lives
	If an intangible asset is determined to have an indefinite life, it should not be amortized until its useful life is determined to be no longer indefinite.  An intangible asset that is not subject to amortization is tested for impairment at least annually or if events or changes in circumstances indicate that the asset might be impaired.  Such impairment test consists of the fair values of assets with their carrying value amounts and an impairment loss is recognized if and when the carrying amounts exceed the fair values.  The estimates of fair values of intangible assets not subject to amortization are determined using various discounted cash flow valuation methodologies.  Significant assumptions are inherent in this process, including estimates of discount rates.
Impairment of long-lived assets and intangible assets with definite life	'
	Impairment of long-lived assets and intangible assets with definite life
	Long-lived assets, such as property and equipment and definite-lived intangible assets are stated at cost less accumulated depreciation or amortization.  Depreciation and amortization is computed principally using the straight-line method.
	The Group evaluates the recoverability of long-lived assets, including identifiable intangible assets, with determinable useful lives whenever events or changes in circumstances indicate that an intangible asset’s carrying amount may not be recoverable.  The Group measures the carrying amount of long-lived asset against the estimated undiscounted future cash flows associated with it.  Impairment exists when the sum of the expected future net cash flows is less than the carrying value of the asset being evaluated.  Impairment loss is calculated as the amount by which the carrying value of the asset exceeds its fair value.  Fair value is estimated based on various valuation techniques, including the discounted value of estimated future cash flows.  The evaluation of asset impairment requires the Group to make assumptions about future cash flows over the life of the asset being evaluated.  These assumptions require significant judgment and actual results may differ from assumed and estimated amounts.
Goodwill	'
	Goodwill
	Goodwill represents the excess of the fair value of consideration paid over the fair value of identifiable net assets acquired in business combinations. Goodwill and intangible assets deemed to have indefinite useful lives are not amortized, but tested for impairment annually or more frequently if event and circumstances indicate that they might be impaired.
	Goodwill is tested for impairment at the reporting unit level on an annual basis (March 31 for the Group) and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. These events or circumstances could include a significant change in the stock prices, business climate, legal factors, operating performance indicators, competition, or sale or disposition of a significant portion of a reporting unit.
	In the evaluation of the goodwill for impairment, the Group may first assess qualitative factors to determine whether it is “more likely than not” that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. If it is more likely than not that the fair value of a reporting unit is less than its carrying amount, goodwill is then tested following a two-step process.
	The first step compares the fair value of each reporting unit to its carrying amount, including goodwill. If the fair value of each reporting unit exceeds its carrying amount, goodwill is not considered to be impaired and the second step will not be required. If the carrying amount of a reporting unit exceeds its fair value, the second step compares the implied fair value of goodwill to the carrying value of a reporting unit’s goodwill. The implied fair value of goodwill is determined in a manner similar to accounting for a business combination with the allocation of the assessed fair value determined in the first step to the assets and liabilities of the reporting unit. The excess of the fair value of the reporting unit over the amounts assigned to the assets and liabilities is the implied fair value of goodwill. An impairment loss is recognized for any excess in the carrying value of goodwill over the implied fair value of goodwill.
	Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities to reporting units, assignment of goodwill to reporting units, and determination of the fair value of each reporting unit. The estimation of fair value of each reporting unit using a discounted cash flow methodology also requires significant judgments, including estimation of future cash flows, which is dependent on internal forecasts, estimation of the long-term rate of growth for the Group’s business, estimation of the useful life over which cash flows will occur, and determination of the Group’s weighted average cost of capital. The estimates used to calculate the fair value of a reporting unit change from year to year based on operating results and market conditions. Changes in these estimates and assumptions could materially affect the determination of fair value and goodwill impairment for the reporting unit.
	The Group did not incur any impairment loss on goodwill for the years ended March 31, 2012, 2013 and 2014.
Cost method investment	'
	Cost method investment
	For investment over which the Group does not have significant influence, the Group carries the investments at cost.  The Group reviews the cost method investment for impairment whenever events or circumstances indicate that an other-than-temporary decline has occurred.  The Group considers available quantitative and qualitative evidence in evaluating potential impairment of its cost method investment.  If the cost of an investment exceeds the investment’s fair value, the Group considers, among other factors, general market conditions, government economic plans, the duration and the extent to which the fair value of the investment is less than the cost, and the Group’s intent and ability to hold the investment.
Revenue recognition	'
	Revenue recognition
	Revenue is stated net of business tax.  The Group’s PRC subsidiaries and VIE entities are subject to a 5% business tax and related surcharges on the revenues earned from providing services and selling products in the PRC.  Certain contracts under specific formalities are exempted from business tax in accordance with the PRC tax laws.  The Group recognized $1,098, $1,576, and $2,084 business tax for the years ended March 31, 2012, 2013 and 2014, respectively.
	The Group recognizes revenues when persuasive evidence of an arrangement exists, service has been provided, the sales price is fixed or determinable, and collectability is reasonably assured.
	The Group offers medical examination and disease screening services and renders such services at the request of its customers.  The Group recognizes revenues when the examination reports are issued and passed to the local couriers if hard copy reports are required by its customers, or when the examination reports are uploaded on line and can be viewed by the customers on line if hard copy reports are not required.  The Group notifies its customers when their examination reports are delivered to the local couriers or ready to be viewed and downloaded on line.
	For individual customers, fees are collected before the performance of the services while corporate customers prepay a portion of service fees upon signing of the master contract, which is recognized as deferred revenue by the Group.  All fees for services rendered are first charged against the corporate customer’s deferred revenues until it is entirely exhausted before the Group starts to invoice the corporate customers.  The Group records accounts receivables from its corporate customers when the examination reports of the employees of corporate customers have been delivered or uploaded on line but the Group has not received remaining payments from the corporate customers.
	Sometimes the Group engages third-party providers to provide medical examination and disease screening services on behalf of the Group.  The Group evaluates the services provided by third parties on behalf of the Group to determine whether to recognize the revenues on a gross or net basis.  The determination is based upon an assessment as to whether the Group acts as a principal or agent when providing the services.  All of the revenues involving third-party providers providing medical examination or disease screening services on behalf of the Group are currently accounted for on a gross basis since the Group is the primary obligor, has the latitude in establishing prices, discretion in third-party provider selection and the credit risks.
	The Group has also historically provided medical concierge services.  The value included in the medical concierge card prepaid by the Group’s customers is initially recorded as deferred revenues, and a predetermined amount which is based on the number of appointments actually made is deducted and recognized as revenue when a customer schedules an appointment with a hospital because the Group has no further service obligation after such appointment is made.  There is no right of return if a card expires, which is on average one to two year from the date of purchase.  Any remaining balance of deferred revenue is recognized upon expiry of the card.
	The Group also provides packages of bundled services principally comprising combinations of the above to its corporate customers.  Components normally expire within one year from the date of purchase and does not include right of return.  The Group allocates revenues from the sale of bundled services to each component using the relative selling price of each component based on the Group’s best estimate.  Revenue recognition criteria for components included in the bundled services is identical to as if the components are sold on a standalone basis.
Value added tax ("VAT")	'
	Value added tax (“VAT”)
	In July 2012, the Ministry of Finance and the State Administration of Taxation jointly issued a circular regarding the pilot collection of VAT in lieu of business tax in certain areas and industries in the PRC. Such VAT pilot program is to be phased in Beijing, Jiangsu, Anhui, Fujian, Guangdong, Tianjin, Zhejiang, and Hubei between September and December 2012. Starting from September 1, 2012, certain subsidiaries became subject to VAT at the rate of 3% on certain service revenues which were previously subject to business tax.
Non-monetary exchange	'
	Non-monetary exchange
	The Group occasionally exchanges medical examination service with advertising agencies for advertising credits. The amount of deferred revenues and prepaid expenses is based on the fair value of the medical examination services surrendered which approximates the price the Group offers to the individual customers and is more readily determinable. The amounts of revenues recognized for non-monetary transactions were $1,291, $972 and $706 for the years ended March 31, 2012, 2013 and 2014, respectively. No direct costs are attributable to the revenues.
Cost of revenues	'
	Cost of revenues
	Cost of revenues consist of expenditures incurred in the generation of the Group’s revenues, includes but not limited to salaries and welfare paid to physicians, nurses, purchase of medical consumables, depreciation and amortization, rental, and fees paid to third-party service providers.
Research and development costs	'
	Research and development costs
	Research and development expenses primarily consist of (i) salaries and benefits for research and development personnel, and (ii) office rental, general expenses and depreciation and amortization expenses associated with the research and development activities.  The Group’s research and development activities primarily consist of the research and development of its information technology platform and technical support for its customer services.
Income taxes	'
	Income taxes
	Current income taxes are provided for in accordance with the laws of the relevant tax authorities.  Deferred income taxes are recognized when temporary differences exist between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements.  Net operating loss carry forwards and credits are applied using enacted statutory tax rates applicable to future years.  Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more-likely-than-not that a portion of or all of the deferred tax assets will not be realized.  The components of the deferred tax assets and liabilities are individually classified as current and non-current based on their characteristics.
	The impact of an uncertain income tax position on the income tax return is recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant tax authority.  An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.  Interest and penalties on income taxes will be classified as a component of the provisions for income taxes.  The Group did not recognize any income tax due to uncertain tax position or incur any interest and penalties related to potential underpaid income tax expenses for the years ended March 31, 2012, 2013 or 2014, respectively.
Share-based compensation	'
	Share-based compensation
	Share-based payment transactions with employees, such as share options are measured based on the grant date fair value of the equity instrument.  The Group recognizes the compensation costs net of an estimated forfeiture rate using the graded vesting attribution method over the requisite service period of the award, which is generally the vesting period of the award.  The estimate of forfeitures will be adjusted over the requisite service period to the extent that actual forfeitures differ, or are expected to differ, from such estimates.  Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of share compensation expense to be recognized in future periods.
	Share awards issued to non-employees, such as advisors, are measured at fair value at the earlier of the commitment date or the date the service is completed and recognized over the period the service is provided.
Earnings (loss) per share	'
	Earnings (loss) per share
	Basic earnings (loss) per common share is computed by dividing net income (loss) attributable to common shareholders by the weighted average number of common shares outstanding during the period.
	The Group’s convertible redeemable preferred shares are participating securities as they participate in undistributed earnings on an as-if-converted basis.  Accordingly, the Group uses the two-class method whereby undistributed net income is allocated on a pro rata basis to the common shares and preferred shares to the extent that each class may share in income for the period; whereas the undistributed net loss for the period is allocated to common shares only because preferred shares are not contractually obligated to share the loss.
	Diluted earnings (loss) per common share reflect the potential dilution that could occur if securities were exercised or converted into common shares.  The Group had convertible redeemable preferred shares, and stock options, which could potentially dilute basic earnings per share in the future.  To calculate the number of shares for diluted income per share, the effect of the convertible redeemable preferred shares is computed using the as-if-converted method; the effect of the stock options is computed using the treasury stock method.
Foreign currency translation	'
	Foreign currency translation
	The functional and reporting currency of the Company is the United States dollar (“U.S. dollar”).  The financial records of the Group’s subsidiaries and VIE entities located in the PRC are maintained in their local currencies, the RMB, which are also the functional currencies of these entities.
	Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency at the rates of exchange ruling at the balance sheet date.  Transactions in currencies other than the functional currency during the year are converted into functional currency at the applicable rates of exchange prevailing when the transactions occurred.  Transaction gains and losses are recognized in the statement of operations.
	The Group’s entities with functional currency of RMB, translate their operating results and financial positions into the U.S. dollar, the Group’s reporting currency.  Assets and liabilities are translated using the exchange rates in effect on the balance sheet date.  Revenues, expenses, gains and losses are translated using the average rate for the year.  Translation adjustments are report as cumulative translation adjustments and are shown as a separate component of other comprehensive income.
Comprehensive income	'
	Comprehensive income
	Comprehensive income includes net income and cumulative foreign currency translation adjustments and is reported in the statement of shareholder’s equity (deficit).
Operating leases	'
	Operating leases
	Leases where the rewards and risks of ownership of assets primarily remain with the lessor are accounted for as operating leases.  Payments made under operating leases are charged to the consolidated statements of operations on a straight-line basis over the lease periods.
Recently issued accounting pronouncements adopted and not yet adopted	'
	Newly adopted accounting pronouncements
	In July 2012, the FASB has issued an authoritative pronouncement related to testing indefinite-lived intangible assets, other than goodwill, for impairment. Under the pronouncement, entities testing indefinite-lived intangible assets for impairment would have the option of performing a qualitative assessment before calculating the fair value of the asset. If an entity determines, on the basis of qualitative factors, that the indefinite-lived intangible asset is not more likely than not impaired, a quantitative fair value calculation would not be needed. The guidance is effective for annual and interim indefinite-lived intangible assets impairment tests performed for fiscal years beginning after September 15, 2012. Early adoption is permitted. The Group has adopted this guidance on April 1, 2013. The adoption of this guidance did not have a material effect on the Group’s consolidated financial statements.
	Recently issued accounting pronouncements not yet adopted
	In January 2014, the FASB issued a pronouncement which provides guidance on the accounting for service concession arrangements. This ASU specifies that an operating entity should not account for a service concession arrangement, within the scope of this ASU, as a lease in accordance with Topic 840, Leases. Service concession arrangements may become more prevalent in the United States as public-sector entities seek alternative ways to provide public services on a more efficient and cost-effective basis.
	An operating entity should refer to other Codification Topics as applicable to account for various aspects of a service concession arrangement. The amendments also specify that the infrastructure used in a service concession arrangement should not be recognized as property, plant, and equipment of the operating entity.
	The amendments in this ASU should be applied on a modified retrospective basis to service concession arrangements that exist at the beginning of an entity’s fiscal year of adoption. The modified retrospective approach requires the cumulative effect of applying this ASU to arrangements existing at the beginning of the period of adoption to be recognized as an adjustment to the opening retained earnings balance for the annual period of adoption. The amendments are effective for a public business entity for annual periods, and interim periods within those annual periods, beginning after December 15, 2014. The Group does not expect the adoption of this guidance will have a material effect on its consolidated financial statements.
	In April 2014, the FASB issued a new pronouncement which amends to change the criteria for reporting discontinued operations while enhancing disclosures in this area. It also addresses sources of confusion and inconsistent application related to financial reporting of discontinued operations guidance in U.S. GAAP.
	Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment.
	In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations.
	The new guidance also requires disclosure of the pre-tax income attributable to a disposal of a significant part of an organization that does not qualify for discontinued operations reporting. This disclosure will provide users with information about the ongoing trends in a reporting organization’s results from continuing operations. The amendments in the ASU are effective in the first quarter of 2015 for public organizations with calendar year ends. Early adoption is permitted. The Group does not expect the adoption of this guidance will have a material effect on its consolidated financial statements.
	In May 2014, the FASB issued a new pronouncement which affects any entity using U.S. GAAP that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). This ASU will supersede the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance. This ASU also supersedes some cost guidance included in Subtopic 605-35, Revenue Recognition—Construction-Type and Production-Type Contracts. In addition, the existing requirements for the recognition of a gain or loss on the transfer of nonfinancial assets that are not in a contract with a customer (e.g., assets within the scope of Topic 360, Property, Plant, and Equipment, and intangible assets within the scope of Topic 350, Intangibles—Goodwill and Other) are amended to be consistent with the guidance on recognition and measurement (including the constraint on revenue) in this ASU.
	The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps:
	·         Step 1: Identify the contract(s) with a customer.
	·         Step 2: Identify the performance obligations in the contract.
	·         Step 3: Determine the transaction price.
	·         Step 4: Allocate the transaction price to the performance obligations in the contract.
	·         Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.
	For a public entity, the amendments in this ASU are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted.
	An entity should apply the amendments in this ASU using one of the following two methods:
	1. Retrospectively to each prior reporting period presented and the entity may elect any of the following practical expedients:
	·         For completed contracts, an entity need not restate contracts that begin and end within the same annual reporting period.
	·         For completed contracts that have variable consideration, an entity may use the transaction price at the date the contract was completed rather than estimating variable consideration amounts in the comparative reporting periods.
	·         For all reporting periods presented before the date of initial application, an entity need not disclose the amount of the transaction price allocated to remaining performance obligations and an explanation of when the entity expects to recognize that amount as revenue.
	2. Retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application. If an entity elects this transition method it also should provide the additional disclosures in reporting periods that include the date of initial application of:
	·         The amount by which each financial statement line item is affected in the current reporting period by the application of this ASU as compared to the guidance that was in effect before the change.
	·         An explanation of the reasons for significant changes.
	The Group is in processing to adopt this pronouncement.
	In June 2014, the FASB issued a new pronouncement which requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Topic 718, Compensation — Stock Compensation, as it relates to awards with performance conditions that affect vesting to account for such awards. The performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved.
	The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted.
	Entities may apply the amendments in this ASU either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. If retrospective transition is adopted, the cumulative effect of applying this ASU as of the beginning of the earliest annual period presented in the financial statements should be recognized as an adjustment to the opening retained earnings balance at that date. In addition, if retrospective transition is adopted, an entity may use hindsight in measuring and recognizing the compensation cost. The Group does not expect the adoption of this guidance will have a material effect on its consolidated financial statements.

ORGANIZATION_AND_PRINCIPAL_ACT1

ORGANIZATION AND PRINCIPAL ACTIVITIES (Table)	12 Months Ended
	Mar. 31, 2014
ORGANIZATION AND PRINCIPAL ACTIVITIES	'
Schedule of details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries	'
						Percentage of
		Later date of				beneficial interest
		incorporation/		Place of		by iKang
	Names	acquisition		incorporation		Healthcare Group, Inc.		Principal activities
	Subsidiaries:
	iKang Guobin Healthcare Group, Inc.(“iKang Guobin”)	24-Dec-03		BVI		100	%	Holding company
	ShanghaiMed iKang, Inc. (“Beijing iKang”)	27-Feb-04		PRC		100	%	Sales of healthcare service
	Shanghai iKang Co., Ltd. (“Shanghai iKang”)	27-Dec-04		PRC		100	%	Sales of healthcare service
	iKang Zhejiang, Inc. (“iKang Zhejiang BVI”)	5-Apr-06		BVI		73	%	Holding company
	iKang HealthManagement (Zhejiang) Co., Ltd. (“Zhejiang iKang”)	11-Jul-06		PRC		73	%	Sales of healthcare service
	Bayley & Jackson (China) Medical Services Limited (“Bayley & Jackson (Hong Kong)”)	10-Oct-06		Hong Kong		100	%	Holding company
	Beijing Bayley & Jackson Clinic Co., Ltd. (“iKang Beijing Ritan”)	10-Oct-06		PRC		100	%	Medical examination & clinical
	Yuanhua Healthcare Limited (HongKong) (“Yuanhua HK”)	31-Jul-13		BVI		100	%	Holding company
	MediFast (Hong Kong) Limited (“MediFast”)	16-Mar-95		Hong Kong		80	%	Medical examination & clinical
	Yuanhua Medical Consultancy Services (Shanghai) Co., Ltd. (“Yuanhua WFOE”)	31-Jul-13		PRC		100	%	Sales of healthcare service
	VIEs:
	Shanghai iKang Guobin Holding Co., Ltd. (“iKang Holding”)	27-Apr-07		PRC		100	%	Holding company
	Hangzhou iKang Guobin Clinic, Co., Ltd. (“iKang Hangzhou Xixi”)	26-Sep-10		PRC		73	%	Medical examination
	Shanghai Yuanhua Information Technology Co., Ltd. (“Yuanhua Information”)	31-Jul-13		PRC		100	%	Holding company
	Jiandatong Health Technology (Beijing) Co., Ltd. (“Beijing Jiandatong”)	1-Apr-13		PRC		80	%	Sales of healthcare service
	VIEs’ subsidiaries:
	iKang Guobin Healthcare Management Group Co., Ltd. (“iKang Online”)	13-Sep-04		PRC		100	%	Sales of healthcare service
	Beijing iKang Guobin Health Technology Co., Ltd. (“iKang Technology”)	3-Feb-05		PRC		100	%	Sales of healthcare service
	Shenzhen iKang Co., Ltd. (“Shenzhen iKang”)	12-Jul-06		PRC		100	%	Sales of healthcare service
	Shanghai Yalong Daoyi Services Co., Ltd. (“Yalong Daoyi”)	20-Dec-06		PRC		100	%	Sales of healthcare service
	Guangzhou iKang Guobin Health Checkup Co., Ltd. (“iKang Guangzhou Huanshi East/Tianhe”)	27-Apr-07		PRC		100	%	Medical examination
	Shanghai Guobin Medical Center Co., Ltd. (“iKang Shanghai Xikang Road”)	27-Apr-07		PRC		100	%	Medical examination & clinical
	Shanghai Wangzu Guobin Medical Center Co., Ltd. (“iKang Shanghai Gubei”)	27-Apr-07		PRC		70	%	Medical examination
	Shanghai iKang Guobin Mingmen Clinic Co., Ltd. (“iKang Shanghai Pudong Avenue”)	27-Apr-07		PRC		100	%	Medical examination
	Shenzhen iKang Guobin Hospital Management, Inc. (“Shenzhen Hospital Management”)	10-Sep-07		PRC		66	%	Holding company
	Shenzhen Puji Clinic Co., Inc. (“iKang Shenzhen Nanshan”)	10-Sep-07		PRC		66	%	Medical examination
	Beijing iKang Guobin Lidu Clinic, Co., Ltd. (“iKang Beijing Lidu”)	3-Dec-07		PRC		100	%	Medical examination
	Chengdu iKang Guobin Blue Coast Health Management Co., Ltd. (“Chengdu Blue Coast”)	7-Dec-07		PRC		100	%	Relaxation and recreation
	Nanjing Joycome Clinic, Co., Ltd (“iKang Nanjing Xinjiekou”)	10-Jan-08		PRC		100	%	Medical examination
	Shenzhen iKang Guobin Clinic Co., Ltd. (“iKang Shenzhen Luohu”)	25-Mar-08		PRC		100	%	Medical examination
						Percentage of
		Later date of				beneficial interest
		incorporation/		Place of		by iKang Guobin
	Names	acquisition		incorporation		Healthcare Group, Inc.		Principal activities
	VIEs’ subsidiaries:
	Beijing iKang Guobin Jianwai Clinic, Co., Ltd. (“iKang Beijing Jianguomen”)	9-Sep-08		PRC		100	%	Medical examination
	Beijing iKang Guobin Zhongguan Clinic, Co., Ltd. (“iKang Beijing Zhongguancun”)	19-Sep-08		PRC		100	%	Medical examination
	Beijing iKang Guobin Zhengqingyuan Clinic, Co., Ltd. (“iKang Beijing Kunming Lake”)	1-Dec-08		PRC		100	%	Medical examination
	Beijing iKang Guobin Jiuxianqiao Clinic, Co., Ltd. (“iKang Beijing Yansha East”)	1-Dec-08		PRC		100	%	Medical examination
	Shanghai iKang Guobin Renren Clinic, Co., Ltd. (“iKang Shanghai Yangpu”)	9-Dec-08		PRC		100	%	Medical examination
	Chengdu iKang Guobin Health Examination Hospital Co., Ltd. (“iKang Chengdu Waishuangnan”)	15-Jan-09		PRC		100	%	Medical examination
	Shanghai iKang Guobin Blue Cross Clinic, Co., Ltd. (“iKang Shanghai Lujiazui”)	28-Jan-10		PRC		100	%	Medical examination
	Shanghai Wenzhong Clinic, Co., Ltd. (“Shanghai Wenzhong”)	12-Feb-10		PRC		71	%	Medical examination
	Beijing iKang Guobin Clinic, Co., Ltd. (“iKang Beijing Xuanwumen”)	5-Aug-10		PRC		100	%	Medical examination
	Nanjing iKang Guobin Clinic Co., Ltd. (“iKang Nanjing Gulou”)	19-Jan-11		PRC		100	%	Medical examination
	Shenzhen Xinglin Clinic Co., Ltd. (“iKang Shenzhen Futian”)	25-Jan-11		PRC		100	%	Medical examination
	Fujian iKang Guobin Health Management Co., Ltd. (“Fujian iKang”)	1-Apr-11		PRC		71	%	Sales of healthcare service
	Fuzhou iKang Guobin General Clinic, Co., Ltd. (“iKang Fuzhou Gulou”)	14-Nov-11		PRC		71	%	Medical examination
	Beijing iKang Guobin Xinei Clinic, Co., Ltd. (“iKang Beijing Xinei”)	30-Jan-12		PRC		100	%	Medical examination
	Shanghai iKang Guobin Fukang Clinic, Co., Ltd. (“Yan’an West Road”)	18-Jan-12		PRC		100	%	Medical examination
	Shanghai Zhonghuan Yipin Clinic, Co., Ltd. (“iKang Shanghai Zhonghuan”)	21-Jan-12		PRC		100	%	Medical examination
	Shanghai Yipin Clinic, Co., Ltd. (“iKang Shanghai Jing’an”)	21-Jan-12		PRC		100	%	Medical examination
	Shanghai iKang Guobin Waizhitan Clinic, Co., Ltd. (“iKang Shanghai Yan’an East Road”)	29-May-12		PRC		100	%	Medical examination
	Shanghai Jianwei Clinic, Co., Ltd. (“iKang Shanghai Jianwei”)	17-Aug-12		PRC		100	%	Medical examination
	Hangzhou iKang Guobin Wenhui Clinic, Co., Ltd. (“iKang Hangzhou Wenhui”)	3-Sep-12		PRC		100	%	Medical examination
	Tianjin Heping Aibin Clinic, Co., Ltd. (“iKang Tianjin Heping”)	15-Oct-12		PRC		100	%	Medical examination
	Suzhou Aibin Clinic, Co., Ltd. (“iKang Suzhou”)	13-Nov-12		PRC		100	%	Medical examination
	Changchun iKang Guobin Jiachang General Clinic, Co., Ltd. (“iKang Changchun”)	5-Nov-12		PRC		100	%	Medical examination
Chengdu Jinjiang iKang Guobin Hongzhaobi Health Examination General Clinic, Co., Ltd. (“iKang Chengdu Jinjiang”)	21-Dec-12		PRC		100	%	Medical examination
Chongqing Aibin Clinic, Co., Ltd. (“iKang Chongqing”)	18-Dec-12		PRC		100	%	Medical examination
Guangzhou Wokang Clinic (“iKang Guangzhou Wokang”)	3-Dec-12		PRC		100	%	Medical examination
Shenzhen Kefa Clinic (“Shenzhen Kefa”)	26-Mar-13		PRC		100	%	Medical examination
Shanghai iKang Jianwei Health Management Co., Ltd (“Shanghai Jianwei Management”)	6-Sep-13		PRC		65	%	Sales of healthcare service
Shanghai Yuanhua Clinic Co., Ltd. (“Yuanhua Clinic”)	31-Jul-13		PRC		100	%	Medical examination
Nanjing Aoyang TCM Clinic Co., Ltd., (“Nanjing Aoyang Clinic”)	1-Sep-13		PRC		100	%	Medical examination
Nanjing Aoyang Shunkang Health Information Consultancy Co., Ltd. (“Nanjing Aoyang Shunkang”)	1-Sep-13		PRC		100	%	Sales of healthcare service
Jiangyin iKang Guobin Clinic Co., Ltd. (“iKang Jiangyin”)	16-Dec-13		PRC		100	%	Medical examination
Zhejiang Huzhou Ailikang Investment Management Co., Ltd. (“Zhejiang Ailikang”)	31-Dec-13		PRC		100	%	Sales of healthcare service
Hangzhou Aibo Huagang Clinic Co. Ltd. (“Hangzhou Aibo”)	31-Dec-13		PRC		100	%	Medical examination
Beijing iKang Jun’an Clinic Co., Ltd. (“iKang Beijing Jun’an”)	28-Nov-13		PRC		100	%	Medical examination
Beijing iKang Guobin Yayun Clinic Co., Ltd. (“iKang Beijing Yayun”)	5-Dec-13		PRC		100	%	Medical examination
Changzhou iKang Guobin Clinic Co., Ltd. (“iKang Changzhou”)	14-Mar-14		PRC		62.5	%	Medical examination
Schedule of financial statements amounts and balances of the VIE entities, included in the accompanying consolidated financial statements (after inter-company elimination)	'
		As of March 31,
		2013			2014
	Cash and cash equivalents	$	13,308		$	11,326
	Account receivable and other current assets	34,789			54,508
	Total current assets	48,097			65,834
	Property and equipment, net	31,511			60,325
	Acquired intangible assets, net	4,475			14,070
	Other noncurrent assets	7,069			38,466
	Total non-current assets	43,055			112,861
	Total assets	91,152			178,695
	Deferred revenues	19,183			22,234
	Account payable and other current liabilities	38,264			62,837
	Total current liabilities	57,447			85,071
	Total non-current liabilities	608			4,857
	Total liabilities	$	58,055		$	89,928
		For the year ended March 31,
		2012			2013			2014
	Net revenues	$	80,563		$	113,506		$	170,226
	Net income	$	9,772		$	11,728		$	20,948
		For the year ended March 31,
		2012			2013			2014
	Net cash provided by operating activities	$	13,310		$	14,978		$	18,327
	Net cash used in investing activities	(12,867		)	(15,944		)	(29,304		)
	Net cash (used in)/ provided by financing activities	$	(2,043	)	$	3,824		$	8,995

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Mar. 31, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
Schedule of estimated useful lives of property and equipment	'
	Computer equipment and application software	5 years
	Furniture and fixture	5 years
	Medical equipment	10 years
	Motor vehicles	5 years
	Leasehold improvement	Shorter of useful life of the asset or the lease term
Schedule of estimated average useful lives of finite-lived intangible assets	'
		Weighted average (years)	range (years)
	Customer relationship	6.8	2.1~10.0
	Non-compete agreement	3	2.0~3.0
	Contract backlog	0.7	0.4~0.9
	Operating license	3.2	0.3~4.8
	Favorable lease contract	8.8	5.1~9.8

ACQUISITION_Tables

ACQUISITION (Tables)	12 Months Ended
	Mar. 31, 2014
iKang Shanghai Jianwei	'
Acquisition	'
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	'
					Estimated
					useful life
	Net tangible assets:
	Current assets	$	39
	Non-current assets	463
	Deferred tax assets	274
	Total	776
	Intangible assets acquired:
	Customer relationship	71			5.3 years
	Operating license	32			1.4 years
	Goodwill	396
	Deferred tax liability	(26		)
	Total	473
	Total consideration	$	1,249
iKang Changchun	'
Acquisition	'
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	'
					Estimated
					useful life
	Net tangible assets:
	Current assets	$	5
	Non-current assets	307
	Total	312
	Intangible assets acquired:
	Customer relationship	165			6.1 years
	Favorable lease contract	21			5.1 years
	Operating license	48			2.5 years
	Goodwill	427
	Deferred tax liability	(58		)
	Total	603
	Total consideration	$	915
iKang Guangzhou Wokang	'
Acquisition	'
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	'
					Estimated
					useful life
	Net tangible assets:
	Current assets	$	117
	Non-current assets	550
	Total	667
	Net tangible liabilities:
	Current liabilities	$	(44	)
	Total	(44		)
	Intangible assets acquired:
	Customer relationship	175			6.0 years
	Favorable lease contract	1,074			9.8 years
	Operating license	48			3.1 years
	Goodwill	1,390
	Deferred tax liability	(324		)
	Total	2,363
	Total consideration	$	2,986
Yuanhua	'
Acquisition	'
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	'
					Estimated
					useful life
	Net tangible assets:
	Current assets	$	8,059
	Non-current assets	1,150
	Deferred tax assets	371
	Total	9,580
	Net tangible liabilities:
	Current liabilities	$	(6,060	)
	Total	(6,060		)
	Intangible assets acquired:
	Trade name	4,830
	Customer relationship	6,307			5.0-7.4 years
	Operating license	49			2.3 years
	Contract backlog	49			0.9 years
	Goodwill	15,654
	Deferred tax liability	(2,809		)
	Total	24,080
	Total consideration	$	27,600
Nanjing Aoyang	'
Acquisition	'
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	'
					Estimated
					useful life
	Net tangible assets:
	Current assets	$	15
	Non-current assets	3,314
	Total	3,329
	Intangible assets acquired:
	Operating license	33			1.3 years
	Goodwill	731
	Deferred tax liability	(8		)
	Total	756
	Total consideration	$	4,085
Zhejiang Ailikang	'
Acquisition	'
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	'
					Estimated
					useful life
	Net tangible assets:
	Current assets	$	2
	Non-current assets	576
	Total	578
	Net tangible liabilities:
	Current liabilities	$	(818	)
	Total	(818		)
	Intangible assets acquired:
	Favorable lease contract	283			5.3 years
	Operating license	83			2.7 years
	Goodwill	1,628
	Deferred tax liability	(91		)
	Total	1,903
	Total consideration	$	1,663
MediFast	'
Acquisition	'
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	'
					Estimated
					useful life
	Net tangible assets:
	Current assets	$	1,944
	Non-current assets	927
	Total	2,871
	Net tangible liabilities:
	Current liabilities	$	(1,431	)
	Total	(1,431		)
	Intangible assets acquired:
	Customer relationship	2,825			5.0-10.0 years
	Non-compete agreement	451			3.0 years
	Trade-name	374			Indefinite
	Goodwill	5,332
	Deferred tax liability	(619		)
	Total	8,363
	Non-controlling interest	$	(1,690	)
	Total consideration	$	8,113
iKang Shanghai Jianwei, iKang Changchun and iKang Guangzhou Wokang	'
Acquisition	'
Summary of the unaudited pro forma information	'
		Year ended March 31,
		2012			2013
		(Unaudited)			(Unaudited)
	Pro forma net revenue	$	98,177		$	137,269
	Pro forma net income attributable to common shareholders of iKang Healthcare Group, Inc.	$	8,657		$	12,334
Yuanhua, Nanjing Aoyang, Shanghai Jianwei Management, Zhejiang Ailikang and MediFast	'
Acquisition	'
Summary of the unaudited pro forma information	'
		Year ended March 31,
		2013			2014
		(Unaudited)			(Unaudited)
	Pro forma net revenue	$	161,447		$	215,104
	Pro forma net income attributable to common shareholders of iKang Healthcare Group, Inc.	$	12,818		$	21,110

ACCOUNTS_RECEIVABLE_NET_Tables

ACCOUNTS RECEIVABLE, NET (Tables)	12 Months Ended
	Mar. 31, 2014
ACCOUNTS RECEIVABLE, NET	'
Schedule of accounts receivable	'
		As of March 31,
		2013			2014
	Accounts receivable	$	33,461		$	41,949
	Less: allowance for doubtful accounts	3,272			4,330
	Accounts receivable, net	$	30,189		$	37,619
Schedule of movement of allowance for doubtful accounts	'
		As of March 31,
		2013			2014
	Balance at beginning of year	$	1,561		$	3,272
	Charge to expenses	1,800			1,100
	Write off	(132		)	(97		)
	Exchange difference	43			55
	Balance at end of year	$	3,272		$	4,330

INVENTORIES_Tables

INVENTORIES (Tables)	12 Months Ended
	Mar. 31, 2014
INVENTORIES	'
Schedule of inventories	'
		As of March 31,
		2013		2014
	Medical consumable	$	1,162	$	1,693

PREPAID_EXPENSES_AND_OTHER_CUR1

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)	12 Months Ended
	Mar. 31, 2014
PREPAID EXPENSES AND OTHER CURRENT ASSETS	'
Schedule of prepaid expenses and other current assets	'
		As of March 31,
		2013		2014
	Advance to suppliers(1)	$	2,191	$	9,022
	Deferred IPO cost	—		3,482
	Prepaid rental expense	1,511		2,226
	Staff advance	939		2,141
	Prepaid acquisition fees(2)	—		1,705
	Prepaid expenses(3)	1,269		792
	Fair value of the forward contracts(4)	—		57
	Other receivable	706		587
		$	6,616	$	20,012
	(1)                 Advance to suppliers represents advance payment to suppliers to purchase medical equipment and consumables.
	(2)                 Prepaid acquisition fees represent advance payments for acquisitions.
	(3)                 Prepaid expenses mainly consist of amounts paid for professional fee and advertisement fees for which relating services have not been provided.
	(4)                 The Bayley & Jackson (Hong Kong) entered into two foreign currency exchange forward contracts with Bank of East Asia (“BEA”) in June and July 2013, respectively. Pursuant to those contracts, Bayley & Jackson (Hong Kong) bought two buy RMB20,000, sell USD foreign exchange forward contracts using the quoted exchange rates at 6.2825 and 6.2620, respectively. The Group carries the forward contracts at fair value in its balance sheet and the changes in the exchange forward contract fair value during the each period end are recorded in the statement of the operations. The Group carries the forward contract as asset at fair value at March 31, 2014. The Group measures the fair value of the forward contract on a recurring basis based on a level 2 measure, i.e. the Group uses the market exchange rate to assess the fair value of the forward contract and recognizes the changes in fair value attributable to the difference between the market exchange rate and contractual exchange rate in change in fair value of the forward contracts. For the year ended March 31, 2014, the Group recorded a gain of $57 in change in fair value of the forward contracts. The forward contracts was settled in June 2014.

PROPERTY_AND_EQUIPMENT_NET_Tab

PROPERTY AND EQUIPMENT, NET (Tables)	12 Months Ended
	Mar. 31, 2014
PROPERTY AND EQUIPMENT, NET	'
Schedule of property and equipment, net	'
		As of March 31,
		2013		2014
	Medical equipment	$	30,805	$	46,275
	Leasehold improvements	22,310		33,807
	Computer equipment and application software	5,569		7,815
	Furniture and fixtures	3,718		5,329
	Motor vehicles	440		732
	Construction in progress	385		8,560
	Less: accumulated depreciation and amortization	30,655		38,874
		$	32,572	$	63,644

ACQUIRED_INTANGIBLE_ASSETS_NET1

ACQUIRED INTANGIBLE ASSETS, NET (Tables)	12 Months Ended
	Mar. 31, 2014
ACQUIRED INTANGIBLE ASSETS, NET	'
Schedule of gross carrying amount, accumulated amortization and net carrying amount of the intangible assets	'
		As of March 31,
		2013		2014
	Acquired intangible assets not subject to amortization
	Trade-name	$	2,078	$	7,212
	Acquired intangible assets subject to amortization
	Customer relationship	3,265		12,303
	Operating license	2,002		2,161
	Favorable lease contract	1,098		1,372
	Contract backlog	39		88
	Non-compete agreement	2		454
	Less: accumulated amortization
	Customer relationship	2,484		4,059
	Operating license	1,024		1,289
	Favorable lease contract	29		169
	Contract backlog	39		80
	Non-compete agreement	1		37
	Less: impairment	427		426
	Intangible assets, net	$	4,480	$	17,530

GOODWILL_Tables

GOODWILL (Tables)	12 Months Ended
	Mar. 31, 2014
GOODWILL.	'
Schedule of changes in carrying amounts of goodwill	'
		As of March 31,
		2013		2014
	Gross amount:
	Beginning balance	$	41,103	$	43,503
	Addition for the year by acquisition of
	iKang Shanghai Jianwei	396		—
	iKang Changchun	427		—
	iKang Guangzhou Wokang	1,390		—
	Nanjing Aoyang	—		731
	Yuanhua	—		15,654
	Shanghai Jianwei Management	—		572
	Zhejiang Ailikang	—		1,628
	MediFast	—		5,332
	Exchange difference	187		(484		)
	Ending balance	43,503		66,936
	Accumulated impairment loss:
	Beginning balance	25,665		25,712
	Exchange difference	47		(188		)
	Ending balance	$	25,712	$	25,524
	Goodwill	$	17,791	$	41,412

ACCRUED_EXPENSES_AND_OTHER_CUR1

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)	12 Months Ended
	Mar. 31, 2014
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	'
Schedule of accrued expenses and other current liabilities	'
		As of March 31,
		2013		2014
	Accrued rental expense	$	2,554	$	4,944
	Accrued payroll and welfare	2,434		4,231
	Acquisitions consideration payable (1)	537		3,628
	Accrued social insurance	2,248		2,368
	Accrued IPO expenses	—		2,268
	Other taxes payable	1,610		2,254
	Accrued outsourcing cost	1,121		1,909
	Accrued professional fees (2)	2,738		55
	Interest expense payable	169		27
	Other payable to shareholders (3)	2,256		—
	Other payables	1,524		2,591
		$	17,191	$	24,275
	(1)     Acquisitions consideration payable consists of remaining payables to sellers of the acquired entities. As of March 31, 2013, the acquisitions consideration payable consisted payable for the acquisition of iKang Shanghai Zhonghuan and iKang Shanghai Jing’an, iKang Shanghai Jianwei, and iKang Changchun amounted $137, $322 and $78, respectively. As of March 31, 2014, the acquisitions consideration payable consisted payable for the acquisition of iKang Shanghai Jianwei, Nanjing Aoyang, Yuanhua, Zhejiang Ailikang, MediFast and Shanghai Huajian Clinic Ltd. amounted $129, $402, $540, $62, $839 and $1,656, respectively.
	(2)     As of March 31, 2013, the balance represents the professional fees for the issuance of Series F convertible redeemable participating preferred shares (“Series F shares”), which was paid in June 2013.
	(3)     In March 2013, pursuant to the share purchase agreement and various agreements among the Company, some existing shareholders and the Series F shares investors, certain existing shareholders sold some of their shares to some series F shares investors. Part of the consideration amounted $2,256 was received by the Company on behalf of the selling shareholders, which was paid back to those selling shareholders in May 2013.

BANK_BORROWINGS_Tables

BANK BORROWINGS (Tables)	12 Months Ended
	Mar. 31, 2014
BANK BORROWINGS	'
Schedule of bank borrowings	'
		As of March 31,
		2013		2014
	Short term borrowings(1)	$	5,482	$	18,201
	Long term borrowings(2)	—		1,865
		$	5,482	$	20,066
	(1)                On June 25, June 28, July 10, September 17 and December 19, 2013, iKang Holding borrowed five one-year loans of $1,627, $1,304, $1,630, $1,606 and $4,941 respectively from BEA, to purchase the property and equipment capital and meet temporary working capital needs of the Group. The annual interest rates are the benchmark interest rate announced by the People’s Bank of China plus 10% of the benchmark interest rate. The loans were guaranteed by Beijing iKang and collateralized by restricted cash. As of March 31, 2013 and 2014, the outstanding short term borrowings were nil and $10,910, respectively.
	In September 2013, iKang Online signed a ten-year loan framework agreement with an amount no more than $2,451 with BEA, to repay the loans from China Merchants Bank which was due in September 2013. On September 17, 2013, iKang Online borrowed a one-year loan of $2,410 according to the framework agreement. The annual interest rate was equal to the benchmark interest rate announced by the People’s Bank of China plus 10% of the benchmark interest rate. The loan was guaranteed by Beijing iKang and collateralized by restricted cash. As of March 31, 2013 and 2014, the outstanding short-term borrowings were nil and $2,372, respectively.
	In March 2014, seven clinics in Beijing signed seven one-year loan framework agreements with an amount no more than $8,896 with Bank of Beijing, to meet temporary working capital needs of the Group. Clinics borrowed total $4,919 in March, 2014. The annual interest rate is the benchmark interest rate announced by the People’s Bank of China plus 15% of the benchmark interest rate. The loans were guaranteed by iKang Online and iKang Holdings. As of March 31, 2013 and 2014, the outstanding short term borrowing were nil and $4,919, respectively.
	(2)                In June 2013, iKang Holding signed a ten-year loan framework agreement with total loan amounts no more than $3,268 with BEA, to meet the Group’s needs to purchase the property and equipment . On June 28, 2013, iKang Holding borrowed a two-year loan of $1,897 according to the framework agreement. The annual interest rate is the benchmark interest rate announced by the People’s Bank of China plus 10% of the benchmark interest rate. The loan was guaranteed by Beijing iKang and collateralized by restricted cash. As of March 31, 2013 and 2014, the outstanding long term borrowings were nil and $1,865, respectively.

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Mar. 31, 2014
INCOME TAXES	'
Schedule of current and deferred portions of income tax expenses included in the consolidated statements of operations, which were all attributable to the Group's PRC subsidiaries and VIE entities	'
		Years ended March 31,
		2012			2013			2014
	Current tax expense	$	3,987		$	7,311		$	12,048
	Deferred tax benefits	(48		)	(1,177		)	(1,947		)
	Income tax expenses	$	3,939		$	6,134		$	10,101
Schedule of principal components of the deferred income tax assets and liabilities	'
		As of March 31,
		2013			2014
	Current deferred tax assets:
	Accrued expenses	$	1,410		$	2,185
	Deferred revenue	158			125
	Accrued payroll	656			1,056
	Bad debt provision	791			995
	Less: Valuation allowance	(141		)	(370		)
	Current deferred tax assets	$	2,874		$	3,991
	Non-current deferred tax assets:
	Depreciation and amortization	$	358		212
	Due to impairment of long-lived assets	102			88
	Net operating tax loss carry-forwards	1,724			3,748
	Less: Valuation allowance	(728		)	(2,041		)
	Non-current deferred tax assets	$	1,456		$	2,007
		As of March 31,
		2013			2014
	Non-current deferred tax liabilities:
	Intangible assets	$	499		$	3,478
	Non-current deferred tax liabilities	$	499		$	3,478
Schedule of reconciliation between the expense (benefit) of income taxes computed by applying the PRC tax rate to income (loss) before income taxes and the actual provision for income taxes	'
		For the year ended March 31,
		2012			2013			2014
	Net income before provision	$	14,331		$	18,583		$	32,183
	PRC statutory tax rate	25		%	25		%	25		%
	Income tax at statutory tax rate	$	3,583		$	4,646		$	8,046
	Change in valuation allowance	(16		)	126			704
	Expenses not deductible for tax purposes	258			631			440
	Effect of income tax rate difference for entities under individual income tax rate of 35%	67			129			390
	Loss utilized for entities under individual income tax rate of 35%	(235		)	(153		)	(99		)
	Effect of income tax rate differences in other jurisdictions	282			755			620
	Income tax expense	$	3,939		$	6,134		$	10,101

NET_INCOME_LOSS_PER_SHARE_Tabl

NET INCOME (LOSS) PER SHARE (Tables)	12 Months Ended
	Mar. 31, 2014
NET INCOME (LOSS) PER SHARE	'
Schedule of calculation of net income (loss) per share	'
		For the year ended March 31,
		2012		2013			2014
	Net income attributable to iKang Healthcare Group, Inc.	$	9,702	$	12,111		$	21,607
	Deemed dividend to Series A shares	—		5,112			—
	Deemed dividend to Series B shares	—		5,204			—
	Deemed dividend to Series C shares	—		4,366			—
	Deemed dividend to Series D shares	—		14,875			1,945
	Deemed dividend to Series E shares	2,312		20,308			—
	Deemed dividend to Series F shares	—		34,441			18,491
	Undistributed earnings allocated to Series A shares	150		150			118
	Undistributed earnings allocated to Series B shares	200		200			130
	Undistributed earnings allocated to Series C shares	265		265			231
	Undistributed earnings allocated to Series D shares	831		831			789
	Undistributed earnings allocated to Series E shares	1,324		1,324			1,323
	Undistributed earnings allocated to Series F shares	—		48			4,719
	Net (loss) income attributed to common and preferred shareholders for computing net income per common share- basic and diluted (1)	4,620		(75,013		)	(6,139		)
	Numerator:
	Series A shares-
	Deemed dividend	—		5,112			—
	Undistributed earnings allocation	150		150			118
	Net income attribution	299		—			—
		449		5,262			118
	Series B shares-
	Deemed dividend	—		5,204			—
	Undistributed earnings allocation	200		200			130
	Net income attribution	228		—			—
		428		5,404			130
	Series C shares-
	Deemed dividend	—		4,366			—
	Undistributed earnings allocation	265		265			231
	Net income attribution	445		—			—
		710		4,631			231
		For the year ended March 31,
		2012		2013			2014
	Series D shares-
	Deemed dividend	—		14,875			1,945
	Undistributed earnings allocation	831		831			789
	Net income attribution	1,309		—			—
		2,140		15,706			2,734
	Series E shares-
	Deemed dividend	2,312		20,308			—
	Undistributed earnings allocation	1,324		1,324			1,323
	Net income attribution	921		—			—
		4,557		21,632			1,323
	Series F shares-
	Deemed dividend	—		34,441			18,491
	Undistributed earnings allocation	—		48			4,719
	Net income attribution	—		—			—
		—		34,489			23,210
	Net (loss) income attributed to common shareholders for computing net income per common share- basic and diluted(1)	1,418		(75,013		)	(6,139		)
	Denominator:
	Weighted average common shares outstanding used in computing diluted net income per common share-basic(2)	6,599,009		6,683,678			6,340,005
	Weighted average shares outstanding used in computing net income per common shares-diluted (2)	6,768,074		6,683,678			6,340,005
	Weighted average shares used in computing basic net income per shares
	Series A shares	1,391,044		1,386,984			1,094,668
	Series B shares	1,059,735		1,054,620			686,368
	Series C shares	2,071,140		2,069,410			1,944,854
	Series D shares	6,091,920		6,088,557			5,717,326
	Series E shares	4,289,457		4,289,457			4,289,457
	Series F shares			63,763			6,075,702
	Net (loss) income per common share attributable to iKang Healthcare Group, Inc.-basic	$	0.22	$	(11.22	)	$	(0.97	)
	Net (loss) income per common share attributable to iKang Healthcare Group, Inc.-diluted	$	0.21	$	(11.22	)	$	(0.97	)
	Net income per Series A shares	$	0.32	$	3.79		$	0.11
Net income per Series B shares	$	0.4	$	5.13		$	0.19
Net income per Series C shares	$	0.34	$	2.24		$	0.12
Net income per Series D shares	$	0.35	$	2.58		$	0.48
Net income per Series E shares	$	1.06	$	5.04		$	0.31
Net income per Series F shares	$	—	$	540.89		$	3.82
Notes:
(1)     The Class A and Class B common shares enjoy the same dividend participating right, therefore earnings per share of each class was not separately presented.
(2)     The calculation of the weighted average number of common shares for the purpose of diluted net income (loss) per share has considered the effect of certain potentially dilutive securities.

SHAREBASED_COMPENSATION_Tables

SHARE-BASED COMPENSATION (Tables)	12 Months Ended
	Mar. 31, 2014
SHARE-BASED COMPENSATION.	'
Summary of information regarding options granted	'
		For the years ended March 31,
		2012								2013								2014
				Weighted			Weighted					Weighted			Weighted					Weighted		Weighted
				average			average					average			average					average		average
				exercise			fair value					exercise			fair value					exercise		fair value
		Number of		price per			per option			Number of		price per			per option			Number of		price per		per option
		options		option			at grant date			options		option			at grant date			options		option		at grant date
	Outstanding on April 1 of year	497,855		$	2.34		$	3.25		434,698		$	2.02		$	3.94		1,284,698		$	4.13	$	6.08
	Granted	61,843		1.67			10.88			850,000		5.21			7.17			629,000		5.51		15.61
	Exercised	(75,000	)	1.8			1.59			—		—			—			—		—		—
	Forfeited	(50,000	)	5.13			9.2			—		—			—			(25,000	)	6		7.13
	Outstanding on March 31 year	434,698		$	2.02		$	3.94		1,284,698		$	4.13		$	6.08		1,888,698		$	4.56	$	9.24
Summary of information with respect to share options outstanding	'
		Option outstanding									Option exercisable
				Weighted	Weighted			Aggregate					Weighted			Aggregate
				average	average			intrinsic					average			intrinsic
				remaining	Exercise			values as of					Exercise			values as of
		Number		contractual	price per			March 31,			Number		price per			March 31,
	Range of exercise price	outstanding		life in years	option			2014			exercisable		option			2014
	$ 0.01	221,843		1.13	$	0.01		$	6,063		—		$	—		$	—
	$ 1.00-$2.00	62,855		2.94	$	1.68		1,613			—		$	—		—
	$ 5.13	1,276,300		8.88	$	5.13		28,348			390,000		$	5.13		8,662
	$ 6.00	327,700		9.48	$	6		6,993			—		$	—		—
		1,888,698						$	43,017		390,000					$	8,662
Schedule of assumptions used on the grant date to estimate fair value of each option granted using the binomial tree pricing model for grants during the applicable periods	'
		Risk-free interest
		rate of return		Contractual term	Volatility		Dividend yield		Exercise price
	December 31, 2010	4.67	%	10 years	40.9	%	—		5.13
	June 8, 2011	1.11	%	2.39 years	42	%	—		0.01
	February 17, 2012	2.99	%	10 years	41	%	—		5.13
	March 18, 2013	2.15	%	10 years	40	%	—		5.13~6.00
	September 12, 2013	3.22		10 years	38.2	%	—		6
	February 27, 2014	3.24	%	10 years	38.09	%	—		5.13~6.00
	(1)                 Risk-free interest rate
	Risk-free interest rate was estimated based on the yield to maturity of China international government bonds with a maturity period close to the expected term of the options.
	(2)                 Contractual term
	The Company used the original contractual term.
	(3)                 Volatility
	The volatility of the underlying common shares during the life of the options was estimated based on the historical stock price volatility of comparable listed companies over a period comparable to the expected term of the options.
	(4)                 Dividend yield
	The dividend yield was estimated by the Group based on its expected dividend policy over the expected term of the options.
	(5)                 Exercise price
	The exercise price of the options was determined by the Group’s board of directors.
	(6)                 Fair value of underlying common shares
	The estimated fair value of the common shares underlying the options as of the respective grant dates was determined based on a retrospective valuation, which used management’s best estimate for projected cash flows as of each valuation date.

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Mar. 31, 2014
FAIR VALUE MEASUREMENTS	'
Schedule of outstanding foreign currency forward contracts	'
		As of March 31,
		2013		2014
	Settlement currency in:
	U.S. dollar of entity with functional currency in RMB
	Notional contract amount (U.S. dollar)	$	—	$	6,377
Schedule of significant unobservable inputs used to measure fair value of the intangible assets	'
		Range
	Discount rate	20.5%-22%
	Timing of cash flows	0.4-10 years

RELATED_PARTY_BALANCES_AND_TRA1

RELATED PARTY BALANCES AND TRANSACTIONS (Tables)	12 Months Ended
	Mar. 31, 2014
RELATED PARTY BALANCES AND TRANSACTIONS	'
Schedule of amounts due from related parties of the Group	'
		As of March 31,
		2013		2014
	Amounts due from related parties - current:
	Amounts due from
	Shanghai Huajian Clinic Ltd. (1)	$	—	$	1,287
	Amounts due from shareholder	483		—
		$	483	$	1,287
Schedule of amounts due to related parties of the Group	'
		As of March 31,
		2013		2014
	Amounts due to related parties - current:
	Amounts due to a former non-controlling interest holder(2)	$	12,379	$	8,049
		$	12,379	$	8,049
	(1)                 Amount represents loan provided by the Group to its equity method investee Shanghai Huajian Clinic Ltd. for daily operating use and the loan is schedule to be repaid in September 2014.
	(2)                 On August 1, 2011, iKang Holding signed an agreement with the non-controlling interest holder of iKang Shanghai Xikang Road to purchase the remaining 35% of the equity interest in iKang Shanghai Xikang Road held by the non-controlling interest holders, with consideration of $15,894.  The transaction was closed on December 31, 2011. The group paid first installment of $1,589 in August 2011 within five days after the agreement was signed.  The second installment of $1,589 was paid in February 2012.  In December 2013, $3,941 was repaid and in March 2014, $991 was paid by the Group for individual income tax on behalf of the former non-controlling interest holder. The remaining balance was settled in June 2014.
	The amounts due to non-controlling interest holder represents amortized cost of the principal amount.
	The group recognized $155, $629 and $504 imputed interest expense for the years ended March 31, 2012, 2013 and 2014, respectively. The effective interest rate of the amount due from non-controlling interest holder is 5.5%.

NONCONTROLLING_INTEREST_Tables

NONCONTROLLING INTEREST (Tables)	12 Months Ended
	Mar. 31, 2014
NONCONTROLLING INTEREST	'
Schedule of noncontrolling interest	'
		iKang			iKang			iKang			iKang						Shenzhen			Shanghai
		Zhejiang			Shanghai			Shanghai			Shanghai			Fujian			Hospital			Jianwei			Beijing						iKang
		BVI			Xikang Road			Gubei			Lujiazui			iKang			Management			Management			Jiandatong			MediFast			Changzhou			Total
	Balance at April 1, 2011	$	(383	)	$	1,516		$	414		$	254		$	—		$	(232	)	$	—		$	—		$	—		$	—		$	1,569
	Change in effective ownership of iKang Zhejiang BVI	95			—			—			—			—			—			—			—			—			—			95
	Capital contribution of non-controlling interest holder of iKang Zhejiang BVI	164			—			—			—			—			—			—			—			—			—			164
	Addition of non-controlling interest in connection with establishment of Fujian iKang	—			—			—			—			305			—			—			—			—			—			305
	Dividend distribution to non-controlling interest holder of iKang Shanghai Xikang Road	—			(420		)	—			—			—			—			—			—			—			—			(420		)
	Share of profit (loss)	164			414			53			29			(107		)	137			—			—			—			—			690
	Purchase of non-controlling interest	—			(1,564		)	—			(176		)	—			29			—			—			—			—			(1,711		)
	Other comprehensive income	(65		)	54			17			8			10			(8		)	—			—			—			—			16
	Balance at March 31, 2012	(25		)	—			484			115			208			(74		)	—			—			—			—			708
	Share of profit	59			—			146			(1		)	39			95			—			—			—			—			338
	Other comprehensive income	(30		)	—			9			2			3			—			—			—			—			—			(16		)
	Balance at March 31, 2013	4			—			639			116			250			21			—			—			—			—			1,030
	Addition of non-controlling interest in connection with establishment of Beijing Jiandatong	—			—			—			—			—			—			—			82			—			—			82
	Addition of non-controlling interest in connection with acquisition of Shanghai iKang Jianwei Health Management Co., Ltd.	—			—			—			—			—			—			172			—			—			—			172
	Addition of non-controlling interest in connection with acquisition of MediFast	—			—			—			—			—			—			—			—			1,690			—			1,690
	Addition of non-controlling interest in connection with establishment of iKang Changzhou	—			—			—			—			—			—			—			—			—			732			732
	Dividend distribution to non-controlling interest holder of Shanghai Wangzu Guobin Medical Center Co., Ltd.	—			—			(44		)	—			—			—			—			—			—			—			(44		)
	Share of profit (loss)	104			—			236			25			143			33			(9		)	(36		)	48			(225		)	319
	Purchase of non-controlling interest	—			—			—			(142		)	—			—			—			—			—			—			(142		)
	Other comprehensive income	(2		)	—			(7		)	1			(4		)	(1		)	(2		)	(1		)	(1		)	(4		)	(21		)
	Balance at March 31, 2014	$	106		$	—		$	824		$	—		$	389		$	53		$	161		$	45		$	1,737		$	503		$	3,818

SEGMENT_INFORMATION_Tables

SEGMENT INFORMATION (Tables)	12 Months Ended
	Mar. 31, 2014
SEGMENT INFORMATION	'
Schedule of components of net revenues	'
		Years ended March 31,
		2012		2013		2014
	Medical examinations	$	78,997	$	116,449	$	173,903
	Disease screening	5,162		9,240		15,017
	Other services	9,554		8,182		13,384
	Total	$	93,713	$	133,871	$	202,304

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Mar. 31, 2014
COMMITMENTS AND CONTINGENCIES	'
Schedule of future minimum lease payments	'
	2015	$	27,870
	2016	25,397
	2017	23,450
	2018	21,131
	2019	16,072
	After 2019	34,608
		$	148,528

ORGANIZATION_AND_PRINCIPAL_ACT2

ORGANIZATION AND PRINCIPAL ACTIVITIES (Details)

0 Months Ended

12 Months Ended

12 Months Ended

Mar. 01, 2014

Jan. 30, 2012

Jul. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Yuanhua

iKang Holding

Mr. Ligang Zhang

Mr. Ligang Zhang

Mr. Boquan He

Mr. Boquan He

iKang Holding

Yalong Daoyi

Mr. Haiqing Hu

Mr. Haiqing Hu

Mr. Lei Zhao

Exclusive Equity Option Agreement

Exclusive Services Agreement

iKang Holding

iKang Hangzhou Xixi

Yuanhua Information

Beijing Jiandatong

iKang Online

iKang Technology

Shenzhen iKang

Yalong Daoyi

iKang Guangzhou Huanshi East/Tianhe

iKang Shanghai Xikang Road

iKang Shanghai Gubei

iKang Shanghai Pudong Avenue

Shenzhen Hospital Management

iKang Shenzhen Nanshan

iKang Beijing Lidu

Chengdu Blue Coast

iKang Nanjing Xinjiekou

iKang Shenzhen Luohu

iKang Beijing Jianguomen

iKang Beijing Zhongguancun

iKang Beijing Kunming Lake

iKang Beijing Yansha East

iKang Shanghai Yangpu

iKang Chengdu Waishuangnan

iKang Shanghai Lujiazui

Shanghai Wenzhong

iKang Beijing Xuanwumen

Nanjing Gulou

Shenzhen Xinglin Clinic Co., Ltd.

Fujian iKang

iKang Fuzhou Gulou

iKang Beijing Xinei

Yan'an West Road

iKang Shanghai Zhonghuan

iKang Shanghai Jing'an

iKang Shanghai Yan'an East Road

iKang Shanghai Jianwei

iKang Hangzhou Wenhui

iKang Tianjin Heping

iKang Suzhou

iKang Changchun

iKang Chengdu Jinjiang

iKang Chongqing

iKang Guangzhou Wokang

iKang Shenzhen Kefa

Shanghai Jianwei Management

Yuanhua Clinic

Nanjing Aoyang Clinic

Nanjing Aoyang Shunkang

iKang Jiangyin

Zhejiang Ailikang

Hangzhou Aibo

iKang Beijing Jun'an

iKang Beijing Yayun

iKang Changzhou

iKang Guobin

Beijing iKang

Shanghai iKang

iKang Zhejiang BVI

Zhejiang iKang

Bayley & Jackson (Hong Kong)

iKang Beijing Ritan

Yuanhua HK (HongKong)

MediFast

Yuanhua WFOE

item

iKang Holding

iKang Holding

iKang Hangzhou Xixi

iKang Hangzhou Xixi

Beijing Jiandatong

Yuanhua Information

Yuanhua Information

Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ratio of shares swap with existing shareholders of iKang Guobin Healthcare Group, Inc.

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of beneficial interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

100.00%

100.00%

73.00%

73.00%

100.00%

100.00%

100.00%

80.00%

100.00%

Percentage of beneficial interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

73.00%

100.00%

80.00%

100.00%

100.00%

100.00%

100.00%

100.00%

100.00%

70.00%

100.00%

66.00%

66.00%

100.00%

100.00%

100.00%

100.00%

100.00%

100.00%

100.00%

100.00%

100.00%

100.00%

100.00%

71.00%

100.00%

100.00%

100.00%

71.00%

71.00%

100.00%

100.00%

100.00%

100.00%

100.00%

100.00%

100.00%

100.00%

100.00%

100.00%

100.00%

100.00%

100.00%

100.00%

65.00%

100.00%

100.00%

100.00%

100.00%

100.00%

100.00%

100.00%

100.00%

62.50%

'

'

'

'

'

'

'

'

'

'

Maximum percentage of direct foreign ownership allowed in business entities providing healthcare services in the PRC

'

70.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest acquired (as a percent)

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term of agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Equity interest held (as a percent)

'

'

'

'

25.60%

50.00%

14.80%

50.00%

80.00%

20.00%

80.00%

80.00%

20.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total equity interest held, including indirect ownership

'

'

'

'

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shareholders who are directors and shareholders of the Company

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

ORGANIZATION_AND_PRINCIPAL_ACT3

ORGANIZATION AND PRINCIPAL ACTIVITIES (Details 2) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2011
Financial statements amounts and balances of the VIE entities included in the accompanying consolidated financial statements	'	'	'	'
Cash and cash equivalents	$30,221	$63,154	$11,875	$14,142
Total current assets	110,830	104,478	'	'
Property and equipment, net	63,644	32,572	'	'
Acquired intangible assets, net	17,530	4,480	'	'
TOTAL ASSETS	250,226	165,361	'	'
Deferred revenues	29,523	24,578	'	'
Total current liabilities	103,442	73,924	'	'
TOTAL LIABILITIES	108,848	74,548	'	'
Net revenues	202,304	133,871	93,713	'
Net income	21,926	12,449	10,392	'
Net cash provided by operating activities	34,303	16,314	14,005	'
Net cash used in investing activities	-96,714	-16,058	-15,706	'
Net cash (used in)/ provided by financing activities	29,342	50,824	-1,161	'
Net revenues from VIE entities as a percentage of consolidated net revenues	84.10%	84.80%	86.00%	'
Assets from VIE entities as a percentage of consolidated total assets	71.40%	55.10%	'	'
Liabilities from VIE entities as a percentage of consolidated total liabilities	82.60%	77.90%	'	'
VIE entities	'	'	'	'
Financial statements amounts and balances of the VIE entities included in the accompanying consolidated financial statements	'	'	'	'
Cash and cash equivalents	11,326	13,308	'	'
Account receivable and other current assets	54,508	34,789	'	'
Total current assets	65,834	48,097	'	'
Property and equipment, net	60,325	31,511	'	'
Acquired intangible assets, net	14,070	4,475	'	'
Other noncurrent assets	38,466	7,069	'	'
Total non-current assets	112,861	43,055	'	'
TOTAL ASSETS	178,695	91,152	'	'
Deferred revenues	22,234	19,183	'	'
Account payable and other current liabilities	62,837	38,264	'	'
Total current liabilities	85,071	57,447	'	'
Total non-current liabilities	4,857	608	'	'
TOTAL LIABILITIES	89,928	58,055	'	'
Net revenues	170,226	113,506	80,563	'
Net income	20,948	11,728	9,772	'
Net cash provided by operating activities	18,327	14,978	13,310	'
Net cash used in investing activities	-29,304	-15,944	-12,867	'
Net cash (used in)/ provided by financing activities	$8,995	$3,824	($2,043)	'

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2011
In Thousands, unless otherwise specified
Foreign currency risk	'	'	'	'
Aggregate amounts of cash and cash equivalent denominated in RMB	$30,221	$63,154	$11,875	$14,142
Foreign currency risk | China, Yuan Renminbi	'	'	'	'
Foreign currency risk	'	'	'	'
Aggregate amounts of cash and cash equivalent denominated in RMB	$15,853	$15,830	'	'

SUMMARY_OF_SIGNIFICANT_ACCOUNT4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Inventories	'	'	'
Inventories write-down	$0	$0	$25

SUMMARY_OF_SIGNIFICANT_ACCOUNT5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)	12 Months Ended
	Mar. 31, 2014
Computer equipment and application software	'
Property and equipment, net	'
Estimated useful life	'5 years
Furniture and fixture	'
Property and equipment, net	'
Estimated useful life	'5 years
Medical equipment	'
Property and equipment, net	'
Estimated useful life	'10 years
Motor vehicles	'
Property and equipment, net	'
Estimated useful life	'5 years

SUMMARY_OF_SIGNIFICANT_ACCOUNT6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 4)	12 Months Ended
	Mar. 31, 2014
Weighted average	'
Intangible assets, net	'
Estimated useful life	'6 years 4 months 24 days
Customer relationship | Weighted average	'
Intangible assets, net	'
Estimated useful life	'6 years 9 months 18 days
Customer relationship | Minimum	'
Intangible assets, net	'
Estimated useful life	'2 years 1 month 6 days
Customer relationship | Maximum	'
Intangible assets, net	'
Estimated useful life	'10 years
Non-compete agreement | Weighted average	'
Intangible assets, net	'
Estimated useful life	'3 years
Non-compete agreement | Minimum	'
Intangible assets, net	'
Estimated useful life	'2 years
Non-compete agreement | Maximum	'
Intangible assets, net	'
Estimated useful life	'3 years
Contract backlog | Weighted average	'
Intangible assets, net	'
Estimated useful life	'8 months 12 days
Contract backlog | Minimum	'
Intangible assets, net	'
Estimated useful life	'4 months 24 days
Contract backlog | Maximum	'
Intangible assets, net	'
Estimated useful life	'10 months 24 days
Operating license | Weighted average	'
Intangible assets, net	'
Estimated useful life	'3 years 2 months 12 days
Operating license | Minimum	'
Intangible assets, net	'
Estimated useful life	'3 months 18 days
Operating license | Maximum	'
Intangible assets, net	'
Estimated useful life	'4 years 9 months 18 days
Favorable lease contract | Weighted average	'
Intangible assets, net	'
Estimated useful life	'8 years 9 months 18 days
Favorable lease contract | Minimum	'
Intangible assets, net	'
Estimated useful life	'5 years 1 month 6 days
Favorable lease contract | Maximum	'
Intangible assets, net	'
Estimated useful life	'9 years 9 months 18 days

SUMMARY_OF_SIGNIFICANT_ACCOUNT7

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 5) (USD $)	12 Months Ended		19 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
	Minimum	Maximum	PRC	PRC subsidiaries and VIE entities	PRC subsidiaries and VIE entities	PRC subsidiaries and VIE entities
				PRC	PRC	PRC
Revenue recognition	'	'	'	'	'	'
Business tax on the revenues earned from providing services and selling products (as a percent)	'	'	'	5.00%	'	'
Business tax recognized	'	'	'	$2,084	$1,576	$1,098
Expiry period of prepaid medical concierge card from date of purchase	'1 year	'2 years	'	'	'	'
Expiry period of components from date of purchase	'	'1 year	'	'	'	'
Value added tax ("VAT")	'	'	'	'	'	'
VAT rate (as a percent)	'	'	3.00%	'	'	'

SUMMARY_OF_SIGNIFICANT_ACCOUNT8

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 6) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Non-monetary exchange	'	'	'
Revenues recognized for non-monetary transactions	$706	$972	$1,291
Direct costs	$0	$0	$0

ACQUISITION_Details

ACQUISITION (Details) (USD $)	0 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Aug. 17, 2012	Mar. 31, 2014	Mar. 31, 2013
Net tangible assets:	'	'	'
Goodwill	'	$41,412	$17,791
iKang Shanghai Jianwei	'	'	'
Acquisition	'	'	'
Percentage of equity interest acquired	100.00%	'	'
Cash consideration	1,249	'	'
Acquisition-related costs	0	'	'
Net tangible assets:	'	'	'
Current assets	39	'	'
Non-current assets	463	'	'
Deferred tax assets	274	'	'
Total	776	'	'
Goodwill	396	'	'
Deferred tax liability	-26	'	'
Total	473	'	'
Total consideration	1,249	'	'
Net revenue	'	1,122	300
Net (loss) income	'	-773	-647
iKang Shanghai Jianwei | Customer relationship	'	'	'
Net tangible assets:	'	'	'
Intangible assets acquired	71	'	'
Estimated useful life	'5 years 3 months 18 days	'	'
iKang Shanghai Jianwei | Operating license	'	'	'
Net tangible assets:	'	'	'
Intangible assets acquired	$32	'	'
Estimated useful life	'1 year 4 months 24 days	'	'

ACQUISITION_Details_2

ACQUISITION (Details 2) (USD $)	0 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Nov. 05, 2012	Mar. 31, 2014	Mar. 31, 2013
Net tangible assets:	'	'	'
Goodwill	'	$41,412	$17,791
iKang Changchun	'	'	'
Acquisition	'	'	'
Percentage of equity interest acquired	100.00%	'	'
Cash consideration	915	'	'
Acquisition-related costs	0	'	'
Net tangible assets:	'	'	'
Current assets	5	'	'
Non-current assets	307	'	'
Total	312	'	'
Goodwill	427	'	'
Deferred tax liability	-58	'	'
Total	603	'	'
Total consideration	915	'	'
Net revenue	'	593	25
Net (loss) income	'	-832	-301
iKang Changchun | Customer relationship	'	'	'
Net tangible assets:	'	'	'
Intangible assets acquired	165	'	'
Estimated useful life	'6 years 1 month 6 days	'	'
iKang Changchun | Favorable lease contract	'	'	'
Net tangible assets:	'	'	'
Intangible assets acquired	21	'	'
Estimated useful life	'5 years 1 month 6 days	'	'
iKang Changchun | Operating license	'	'	'
Net tangible assets:	'	'	'
Intangible assets acquired	$48	'	'
Estimated useful life	'2 years 6 months	'	'

ACQUISITION_Details_3

ACQUISITION (Details 3) (USD $)	0 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Dec. 03, 2012	Mar. 31, 2014	Mar. 31, 2013
Net tangible liabilities:	'	'	'
Goodwill	'	$41,412	$17,791
iKang Guangzhou Wokang	'	'	'
Acquisition	'	'	'
Percentage of equity interest acquired	100.00%	'	'
Cash consideration	2,986	'	'
Acquisition-related costs	0	'	'
Net tangible assets:	'	'	'
Current assets	117	'	'
Non-current assets	550	'	'
Total	667	'	'
Net tangible liabilities:	'	'	'
Current liabilities	-44	'	'
Total	-44	'	'
Goodwill	1,390	'	'
Deferred tax liability	-324	'	'
Total	2,363	'	'
Total consideration	2,986	'	'
Net revenue	'	2,737	7
Net (loss) income	'	964	-273
iKang Guangzhou Wokang | Customer relationship	'	'	'
Net tangible liabilities:	'	'	'
Intangible assets acquired	175	'	'
Estimated useful life	'6 years	'	'
iKang Guangzhou Wokang | Favorable lease contract	'	'	'
Net tangible liabilities:	'	'	'
Intangible assets acquired	1,074	'	'
Estimated useful life	'9 years 9 months 18 days	'	'
iKang Guangzhou Wokang | Operating license	'	'	'
Net tangible liabilities:	'	'	'
Intangible assets acquired	$48	'	'
Estimated useful life	'3 years 1 month 6 days	'	'

ACQUISITION_Details_4

ACQUISITION (Details 4) (USD $)

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Jul. 31, 2013

Mar. 31, 2014

Jul. 31, 2013

Jul. 31, 2013

Jul. 31, 2013

Jul. 31, 2013

Jul. 31, 2013

Jul. 31, 2013

In Thousands, unless otherwise specified

Customer relationship

Customer relationship

Operating license

Operating license

Contract backlog

Contract backlog

Yuanhua

Yuanhua

Yuanhua

Yuanhua

Yuanhua

Yuanhua

Yuanhua

Yuanhua

Minimum

Maximum

Minimum

Maximum

Minimum

Maximum

Customer relationship

Customer relationship

Customer relationship

Operating license

Contract backlog

Trade-name

Minimum

Maximum

Acquisition

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of equity interest acquired

'

'

'

'

'

'

'

'

100.00%

'

'

'

'

'

'

'

Cash consideration

'

'

'

'

'

'

'

'

$27,600

'

'

'

'

'

'

'

Acquisition-related costs

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

Net tangible assets:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Current assets

'

'

'

'

'

'

'

'

8,059

'

'

'

'

'

'

'

Non-current assets

'

'

'

'

'

'

'

'

1,150

'

'

'

'

'

'

'

Deferred tax assets

'

'

'

'

'

'

'

'

371

'

'

'

'

'

'

'

Total

'

'

'

'

'

'

'

'

9,580

'

'

'

'

'

'

'

Net tangible liabilities:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Current liabilities

'

'

'

'

'

'

'

'

-6,060

'

'

'

'

'

'

'

Total

'

'

'

'

'

'

'

'

-6,060

'

'

'

'

'

'

'

Indefinite-lived intangible assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,830

Finite-lived intangible assets

'

'

'

'

'

'

'

'

'

'

6,307

'

'

49

49

'

Goodwill

41,412

17,791

'

'

'

'

'

'

15,654

'

'

'

'

'

'

'

Deferred tax liability

'

'

'

'

'

'

'

'

-2,809

'

'

'

'

'

'

'

Total

'

'

'

'

'

'

'

'

24,080

'

'

'

'

'

'

'

Total consideration

'

'

'

'

'

'

'

'

27,600

'

'

'

'

'

'

'

Estimated useful life

'

'

'2 years 1 month 6 days

'10 years

'3 months 18 days

'4 years 9 months 18 days

'4 months 24 days

'10 months 24 days

'

'

'

'5 years

'7 years 4 months 24 days

'2 years 3 months 18 days

'10 months 24 days

'

Net revenue

'

'

'

'

'

'

'

'

'

10,091

'

'

'

'

'

'

Net (loss) income

'

'

'

'

'

'

'

'

'

($1,023)

'

'

'

'

'

'

ACQUISITION_Details_5

ACQUISITION (Details 5) (USD $)	Mar. 31, 2014	Mar. 31, 2013	Sep. 01, 2013	Mar. 31, 2014	Sep. 01, 2013
In Thousands, unless otherwise specified			Nanjing Aoyang	Nanjing Aoyang	Nanjing Aoyang
					Operating license
Acquisition	'	'	'	'	'
Percentage of equity interest acquired	'	'	100.00%	'	'
Cash consideration	'	'	$4,085	'	'
Acquisition-related costs	'	'	0	'	'
Net tangible assets:	'	'	'	'	'
Current assets	'	'	15	'	'
Non-current assets	'	'	3,314	'	'
Total	'	'	3,329	'	'
Intangible assets acquired	'	'	'	'	33
Goodwill	41,412	17,791	731	'	'
Deferred tax liability	'	'	-8	'	'
Total	'	'	756	'	'
Total consideration	'	'	4,085	'	'
Estimated useful life	'	'	'	'	'1 year 3 months 18 days
Net revenue	'	'	'	218	'
Net (loss) income	'	'	'	($1,145)	'

ACQUISITION_Details_6

ACQUISITION (Details 6) (USD $)	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2013
In Thousands, unless otherwise specified			Zhejiang Ailikang	Zhejiang Ailikang	Zhejiang Ailikang	Zhejiang Ailikang	Zhejiang Ailikang
			Hangzhou Aibo			Favorable lease contract	Operating license
Acquisition	'	'	'	'	'	'	'
Percentage of equity interest acquired	'	'	'	100.00%	'	'	'
Acquiree ownership interest in subsidiary (as a percent)	'	'	100.00%	'	'	'	'
Cash consideration	'	'	'	$1,663	'	'	'
Acquisition-related costs	'	'	'	0	'	'	'
Net tangible assets:	'	'	'	'	'	'	'
Current assets	'	'	'	2	'	'	'
Non-current assets	'	'	'	576	'	'	'
Total	'	'	'	578	'	'	'
Net tangible liabilities:	'	'	'	'	'	'	'
Current liabilities	'	'	'	-818	'	'	'
Total	'	'	'	-818	'	'	'
Intangible assets acquired	'	'	'	'	'	283	83
Goodwill	41,412	17,791	'	1,628	'	'	'
Deferred tax liability	'	'	'	-91	'	'	'
Total	'	'	'	1,903	'	'	'
Total consideration	'	'	'	1,663	'	'	'
Estimated useful life	'	'	'	'	'	'5 years 3 months 18 days	'2 years 8 months 12 days
Net revenue	'	'	'	'	0	'	'
Net (loss) income	'	'	'	'	($158)	'	'

ACQUISITION_Details_7

ACQUISITION (Details 7) (USD $)

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Jan. 14, 2014

Mar. 31, 2014

Jan. 14, 2014

Jan. 14, 2014

Jan. 14, 2014

Jan. 14, 2014

Jan. 14, 2014

In Thousands, unless otherwise specified

Customer relationship

Customer relationship

Non-compete agreement

Non-compete agreement

MediFast

MediFast

MediFast

MediFast

MediFast

MediFast

MediFast

Minimum

Maximum

Minimum

Maximum

Customer relationship

Customer relationship

Customer relationship

Non-compete agreement

Trade-name

Minimum

Maximum

Acquisition

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of equity interest acquired

'

'

'

'

'

'

80.00%

'

'

'

'

'

'

Cash consideration

'

'

'

'

'

'

$8,113

'

'

'

'

'

'

Acquisition-related costs

'

'

'

'

'

'

0

'

'

'

'

'

'

Net tangible assets:

'

'

'

'

'

'

'

'

'

'

'

'

'

Current assets

'

'

'

'

'

'

1,944

'

'

'

'

'

'

Non-current assets

'

'

'

'

'

'

927

'

'

'

'

'

'

Total

'

'

'

'

'

'

2,871

'

'

'

'

'

'

Net tangible liabilities:

'

'

'

'

'

'

'

'

'

'

'

'

'

Current liabilities

'

'

'

'

'

'

-1,431

'

'

'

'

'

'

Total

'

'

'

'

'

'

-1,431

'

'

'

'

'

'

Finite-lived intangible assets

'

'

'

'

'

'

'

'

2,825

'

'

451

'

Indefinite-lived intangible assets

'

'

'

'

'

'

'

'

'

'

'

'

374

Goodwill

41,412

17,791

'

'

'

'

5,332

'

'

'

'

'

'

Deferred tax liability

'

'

'

'

'

'

-619

'

'

'

'

'

'

Total

'

'

'

'

'

'

8,363

'

'

'

'

'

'

Non-controlling interest

'

'

'

'

'

'

-1,690

'

'

'

'

'

'

Total consideration

'

'

'

'

'

'

8,113

'

'

'

'

'

'

Estimated useful life

'

'

'2 years 1 month 6 days

'10 years

'2 years

'3 years

'

'

'

'5 years

'10 years

'3 years

'

Net revenue

'

'

'

'

'

'

'

2,570

'

'

'

'

'

Net (loss) income

'

'

'

'

'

'

'

$328

'

'

'

'

'

ACQUISITION_Details_8

ACQUISITION (Details 8) (USD $)	Mar. 26, 2013	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2014	Mar. 31, 2013
In Thousands, unless otherwise specified	Shenzhen Kefa Clinic	iKang Shanghai Jianwei, iKang Changchun and iKang Guangzhou Wokang	iKang Shanghai Jianwei, iKang Changchun and iKang Guangzhou Wokang	Yuanhua, Nanjing Aoyang, Shanghai Jianwei Management, Zhejiang Ailikang and MediFast	Yuanhua, Nanjing Aoyang, Shanghai Jianwei Management, Zhejiang Ailikang and MediFast
	Operating license
Pro forma financial information	'	'	'	'	'
Pro forma net revenue	'	$137,269	$98,177	$215,104	$161,447
Pro forma net income attributable to common shareholders of iKang Healthcare Group, Inc	'	12,334	8,657	21,110	12,818
Cash consideration	$167	'	'	'	'

ACCOUNTS_RECEIVABLE_NET_Detail

ACCOUNTS RECEIVABLE, NET (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Accounts receivable	'	'	'
Accounts receivable	$41,949	$33,461	'
Less: allowance for doubtful accounts	4,330	3,272	1,561
Accounts receivable, net	37,619	30,189	'
Movement of allowance for doubtful accounts	'	'	'
Balance at beginning of year	3,272	1,561	'
Charge to expenses	1,100	1,800	481
Write off	-97	-132	'
Exchange difference	55	43	'
Balance at end of year	$4,330	$3,272	$1,561

INVENTORIES_Details

INVENTORIES (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2013
In Thousands, unless otherwise specified
INVENTORIES	'	'
Medical consumable	$1,693	$1,162
Medical consumable	'	'
INVENTORIES	'	'
Medical consumable	$1,693	$1,162

PREPAID_EXPENSES_AND_OTHER_CUR2

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2014	Jul. 31, 2013	Mar. 31, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified	USD ($)	USD ($)	Bayley & Jackson (Hong Kong)	Bayley & Jackson (Hong Kong)	Bayley & Jackson (Hong Kong)	Bayley & Jackson (Hong Kong)	Bayley & Jackson (Hong Kong)
			Foreign currency exchange forward contracts	Foreign currency exchange forward contracts	Foreign currency exchange forward contracts	Foreign currency exchange forward contracts, one	Foreign currency exchange forward contracts, two
			Buy	Buy	Buy	Buy	Buy
			USD ($)	CNY	item
PREPAID EXPENSES AND OTHER CURRENT ASSETS	'	'	'	'	'	'	'
Advance to suppliers	$9,022	$2,191	'	'	'	'	'
Deferred IPO cost	3,482	'	'	'	'	'	'
Prepaid rental expense	2,226	1,511	'	'	'	'	'
Staff advance	2,141	939	'	'	'	'	'
Prepaid acquisition fees	1,705	'	'	'	'	'	'
Prepaid expenses	792	1,269	'	'	'	'	'
Fair value of the forward contracts	57	'	'	'	'	'	'
Other receivable	587	706	'	'	'	'	'
Total	20,012	6,616	'	'	'	'	'
Forward contracts	'	'	'	'	'	'	'
Number of forward contracts	'	'	'	'	2	'	'
Notional amount	'	'	'	20,000	'	'	'
Exchange rates	'	'	'	'	'	6.2825	6.262
Gain from change in fair value of the forward contracts	'	'	$57	'	'	'	'

PROPERTY_AND_EQUIPMENT_NET_Det

PROPERTY AND EQUIPMENT, NET (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Property and equipment, net	'	'	'
Less: accumulated depreciation and amortization	$38,874	$30,655	'
Property and equipment, net	63,644	32,572	'
Depreciation expenses	8,874	7,112	5,722
Medical equipment	'	'	'
Property and equipment, net	'	'	'
Property and equipment, gross	46,275	30,805	'
Leasehold improvements	'	'	'
Property and equipment, net	'	'	'
Property and equipment, gross	33,807	22,310	'
Computer equipment and application software	'	'	'
Property and equipment, net	'	'	'
Property and equipment, gross	7,815	5,569	'
Furniture and fixtures	'	'	'
Property and equipment, net	'	'	'
Property and equipment, gross	5,329	3,718	'
Motor vehicles	'	'	'
Property and equipment, net	'	'	'
Property and equipment, gross	732	440	'
Construction in progress	'	'	'
Property and equipment, net	'	'	'
Property and equipment, gross	$8,560	$385	'

ACQUIRED_INTANGIBLE_ASSETS_NET2

ACQUIRED INTANGIBLE ASSETS, NET (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Acquired intangible assets, net	'	'	'
Less: impairment	$426	$427	'
Intangible assets, net	17,530	4,480	'
Amortization expenses	1,885	598	563
Future amortization expenses	'	'	'
2015	2,865	'	'
2016	2,292	'	'
2017	1,785	'	'
2018	1,264	'	'
2019	838	'	'
thereafter	1,274	'	'
Amount of impairment loss recognized on acquired intangible assets	0	0	0
Customer relationship	'	'	'
Acquired intangible assets, net	'	'	'
Acquired intangible assets subject to amortization	12,303	3,265	'
Less: accumulated amortization	4,059	2,484	'
Operating license	'	'	'
Acquired intangible assets, net	'	'	'
Acquired intangible assets subject to amortization	2,161	2,002	'
Less: accumulated amortization	1,289	1,024	'
Favorable lease contract	'	'	'
Acquired intangible assets, net	'	'	'
Acquired intangible assets subject to amortization	1,372	1,098	'
Less: accumulated amortization	169	29	'
Contract backlog	'	'	'
Acquired intangible assets, net	'	'	'
Acquired intangible assets subject to amortization	88	39	'
Less: accumulated amortization	80	39	'
Non-compete agreement	'	'	'
Acquired intangible assets, net	'	'	'
Acquired intangible assets subject to amortization	454	2	'
Less: accumulated amortization	37	1	'
Trade-name	'	'	'
Acquired intangible assets, net	'	'	'
Acquired intangible assets not subject to amortization	$7,212	$2,078	'

GOODWILL_Details

GOODWILL (Details) (USD $)

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2013

Aug. 17, 2012

Mar. 31, 2013

Nov. 05, 2012

Mar. 31, 2013

Dec. 03, 2012

Mar. 31, 2014

Sep. 01, 2013

Mar. 31, 2014

Jul. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Jan. 14, 2014

iKang Shanghai Jianwei

iKang Shanghai Jianwei

iKang Changchun

iKang Changchun

iKang Guangzhou Wokang

iKang Guangzhou Wokang

Nanjing Aoyang

Nanjing Aoyang

Yuanhua

Yuanhua

Shanghai Jianwei Management

Zhejiang Ailikang

Zhejiang Ailikang

MediFast

MediFast

Changes in carrying amounts of goodwill

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross amount, Beginning balance

$43,503

$41,103

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross amount, Addition for the year by acquisition

'

'

396

'

427

'

1,390

'

731

'

15,654

'

572

1,628

'

5,332

'

Gross amount, Exchange difference

-484

187

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross amount, Ending balance

66,936

43,503

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accumulated impairment loss, Beginning balance

25,712

25,665

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accumulated impairment loss, Exchange difference

-188

47

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accumulated impairment loss, Ending balance

25,524

25,712

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill

$41,412

$17,791

'

$396

'

$427

'

$1,390

'

$731

'

$15,654

'

'

$1,628

'

$5,332

ACCRUED_EXPENSES_AND_OTHER_CUR2

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2013
In Thousands, unless otherwise specified
Accrued expenses and other current liabilities	'	'
Accrued rental expense	$4,944	$2,554
Accrued payroll and welfare	4,231	2,434
Acquisitions consideration payable	3,628	537
Accrued social insurance	2,368	2,248
Accrued IPO expenses	2,268	'
Other taxes payable	2,254	1,610
Accrued outsourcing cost	1,909	1,121
Accrued professional fees	55	2,738
Interest expense payable	27	169
Other payable to shareholders	'	2,256
Other payables	2,591	1,524
Total	24,275	17,191
iKang Shanghai Zhonghuan and iKang Shanghai Jing'an	'	'
Accrued expenses and other current liabilities	'	'
Acquisitions consideration payable	'	137
iKang Shanghai Jianwei	'	'
Accrued expenses and other current liabilities	'	'
Acquisitions consideration payable	129	322
iKang Changchun	'	'
Accrued expenses and other current liabilities	'	'
Acquisitions consideration payable	'	78
Nanjing Aoyang	'	'
Accrued expenses and other current liabilities	'	'
Acquisitions consideration payable	402	'
Yuanhua	'	'
Accrued expenses and other current liabilities	'	'
Acquisitions consideration payable	540	'
Zhejiang Ailikang	'	'
Accrued expenses and other current liabilities	'	'
Acquisitions consideration payable	62	'
MediFast	'	'
Accrued expenses and other current liabilities	'	'
Acquisitions consideration payable	839	'
Shanghai Huajian Clinic Ltd	'	'
Accrued expenses and other current liabilities	'	'
Acquisitions consideration payable	$1,656	'

BANK_BORROWINGS_Details

BANK BORROWINGS (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2013
In Thousands, unless otherwise specified
BANK BORROWINGS	'	'
Short term borrowings	$18,201	$5,482
Long term borrowings	1,865	'
Total	$20,066	$5,482

BANK_BORROWINGS_Details_2

BANK BORROWINGS (Details 2) (USD $)

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Dec. 19, 2013

Mar. 31, 2014

Sep. 17, 2013

Jul. 10, 2013

Jun. 28, 2013

Jun. 25, 2013

Mar. 31, 2013

Sep. 30, 2013

Sep. 17, 2013

Mar. 31, 2014

Mar. 31, 2013

In Thousands, unless otherwise specified

One-year loan framework agreement with Bank of Beijing signed in March 2014

One-year loan framework agreement with Bank of Beijing signed in March 2014

iKang Holding

iKang Holding

iKang Holding

iKang Holding

iKang Holding

iKang Holding

iKang Holding

iKang Online

iKang Online

iKang Online

iKang Online

Bank of Beijing

Bank of Beijing

BEA

BEA

BEA

BEA

BEA

BEA

BEA

Ten-year loan framework agreement with BEA signed on September 2013

Ten-year loan framework agreement with BEA signed on September 2013

Ten-year loan framework agreement with BEA signed on September 2013

Ten-year loan framework agreement with BEA signed on September 2013

item

item

BEA

BEA

BEA

Short term borrowings

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of loans borrowed

'

'

'

'

5

'

'

'

'

'

'

'

'

'

'

Number of loan agreements signed

'

'

7

'

'

'

'

'

'

'

'

'

'

'

'

Term of loan

'

'

'

'

'1 year

'

'

'

'

'

'

'

'1 year

'

'

Amount borrowed

'

'

$4,919

'

$4,941

'

$1,606

$1,630

$1,304

$1,627

'

'

$2,410

'

'

Variable rate basis

'

'

'benchmark interest rate announced by the People's Bank of China

'

'benchmark interest rate announced by the People's Bank of China

'

'

'

'

'

'

'

'benchmark interest rate announced by the People's Bank of China

'

'

Percentage of benchmark interest rate added to benchmark interest rate to calculate annual interest rate

'

'

15.00%

'

10.00%

'

'

'

'

'

'

'

10.00%

'

'

Amount outstanding

18,201

5,482

4,919

0

'

10,910

'

'

'

'

0

'

'

2,372

0

Term of framework loan facility

'

'

'

'

'1 year

'

'

'

'

'

'

'10 years

'

'

'

Maximum borrowing capacity

'

'

$8,896

'

'

'

'

'

'

'

'

$2,451

'

'

'

Number of clinics signed loan framework agreements

'

'

7

'

'

'

'

'

'

'

'

'

'

'

'

BANK_BORROWINGS_Details_3

BANK BORROWINGS (Details 3) (USD $)	12 Months Ended			1 Months Ended	0 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012	Jun. 30, 2013	Jun. 28, 2013	Mar. 31, 2014	Mar. 31, 2013
				iKang Holding	The Bank of East Asia-secured	The Bank of East Asia-secured	The Bank of East Asia-secured
				Loan framework agreement with BEA	iKang Holding	iKang Holding	iKang Holding
					Loan framework agreement with BEA	Loan framework agreement with BEA	Loan framework agreement with BEA
Long term borrowings	'	'	'	'	'	'	'
Term of framework loan facility	'	'	'	'10 years	'	'	'
Maximum borrowing capacity	'	'	'	$3,268	'	'	'
Term of loan	'	'	'	'	'2 years	'	'
Amount borrowed	'	'	'	'	1,897	'	'
Variable rate basis	'	'	'	'	'benchmark interest rate announced by the People's Bank of China's interest rate	'	'
Percentage of benchmark interest rate added to benchmark interest rate to calculate annual interest rate	'	'	'	'	10.00%	'	'
Long term borrowings	1,865	'	'	'	'	1,865	0
Interest expense	$827	$477	$5	'	'	'	'
Weighted average effective interest rate (as a percent)	7.00%	7.80%	8.20%	'	'	'	'

CONVERTIBLE_LOAN_Details

CONVERTIBLE LOAN (Details) (Convertible loan, USD $)	1 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2013	31-May-12
Convertible loan	'	'
Convertible loans	'	'
Face amount	'	$2,000
Annual interest rate (as a percent)	'	8.00%
Repayment of loan and accrued interest	$2,300	'

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)

12 Months Ended

75 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2007

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2007

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2008

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Hong Kong

Hong Kong

Hong Kong

PRC

PRC

PRC

PRC

PRC

PRC

PRC

PRC

PRC

PRC

PRC

PRC

PRC

PRC

PRC

PRC

Bayley & Jackson (Hong Kong)

MediFast

Yuanhua HK

Shanghai iKang

Shanghai iKang

Shanghai iKang

Shanghai iKang

Shanghai iKang

iKang Holding

iKang Holding

iKang Holding

iKang Holding

iKang Holding

iKang Shenzhen Nanshan

iKang Shenzhen Luohu

iKang Shenzhen Futian

Shenzhen Kefa Clinic

Income taxes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income tax rate (as a percent)

25.00%

25.00%

25.00%

16.50%

16.50%

16.50%

'

25.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferential tax rate (as a percent)

'

'

'

'

'

'

'

'

15.00%

24.00%

22.00%

20.00%

18.00%

15.00%

24.00%

22.00%

20.00%

18.00%

'

'

'

'

Individual income tax rate (as a percent)

35.00%

35.00%

35.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

35.00%

35.00%

35.00%

35.00%

Withholding tax rate (as a percent)

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum percentage of equity interest in a PRC-resident enterprise to be held by a qualified Hong Kong tax resident for reduced withholding tax rate

'

'

'

'

'

'

25.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reduced withholding tax rate, if 25% or more equity interest in a PRC-resident enterprise is held by a qualified Hong Kong tax resident (as a percent)

'

'

'

'

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate undistributed earnings of Company's subsidiaries

'

'

'

'

'

'

$6,309

$6,309

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued deferred tax liability

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate undistributed earnings of the Company's VIEs and its VIEs' subsidiaries

'

'

'

'

'

'

$52,786

$52,786

'

'

'

'

'

'

'

'

'

'

'

'

'

'

INCOME_TAXES_Details_2

INCOME TAXES (Details 2) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Current and deferred portions of income tax expenses included in the consolidated statements of operations, which were all attributable to the Group's PRC subsidiaries and VIE entities	'	'	'
Current tax expense	$12,048	$7,311	$3,987
Deferred tax benefits	-1,947	-1,177	-48
Income tax expenses	10,101	6,134	3,939
Current deferred tax assets:	'	'	'
Accrued expenses	2,185	1,410	'
Deferred revenue	125	158	'
Accrued payroll	1,056	656	'
Bad debt provision	995	791	'
Less: Valuation allowance	-370	-141	'
Current deferred tax assets	3,991	2,874	'
Non-current deferred tax assets:	'	'	'
Depreciation and amortization	212	358	'
Due to impairment of long-lived assets	88	102	'
Net operating tax loss carry-forwards	3,748	1,724	'
Less: Valuation allowance	-2,041	-728	'
Non-current deferred tax assets	2,007	1,456	'
Non-current deferred tax liabilities:	'	'	'
Intangible assets	3,478	499	'
Non-current deferred tax liabilities	$3,478	$499	'

INCOME_TAXES_Details_3

INCOME TAXES (Details 3) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
INCOME TAXES	'	'	'
Tax loss carry-forward	$14,993	'	'
Reconciliation between the expense (benefit) of income taxes computed by applying the PRC tax rate to income (loss) before income taxes and the actual provision for income taxes	'	'	'
Net income before provision	32,183	18,583	14,331
PRC statutory tax rate (as a percent)	25.00%	25.00%	25.00%
Income tax at statutory tax rate	8,046	4,646	3,583
Change in valuation allowance	704	126	-16
Expenses not deductible for tax purposes	440	631	258
Effect of income tax rate difference for entities under individual income tax rate of 35%	390	129	67
Loss utilized for entities under individual income tax rate of 35%	-99	-153	-235
Effect of income tax rate differences in other jurisdictions	620	755	282
Income tax expenses	$10,101	$6,134	$3,939
Individual income tax rate (as a percent)	35.00%	35.00%	35.00%

COMMON_SHARE_Details

COMMON SHARE (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2013
Common share	'	'
Common shares, authorized	39,268,485	37,596,704
Common shares, par value (in dollars per share)	$0.01	$0.01
Class A common shares	'	'
Common share	'	'
Common shares, authorized	37,698,485	36,026,704
Common shares, par value (in dollars per share)	$0.01	$0.01
Class B common shares	'	'
Common share	'	'
Common shares, authorized	1,570,000	1,570,000
Common shares, par value (in dollars per share)	$0.01	$0.01

CONVERTIBLE_REDEEMABLE_PREFERR1

CONVERTIBLE REDEEMABLE PREFERRED SHARES (Details) (USD $)

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

In Thousands, except Share data, unless otherwise specified

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Oct. 16, 2013

Aug. 28, 2013

Oct. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Oct. 16, 2013

Series A,B,C,D,E shares

Series A shares

Series A shares

Series B shares

Series B shares

Series C shares

Series C1 shares

Series C1 shares

Series C2 shares

Series C2 shares

Series C3 shares

Series C3 shares

Series D shares

Series D1 shares

Series D1 shares

Series D2 shares

Series D2 shares

Series E shares

Series E shares

Series F shares

Series F shares

Series F shares

Series F shares

Series F shares

Series F shares

Class A common shares and Series D1 and D2 preferred shares

item

Minimum

Convertible redeemable preferred shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred shares outstanding

'

'

'

1,094,668

1,094,668

686,368

686,368

'

794,250

794,250

126,286

126,286

1,024,318

1,024,318

'

3,488,864

3,538,864

2,072,624

2,307,536

4,289,457

4,289,457

'

'

'

7,204,680

4,654,697

'

'

Shares issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,953,499

'

'

'

'

'

Issued amount

$25,181

$45,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$25,181

'

'

'

'

'

Number of shares sold

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

596,484

Share price (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$14.18

'

'

'

'

'

$12.03

Number of shares redesignated to

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

596,484

'

'

'

'

'

'

Total sold price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,176

Difference amount received due to conversion

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,281

'

'

'

'

Interest on preferred shares compounded annually (as a percent)

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Redemption premium amount recognized upon issuance

'

'

26,353

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Redemption premium amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,312

'

'

'

'

'

'

'

'

Interest in consolidated revenue (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.00%

'

Interest in consolidated assets (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.00%

'

Restructuring period from expiry condition

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'18 months

'

'

'

Period in which restructuring to be completed from date of Restricted Venue Resolution

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2 years

'

'

'

Interest on preferred shares compounded annually in the event of redemption for any event other than the restructuring not being completed and consummation of qualified initial public offering (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

Interest on preferred shares compounded annually if qualified IPO has not been consummated (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12.00%

'

'

'

Number of votes of the board directors required to approve redemption of preferred shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5

'

'

'

Number of votes of the board directors

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9

'

'

'

Interest on preferred shares compounded annually upon issuance of series F preferred stock (as a percent)

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Redemption premium amount upon issuance of series F

17,763

74,075

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Rate of dividend on preferred stock (as a percent)

6.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock conversion ratio

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount recorded as benefit upon conversion of preferred stock into common shares

'

'

'

$0

'

$0

'

$328

'

'

'

'

'

'

$0

'

'

'

'

$0

'

'

'

'

$0

'

'

'

Liquidation payment as percentage of original purchase price

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

NET_INCOME_LOSS_PER_SHARE_Deta

NET INCOME (LOSS) PER SHARE (Details) (USD $)

12 Months Ended

1 Months Ended

In Thousands, except Share data, unless otherwise specified

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2014

Mar. 31, 2013

Oct. 31, 2010

Options

Options

Series A shares

Series A shares

Series A shares

Series B shares

Series B shares

Series B shares

Series C shares

Series C shares

Series C shares

Series D shares

Series D shares

Series D shares

Series E shares

Series E shares

Series E shares

Series F shares

Series F shares

Class A common shares

Net income (loss) per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net income attributable to iKang Healthcare Group, Inc.

$21,607

$12,111

$9,702

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deemed dividend

20,436

84,306

2,312

'

'

'

5,112

'

'

5,204

'

'

4,366

'

1,945

14,875

'

'

20,308

2,312

18,491

34,441

'

Undistributed earnings allocated to preferred shareholders

7,310

2,818

2,770

'

'

118

150

150

130

200

200

231

265

265

789

831

831

1,323

1,324

1,324

4,719

48

'

Net income (loss) attributable to common and preferred shareholders of iKang Healthcare Group, Inc.

-6,139

-75,013

4,620

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Numerator:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net income attribution

'

'

'

'

'

'

'

299

'

'

228

'

'

445

'

'

1,309

'

'

921

'

'

'

Total attribution to participating preferred stockholders

'

'

'

'

'

118

5,262

449

130

5,404

428

231

4,631

710

2,734

15,706

2,140

1,323

21,632

4,557

23,210

34,489

'

Net (loss) income attributed to common and preferred shareholders for computing net income per common share- basic and diluted

($6,139)

($75,013)

$1,418

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Denominator:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average common shares outstanding used in computing diluted net income per common share-basic

6,340,005

6,683,678

6,599,009

'

'

1,094,668

1,386,984

1,391,044

686,368

1,054,620

1,059,735

1,944,854

2,069,410

2,071,140

5,717,326

6,088,557

6,091,920

4,289,457

4,289,457

4,289,457

6,075,702

63,763

'

Weighted average shares outstanding used in computing net income per common shares-diluted

6,340,005

6,683,678

6,768,074

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net (loss) income per common share attributable to iKang Guobin Healthcare Group, Inc.-basic (in dollars per share)

($0.97)

($11.22)

$0.22

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net (loss) income per common share attributable to iKang Guobin Healthcare Group, Inc.-diluted (in dollars per share)

($0.97)

($11.22)

$0.21

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net income per convertible redeemable participating preferred shares (in dollars per share)

'

'

'

'

'

$0.11

$3.79

$0.32

$0.19

$5.13

$0.40

$0.12

$2.24

$0.34

$0.48

$2.58

$0.35

$0.31

$5.04

$1.06

$3.82

$540.89

'

Additional disclosures

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock dividend (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

251,079

Incremental weighted average number of common shares from assumed exercise of share options

'

'

169,065

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common shares resulting from the assumed conversion were excluded as their effect was anti-dilutive

'

'

'

988,507

355,410

1,094,668

1,386,984

1,391,044

686,368

1,054,620

1,059,735

1,944,954

2,069,410

2,071,140

5,717,326

6,088,557

6,091,920

4,289,457

4,289,457

4,289,457

6,075,702

63,763

'

SHAREBASED_COMPENSATION_Detail

SHARE-BASED COMPENSATION (Details) (USD $)

12 Months Ended

0 Months Ended

48 Months Ended

96 Months Ended

0 Months Ended

In Thousands, except Share data, unless otherwise specified

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2014

Jun. 08, 2011

Mar. 31, 2010

Mar. 31, 2010

Mar. 31, 2010

Mar. 31, 2011

Feb. 17, 2012

Mar. 18, 2013

Feb. 27, 2014

Mar. 18, 2013

Feb. 27, 2014

Mar. 18, 2013

Sep. 12, 2013

Options exercisable only when the Company's common stocks become publicly traded or upon a liquidation of the Company

Management

Management

Management

Management

Executives and consultants

Employee

Directors and employees

Directors and employees

Directors and employees

Directors and employees

Directors and employees

Director

Minimum

Maximum

$5.13

$5.13

$6.00

$6.00

Share-based compensation

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share options granted (in shares)

629,000

850,000

61,843

'

41,843

240,000

'

'

302,855

80,000

330,000

356,300

440,000

72,700

80,000

200,000

Service period

'

'

'

'

'

'

'3 years

'4 years

'

'

'

'

'

'

'

'

Exercise price (in dollars per share)

$5.51

$5.21

$1.67

'

$0.01

'

'

'

'

$5.13

$5.13

$5.13

$5.13

$6

$6

$6

Number of options modified (in shares)

'

'

'

'

'

'

'

'

'

60,000

'

'

'

'

'

'

Exercise price of options modified (in dollars per share)

'

'

'

'

'

'

'

'

'

$5.13

'

'

'

'

'

'

Vesting period

'

'

'

'

'

'

'

'

'

'

'

'1 year 4 months 6 days

'

'1 year 10 months 28 days

'

'3 years 6 months 18 days

Number of options modified (in shares)

25,000

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of options modified (in dollars per share)

$6

'

$5.13

'

'

'

'

'

'

'

'

'

'

'

'

'

Period for which former employee should not engage with any entity or business of healthcare management and consulting business in the PRC for exercise of options

'

'

'

'

'

'

'

'

'

'2 years

'

'

'

'

'

'

Share-based compensation expenses

$930

$2,273

$216

'

'

'

'

'

'

'

'

'

'

'

'

'

Compensation cost related to options that will be recognized when the Company's common stock becomes publicly traded or a Company Sale

'

'

'

$5,966

'

'

'

'

'

'

'

'

'

'

'

'

SHAREBASED_COMPENSATION_Detail1

SHARE-BASED COMPENSATION (Details 2) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Number of options	'	'	'
Outstanding at the beginning of the period (in shares)	1,284,698	434,698	497,855
Granted (in shares)	629,000	850,000	61,843
Exercised (in shares)	'	'	-75,000
Forfeited (in shares)	-25,000	'	-50,000
Outstanding at the end of the period (in shares)	1,888,698	1,284,698	434,698
Weighted average exercise price per option	'	'	'
Outstanding at the beginning of the period (in dollars per share)	$4.13	$2.02	$2.34
Granted (in dollars per share)	$5.51	$5.21	$1.67
Exercised (in dollars per share)	'	'	$1.80
Forfeited (in dollars per share)	$6	'	$5.13
Outstanding at the end of the period (in dollars per share)	$4.56	$4.13	$2.02
Weighted average fair value per option at grant date	'	'	'
Outstanding at the beginning of the period (in dollars per share)	$6.08	$3.94	$3.25
Granted (in dollars per share)	$15.61	$7.17	$10.88
Exercised (in dollars per share)	'	'	$1.59
Forfeited (in dollars per share)	$7.13	'	$9.20
Outstanding at the end of the period (in dollars per share)	$9.24	$6.08	$3.94
Additional information	'	'	'
Vested options (in shares)	390,000	'	'
Options expected to vest (in shares)	1,498,698	'	'
Weighted-average exercise price of options expected to vest (in dollars per share)	$4.42	'	'
Aggregate intrinsic value of options expected to vest	$34,355	'	'
Total intrinsic value of options exercised	$0	$0	$458

SHAREBASED_COMPENSATION_Detail2

SHARE-BASED COMPENSATION (Details 3) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014
Option outstanding	'
Number outstanding (in shares)	1,888,698
Aggregate intrinsic value	$43,017
Option exercisable	'
Number exercisable (in shares)	390,000
Aggregate intrinsic value	8,662
$0.01	'
Information with respect to share options outstanding at the end of the period	'
Low end of range of exercise prices (in dollars per share)	$0.01
Option outstanding	'
Number outstanding (in shares)	221,843
Weighted average remaining contractual life	'1 year 1 month 17 days
Weighted Average Exercise price per option (in dollars per share)	$0.01
Aggregate intrinsic value	6,063
$1.00-$2.00	'
Information with respect to share options outstanding at the end of the period	'
Low end of range of exercise prices (in dollars per share)	$1
High end of range of exercise prices (in dollars per share)	$2
Option outstanding	'
Number outstanding (in shares)	62,855
Weighted average remaining contractual life	'2 years 11 months 8 days
Weighted Average Exercise price per option (in dollars per share)	$1.68
Aggregate intrinsic value	1,613
$5.13	'
Information with respect to share options outstanding at the end of the period	'
Low end of range of exercise prices (in dollars per share)	$5.13
Option outstanding	'
Number outstanding (in shares)	1,276,300
Weighted average remaining contractual life	'8 years 10 months 17 days
Weighted Average Exercise price per option (in dollars per share)	$5.13
Aggregate intrinsic value	28,348
Option exercisable	'
Number exercisable (in shares)	390,000
Weighted Average Exercise price per option (in dollars per share)	$5.13
Aggregate intrinsic value	8,662
$6.00	'
Information with respect to share options outstanding at the end of the period	'
Low end of range of exercise prices (in dollars per share)	$6
Option outstanding	'
Number outstanding (in shares)	327,700
Weighted average remaining contractual life	'9 years 5 months 23 days
Weighted Average Exercise price per option (in dollars per share)	$6
Aggregate intrinsic value	$6,993

SHAREBASED_COMPENSATION_Detail3

SHARE-BASED COMPENSATION (Details 4) (USD $)	0 Months Ended						12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Feb. 27, 2014	Sep. 12, 2013	Mar. 18, 2013	Feb. 17, 2012	Jun. 08, 2011	Dec. 31, 2010	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Assumptions used on the grant date to estimate fair value of each option granted using the binomial tree pricing model for grants during the applicable periods	'	'	'	'	'	'	'	'	'
Risk-free interest rate of return (as a percent)	3.24%	3.22%	2.15%	2.99%	1.11%	4.67%	'	'	'
Contractual term	'10 years	'10 years	'10 years	'10 years	'2 years 4 months 20 days	'10 years	'	'	'
Volatility (as a percent)	38.09%	38.20%	40.00%	41.00%	42.00%	40.90%	'	'	'
Exercise price (in dollars per share)	'	$6	'	$5.13	$0.01	$5.13	'	'	'
Additional disclosure	'	'	'	'	'	'	'	'	'
Share-based compensation	'	'	'	'	'	'	$930	$2,273	$216
Unrecognized compensation expense	'	'	'	'	'	'	$7,383	'	'
Period over which total unrecognized compensation expense relating to unvested share options will be recognized	'	'	'	'	'	'	'3 years	'	'
Weighted-average remaining contractual term of options outstanding	'	'	'	'	'	'	'7 years 10 months 17 days	'	'
Minimum	'	'	'	'	'	'	'	'	'
Assumptions used on the grant date to estimate fair value of each option granted using the binomial tree pricing model for grants during the applicable periods	'	'	'	'	'	'	'	'	'
Exercise price (in dollars per share)	5.13	'	5.13	'	'	'	'	'	'
Maximum	'	'	'	'	'	'	'	'	'
Assumptions used on the grant date to estimate fair value of each option granted using the binomial tree pricing model for grants during the applicable periods	'	'	'	'	'	'	'	'	'
Exercise price (in dollars per share)	6	'	6	'	'	'	'	'	'

FAIR_VALUE_MEASUREMENTS_Detail

FAIR VALUE MEASUREMENTS (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2013
In Thousands, unless otherwise specified
Fair value measurements	'	'
Fair value of foreign currency forward contracts	$57	'
Foreign currency forward contracts | Level 2 | Recurring basis	'	'
Fair value measurements	'	'
Fair value of foreign currency forward contracts	57	0
Notional contract amount	$6,377	'

FAIR_VALUE_MEASUREMENTS_Detail1

FAIR VALUE MEASUREMENTS (Details 2) (Non-recurring basis, Intangible assets)	12 Months Ended
	Mar. 31, 2014
Minimum	'
Significant unobservable inputs used to measure fair value of the intangible assets	'
Discount rate (as a percent)	20.50%
Timing of cash flows	'4 months 24 days
Maximum	'
Significant unobservable inputs used to measure fair value of the intangible assets	'
Discount rate (as a percent)	22.00%
Timing of cash flows	'10 years

RELATED_PARTY_BALANCES_AND_TRA2

RELATED PARTY BALANCES AND TRANSACTIONS (Details) (USD $)	12 Months Ended			0 Months Ended	1 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012	Aug. 01, 2011	Mar. 31, 2014	Dec. 31, 2013	Feb. 29, 2012	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
				iKang Holding	iKang Holding	iKang Holding	iKang Holding	Shanghai Huajian Clinic Ltd	Shareholder	Former non-controlling interest holder	Former non-controlling interest holder
				iKang Shanghai Xikang Road	iKang Shanghai Xikang Road	iKang Shanghai Xikang Road	iKang Shanghai Xikang Road
Amounts due from related parties - current:	'	'	'	'	'	'	'	'	'	'	'
Amounts due from related parties - current	$1,287	$483	'	'	'	'	'	$1,287	$483	'	'
Amounts due to related parties - current:	'	'	'	'	'	'	'	'	'	'	'
Amounts due to related parties - current	8,049	12,379	'	'	'	'	'	'	'	8,049	12,379
Remaining equity interest purchased (as a percent)	'	'	'	35.00%	'	'	'	'	'	'	'
Consideration to purchase equity interest	'	'	'	15,894	'	'	'	'	'	'	'
Amount paid	'	'	'	1,589	991	3,941	1,589	'	'	'	'
Period within which the first installment of consideration was paid after signing of the agreement	'	'	'	'5 days	'	'	'	'	'	'	'
Imputed interest expense	$504	$629	$155	'	'	'	'	'	'	'	'
Effective interest rate of the amount due from non-controlling interest holder (as a percent)	5.50%	'	'	'	'	'	'	'	'	'	'

NONCONTROLLING_INTEREST_Detail

NONCONTROLLING INTEREST (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Noncontrolling interest	'	'	'
Balance at the beginning of the period	$1,030	$708	$1,569
Change in effective ownership	'	'	95
Capital contribution of non-controlling interest holder	'	'	164
Share of profit (loss)	319	338	690
Purchase of non-controlling interest	-142	'	-1,711
Other comprehensive income	-21	-16	16
Balance at the end of the period	3,818	1,030	708
iKang Zhejiang BVI	'	'	'
Noncontrolling interest	'	'	'
Balance at the beginning of the period	4	-25	-383
Change in effective ownership	'	'	95
Capital contribution of non-controlling interest holder	'	'	164
Share of profit (loss)	104	59	164
Other comprehensive income	-2	-30	-65
Balance at the end of the period	106	4	-25
iKang Shanghai Xikang Road	'	'	'
Noncontrolling interest	'	'	'
Balance at the beginning of the period	'	'	1,516
Dividend distribution to non-controlling interest holder	'	'	-420
Share of profit (loss)	'	'	414
Purchase of non-controlling interest	'	'	-1,564
Other comprehensive income	'	'	54
iKang Shanghai Gubei	'	'	'
Noncontrolling interest	'	'	'
Balance at the beginning of the period	639	484	414
Dividend distribution to non-controlling interest holder	-44	'	'
Share of profit (loss)	236	146	53
Other comprehensive income	-7	9	17
Balance at the end of the period	824	639	484
iKang Shanghai Lujiazui	'	'	'
Noncontrolling interest	'	'	'
Balance at the beginning of the period	116	115	254
Share of profit (loss)	25	-1	29
Purchase of non-controlling interest	-142	'	-176
Other comprehensive income	1	2	8
Balance at the end of the period	'	116	115
Fujian iKang	'	'	'
Noncontrolling interest	'	'	'
Balance at the beginning of the period	250	208	'
Addition of non-controlling interest	'	'	305
Share of profit (loss)	143	39	-107
Other comprehensive income	-4	3	10
Balance at the end of the period	389	250	208
Shenzhen Hospital Management	'	'	'
Noncontrolling interest	'	'	'
Balance at the beginning of the period	21	-74	-232
Share of profit (loss)	33	95	137
Purchase of non-controlling interest	'	'	29
Other comprehensive income	-1	'	-8
Balance at the end of the period	53	21	-74
Shanghai Jianwei Management	'	'	'
Noncontrolling interest	'	'	'
Addition of non-controlling interest	172	'	'
Share of profit (loss)	-9	'	'
Other comprehensive income	-2	'	'
Balance at the end of the period	161	'	'
Beijing Jiandatong	'	'	'
Noncontrolling interest	'	'	'
Addition of non-controlling interest	82	'	'
Share of profit (loss)	-36	'	'
Other comprehensive income	-1	'	'
Balance at the end of the period	45	'	'
MediFast (Hong Kong) Limited	'	'	'
Noncontrolling interest	'	'	'
Addition of non-controlling interest	1,690	'	'
Share of profit (loss)	48	'	'
Other comprehensive income	-1	'	'
Balance at the end of the period	1,737	'	'
iKang Changzhou	'	'	'
Noncontrolling interest	'	'	'
Addition of non-controlling interest	732	'	'
Share of profit (loss)	-225	'	'
Other comprehensive income	-4	'	'
Balance at the end of the period	$503	'	'

SEGMENT_INFORMATION_Details

SEGMENT INFORMATION (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
	item
SEGMENT INFORMATION	'	'	'
Number of operating segments	1	'	'
Components of net revenues	'	'	'
Medical examinations	$173,903	$116,449	$78,997
Disease screening	15,017	9,240	5,162
Other services	13,384	8,182	9,554
Total	$202,304	$133,871	$93,713

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
COMMITMENTS AND CONTINGENCIES	'	'	'
Rental expenses under operating leases	$28,129	$16,436	$11,051
Future minimum lease payments	'	'	'
2015	27,870	'	'
2016	25,397	'	'
2017	23,450	'	'
2018	21,131	'	'
2019	16,072	'	'
After 2019	34,608	'	'
Total	$148,528	'	'
Contingent liabilities	'	'	'
Income tax on capital gain payable by individual when corporation purchases equity interest from individuals pursuant to PRC individual income tax law (as a percent)	20.00%	'	'

EMPLOYEE_BENEFIT_PLAN_Details

EMPLOYEE BENEFIT PLAN (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
EMPLOYEE BENEFIT PLAN	'	'	'
Total provision under government-mandated defined contribution plan	$7,249	$4,908	$3,365

STATUTORY_RESERVE_AND_RESTRICT1

STATUTORY RESERVE AND RESTRICTED NET ASSETS (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
STATUTORY RESERVE AND RESTRICTED NET ASSETS	'	'	'
Percentage of after-tax profits required to be appropriated to general reserve	10.00%	'	'
General reserve as a percentage of registered capital up to which after-tax profit of PRC subsidiaries and VIEs shall be transferred	50.00%	'	'
Amount appropriated to statutory reserve	$2,738	$1,296	$470
Aggregate amounts of capital and statutory reserves restricted	$103,355	'	'

SUBSEQUENT_EVENTS_Details

SUBSEQUENT EVENTS (Details) (USD $)

12 Months Ended

1 Months Ended

6 Months Ended

0 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

2 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

In Thousands, except Share data, unless otherwise specified

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2014

Dec. 19, 2013

Sep. 17, 2013

Jul. 10, 2013

Jun. 28, 2013

Jun. 25, 2013

Apr. 09, 2014

Apr. 09, 2014

Apr. 09, 2014

Apr. 09, 2014

Jun. 30, 2014

31-May-14

31-May-14

31-May-14

5-May-14

5-May-14

5-May-14

Jun. 30, 2014

Jun. 30, 2014

31-May-14

Jun. 30, 2014

Jun. 30, 2014

Apr. 09, 2014

Apr. 09, 2014

Apr. 09, 2014

Apr. 09, 2014

9-May-14

9-May-14

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Bank of Beijing

iKang Holding

iKang Holding

iKang Holding

iKang Holding

iKang Holding

Subsequent events

Subsequent events

Subsequent events

Subsequent events

Subsequent events

Subsequent events

Subsequent events

Subsequent events

Subsequent events

Subsequent events

Subsequent events

Subsequent events

Subsequent events

Subsequent events

Subsequent events

Subsequent events

Subsequent events

Subsequent events

Subsequent events

Subsequent events

Subsequent events

Subsequent events

Subsequent events

Subsequent events

Subsequent events

One-year loan framework agreement with Bank of Beijing signed in March 2014

The Bank of East Asia

The Bank of East Asia

The Bank of East Asia

The Bank of East Asia

The Bank of East Asia

iKang Beijing Ritan

iKang Beijing Ritan

iKang Beijing Xuanwumen

iKang Beijing Xuanwumen

iKang Holding

iKang Holding

iKang Holding

iKang Holding

iKang Online

iKang Online

iKang Online

iKang Online

Huajian

Huajian

Huajian

iKang Shanghai Xikang Road

IPO

IPO

IPO

Private placement

Green shoe option

Green shoe option

Forecast

Forecast

Forecast

item

Bank of Beijing

Bank of Beijing

Bank of Beijing

Bank of Beijing

China Merchants Bank

China Merchants Bank

China Merchants Bank

China Merchants Bank

The Bank of East Asia

The Bank of East Asia

The Bank of East Asia

Xiamen International Bank

item

Shanghai GaoTong Supporting Services Management Ltd

Shanghai Huajian Investment Management Ltd

iKang Online

ADS

Class A common shares

Class A common shares

ADS

Class A common shares

Huajian

Huajian

Class A common shares

One-year loan framework agreement with Bank of Beijing signed in March 2014

One-year loan framework agreement with Bank of Beijing signed in March 2014

One-year loan framework agreement with Bank of Beijing signed in March 2014

One-year loan framework agreement with Bank of Beijing signed in March 2014

item

Loan one with China Merchants Bank

Loan two with China Merchants Bank

item

Loan one with BEA

Loan two with BEA

Best Investment Corporation

Another shareholder

Ex-shareholder

Huajian

Ex-shareholder

Subsequent events

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,904,846

5,452,423

1,428,571

1,029,112

514,556

'

'

'

Net proceeds from issuance of shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$87,900

'

'

'

$13,400

'

'

'

'

Total purchase price of shares issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

40,000

'

'

'

'

'

Net proceeds from issuance of shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

37,200

'

'

'

'

'

Price of shares issued (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$14

'

'

'

'

Number of share purchase agreements entered

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of equity interest acquired

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

63.00%

37.00%

30.00%

35.00%

'

'

'

'

'

'

30.00%

33.00%

'

Cash consideration

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,121

5,373

'

'

'

'

'

'

'

'

'

'

Option granted (in shares)

629,000

850,000

61,843

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

Exercise price (in dollars per share)

$5.51

$5.21

$1.67

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$16.18

'

Amount borrowed

'

'

'

$4,919

$4,941

$1,606

$1,630

$1,304

$1,627

'

$657

'

$692

$1,432

'

$1,234

$4,275

'

$2,252

$2,245

$14,523

'

'

'

'

'

'

'

'

'

'

'

'

'

Variable rate basis

'

'

'

'benchmark interest rate announced by the People's Bank of China

'benchmark interest rate announced by the People's Bank of China

'

'

'

'

'benchmark interest rate announced by the People's Bank of China's interest rate

'

'benchmark interest rate announced by the People's Bank of China's interest rate

'

'benchmark interest rate announced by the People's Bank of China's interest rate

'benchmark interest rate announced by the People's Bank of China's interest rate

'

'

'benchmark interest rate announced by the People's Bank of China's interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of benchmark interest rate added to benchmark interest rate to calculate annual interest rate

'

'

'

15.00%

10.00%

'

'

'

'

15.00%

'

15.00%

'

20.00%

20.00%

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of loans borrowed

'

'

'

'

5

'

'

'

'

'

'

'

'

'

2

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term of agreement

'

'

'

'

'1 year

'

'

'

'

'

'

'

'

'1 year

'1 year

'

'

'1 year

'

'

'1 year

'

'

'

'

'

'

'

'

'

'

'

'

'

FINANCIAL_STATEMENT_SCHEDULE_I1

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2011
In Thousands, unless otherwise specified
Current assets:	'	'	'	'
Cash and cash equivalents	$30,221	$63,154	$11,875	$14,142
Amount due from related parties	1,287	483	'	'
Prepaid expenses and other current assets	20,012	6,616	'	'
Total current assets	110,830	104,478	'	'
Property and equipment, net	63,644	32,572	'	'
TOTAL ASSETS	250,226	165,361	'	'
Current liabilities:	'	'	'	'
Convertible loan	'	2,000	'	'
Accrued expenses and other current liabilities	24,275	17,191	'	'
Amount due to related parties	8,049	12,379	'	'
Total current liabilities	103,442	73,924	'	'
Equity:	'	'	'	'
Additional paid-in capital	1,342	4,341	'	'
Accumulated deficit	-137,129	-135,390	'	'
Accumulated other comprehensive income	3,764	4,522	'	'
Total iKang Healthcare Group, Inc. shareholders' deficit	-126,957	-124,195	'	'
TOTAL LIABILITIES, MEZZANINE EQUITY AND EQUITY	250,226	165,361	'	'
PARENT COMPANY	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	13,937	47,290	80	210
Amount due from related parties	27,622	9,780	'	'
Prepaid expenses and other current assets	334	'	'	'
Total current assets	41,893	57,070	'	'
Property and equipment, net	1	1	'	'
Investment in subsidiaries and VIE entities	99,584	40,908	'	'
TOTAL ASSETS	141,478	97,979	'	'
Current liabilities:	'	'	'	'
Convertible loan	'	2,000	'	'
Accrued expenses and other current liabilities	2,767	5,180	'	'
Amount due to related parties	1,151	1,016	'	'
Total current liabilities	3,918	8,196	'	'
Equity:	'	'	'	'
Additional paid-in capital	1,342	4,341	'	'
Accumulated deficit	-132,124	-133,123	'	'
Accumulated other comprehensive income	3,764	4,522	'	'
Total iKang Healthcare Group, Inc. shareholders' deficit	-126,957	-124,195	-52,212	-48,245
TOTAL LIABILITIES, MEZZANINE EQUITY AND EQUITY	141,478	97,979	'	'
Series A convertible redeemable participating preferred shares	'	'	'	'
Mezzanine Equity:	'	'	'	'
Convertible redeemable participating preferred shares	6,496	6,496	'	'
Series A convertible redeemable participating preferred shares | PARENT COMPANY	'	'	'	'
Mezzanine Equity:	'	'	'	'
Convertible redeemable participating preferred shares	6,496	6,496	'	'
Series B convertible redeemable participating preferred shares	'	'	'	'
Mezzanine Equity:	'	'	'	'
Convertible redeemable participating preferred shares	6,512	6,512	'	'
Series B convertible redeemable participating preferred shares | PARENT COMPANY	'	'	'	'
Mezzanine Equity:	'	'	'	'
Convertible redeemable participating preferred shares	6,512	6,512	'	'
Series C1 convertible redeemable participating preferred shares	'	'	'	'
Mezzanine Equity:	'	'	'	'
Convertible redeemable participating preferred shares	5,700	5,700	'	'
Series C1 convertible redeemable participating preferred shares | PARENT COMPANY	'	'	'	'
Mezzanine Equity:	'	'	'	'
Convertible redeemable participating preferred shares	5,700	5,700	'	'
Series C2 convertible redeemable participating preferred shares	'	'	'	'
Mezzanine Equity:	'	'	'	'
Convertible redeemable participating preferred shares	1,709	1,709	'	'
Series C2 convertible redeemable participating preferred shares | PARENT COMPANY	'	'	'	'
Mezzanine Equity:	'	'	'	'
Convertible redeemable participating preferred shares	1,709	1,709	'	'
Series C3 convertible redeemable participating preferred shares	'	'	'	'
Mezzanine Equity:	'	'	'	'
Convertible redeemable participating preferred shares	4,157	4,157	'	'
Series C3 convertible redeemable participating preferred shares | PARENT COMPANY	'	'	'	'
Mezzanine Equity:	'	'	'	'
Convertible redeemable participating preferred shares	4,157	4,157	'	'
Series D1 convertible redeemable participating preferred shares	'	'	'	'
Mezzanine Equity:	'	'	'	'
Convertible redeemable participating preferred shares	29,750	30,176	'	'
Series D1 convertible redeemable participating preferred shares | PARENT COMPANY	'	'	'	'
Mezzanine Equity:	'	'	'	'
Convertible redeemable participating preferred shares	29,750	30,176	'	'
Series D2 convertible redeemable participating preferred shares	'	'	'	'
Mezzanine Equity:	'	'	'	'
Convertible redeemable participating preferred shares	11,300	12,356	'	'
Series D2 convertible redeemable participating preferred shares | PARENT COMPANY	'	'	'	'
Mezzanine Equity:	'	'	'	'
Convertible redeemable participating preferred shares	11,300	12,356	'	'
Series E convertible redeemable participating preferred shares	'	'	'	'
Mezzanine Equity:	'	'	'	'
Convertible redeemable participating preferred shares	54,098	54,098	'	'
Series E convertible redeemable participating preferred shares | PARENT COMPANY	'	'	'	'
Mezzanine Equity:	'	'	'	'
Convertible redeemable participating preferred shares	54,098	54,098	'	'
Series F convertible redeemable participating preferred shares	'	'	'	'
Mezzanine Equity:	'	'	'	'
Convertible redeemable participating preferred shares	144,795	92,774	'	'
Series F convertible redeemable participating preferred shares | PARENT COMPANY	'	'	'	'
Mezzanine Equity:	'	'	'	'
Convertible redeemable participating preferred shares	144,795	92,774	'	'
Class A common shares	'	'	'	'
Equity:	'	'	'	'
Common shares	45	49	'	'
Class A common shares | PARENT COMPANY	'	'	'	'
Equity:	'	'	'	'
Common shares	45	49	'	'
Class B common shares	'	'	'	'
Equity:	'	'	'	'
Common shares	16	16	'	'
Class B common shares | PARENT COMPANY	'	'	'	'
Equity:	'	'	'	'
Common shares	$16	$16	'	'

FINANCIAL_STATEMENT_SCHEDULE_I2

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY (Details) (Parenthetical) (USD $)	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
In Thousands, except Share data, unless otherwise specified
CONDENSED BALANCE SHEETS	'	'	'
Common shares, par value (in dollars per share)	$0.01	$0.01	'
Common shares, authorized	39,268,485	37,596,704	'
PARENT COMPANY	'	'	'
CONDENSED BALANCE SHEETS	'	'	'
Common shares, par value (in dollars per share)	$0.01	'	'
Series A convertible redeemable participating preferred shares	'	'	'
CONDENSED BALANCE SHEETS	'	'	'
Convertible redeemable participating preferred shares, par value (in dollars per share)	$0.01	$0.01	'
Convertible redeemable participating preferred shares, authorized	1,094,668	1,391,044	'
Convertible redeemable participating preferred shares, issued	1,094,668	1,094,668	'
Convertible redeemable participating preferred shares, outstanding	1,094,668	1,094,668	'
Convertible redeemable participating preferred shares, liquidation value (in dollars)	$1,970	$1,970	'
Series A convertible redeemable participating preferred shares | PARENT COMPANY	'	'	'
CONDENSED BALANCE SHEETS	'	'	'
Convertible redeemable participating preferred shares, par value (in dollars per share)	$0.01	$0.01	'
Convertible redeemable participating preferred shares, authorized	1,094,668	1,391,044	'
Convertible redeemable participating preferred shares, issued	1,094,668	1,094,668	'
Convertible redeemable participating preferred shares, outstanding	1,094,668	1,094,668	'
Convertible redeemable participating preferred shares, liquidation value (in dollars)	1,970	1,970	'
Series B convertible redeemable participating preferred shares	'	'	'
CONDENSED BALANCE SHEETS	'	'	'
Convertible redeemable participating preferred shares, par value (in dollars per share)	$0.01	$0.01	'
Convertible redeemable participating preferred shares, authorized	686,368	1,059,735	'
Convertible redeemable participating preferred shares, issued	686,368	686,368	'
Convertible redeemable participating preferred shares, outstanding	686,368	686,368	'
Convertible redeemable participating preferred shares, liquidation value (in dollars)	2,162	2,162	'
Series B convertible redeemable participating preferred shares | PARENT COMPANY	'	'	'
CONDENSED BALANCE SHEETS	'	'	'
Convertible redeemable participating preferred shares, par value (in dollars per share)	$0.01	$0.01	'
Convertible redeemable participating preferred shares, authorized	686,368	1,059,735	'
Convertible redeemable participating preferred shares, issued	686,368	686,368	'
Convertible redeemable participating preferred shares, outstanding	686,368	686,368	'
Convertible redeemable participating preferred shares, liquidation value (in dollars)	2,162	2,162	'
Series C1 convertible redeemable participating preferred shares	'	'	'
CONDENSED BALANCE SHEETS	'	'	'
Convertible redeemable participating preferred shares, par value (in dollars per share)	$0.01	$0.01	'
Convertible redeemable participating preferred shares, authorized	794,250	794,250	'
Convertible redeemable participating preferred shares, issued	794,250	794,250	'
Convertible redeemable participating preferred shares, outstanding	794,250	794,250	'
Convertible redeemable participating preferred shares, liquidation value (in dollars)	1,893	1,893	'
Series C1 convertible redeemable participating preferred shares | PARENT COMPANY	'	'	'
CONDENSED BALANCE SHEETS	'	'	'
Convertible redeemable participating preferred shares, par value (in dollars per share)	$0.01	$0.01	'
Convertible redeemable participating preferred shares, authorized	794,250	794,250	'
Convertible redeemable participating preferred shares, issued	794,250	794,250	'
Convertible redeemable participating preferred shares, outstanding	794,250	794,250	'
Convertible redeemable participating preferred shares, liquidation value (in dollars)	1,893	1,893	'
Series C2 convertible redeemable participating preferred shares	'	'	'
CONDENSED BALANCE SHEETS	'	'	'
Convertible redeemable participating preferred shares, par value (in dollars per share)	$0.01	$0.01	'
Convertible redeemable participating preferred shares, authorized	126,286	252,572	'
Convertible redeemable participating preferred shares, issued	126,286	126,286	'
Convertible redeemable participating preferred shares, outstanding	126,286	126,286	'
Convertible redeemable participating preferred shares, liquidation value (in dollars)	568	568	'
Series C2 convertible redeemable participating preferred shares | PARENT COMPANY	'	'	'
CONDENSED BALANCE SHEETS	'	'	'
Convertible redeemable participating preferred shares, par value (in dollars per share)	$0.01	$0.01	'
Convertible redeemable participating preferred shares, authorized	126,286	252,572	'
Convertible redeemable participating preferred shares, issued	126,286	126,286	'
Convertible redeemable participating preferred shares, outstanding	126,286	126,286	'
Convertible redeemable participating preferred shares, liquidation value (in dollars)	568	568	'
Series C3 convertible redeemable participating preferred shares	'	'	'
CONDENSED BALANCE SHEETS	'	'	'
Convertible redeemable participating preferred shares, par value (in dollars per share)	$0.01	$0.01	'
Convertible redeemable participating preferred shares, authorized	1,024,318	1,024,318	'
Convertible redeemable participating preferred shares, issued	1,024,318	1,024,318	'
Convertible redeemable participating preferred shares, outstanding	1,024,318	1,024,318	'
Convertible redeemable participating preferred shares, liquidation value (in dollars)	1,382	1,382	'
Series C3 convertible redeemable participating preferred shares | PARENT COMPANY	'	'	'
CONDENSED BALANCE SHEETS	'	'	'
Convertible redeemable participating preferred shares, par value (in dollars per share)	$0.01	$0.01	'
Convertible redeemable participating preferred shares, authorized	1,024,318	1,024,318	'
Convertible redeemable participating preferred shares, issued	1,024,318	1,024,318	'
Convertible redeemable participating preferred shares, outstanding	1,024,318	1,024,318	'
Convertible redeemable participating preferred shares, liquidation value (in dollars)	1,382	1,382	'
Series D1 convertible redeemable participating preferred shares	'	'	'
CONDENSED BALANCE SHEETS	'	'	'
Convertible redeemable participating preferred shares, par value (in dollars per share)	$0.01	$0.01	'
Convertible redeemable participating preferred shares, authorized	3,488,864	3,655,151	'
Convertible redeemable participating preferred shares, issued	3,538,864	3,538,864	'
Convertible redeemable participating preferred shares, outstanding	3,488,864	3,538,864	'
Convertible redeemable participating preferred shares, liquidation value (in dollars)	10,083	10,227	'
Series D1 convertible redeemable participating preferred shares | PARENT COMPANY	'	'	'
CONDENSED BALANCE SHEETS	'	'	'
Convertible redeemable participating preferred shares, par value (in dollars per share)	$0.01	$0.01	'
Convertible redeemable participating preferred shares, authorized	3,488,864	3,655,151	'
Convertible redeemable participating preferred shares, issued	3,488,864	3,538,864	'
Convertible redeemable participating preferred shares, outstanding	3,488,864	3,538,864	'
Convertible redeemable participating preferred shares, liquidation value (in dollars)	10,083	10,227	'
Series D2 convertible redeemable participating preferred shares	'	'	'
CONDENSED BALANCE SHEETS	'	'	'
Convertible redeemable participating preferred shares, par value (in dollars per share)	$0.01	$0.01	'
Convertible redeemable participating preferred shares, authorized	2,072,624	2,436,769	'
Convertible redeemable participating preferred shares, issued	2,307,536	2,307,536	'
Convertible redeemable participating preferred shares, outstanding	2,072,624	2,307,536	'
Convertible redeemable participating preferred shares, liquidation value (in dollars)	2,798	3,115	'
Series D2 convertible redeemable participating preferred shares | PARENT COMPANY	'	'	'
CONDENSED BALANCE SHEETS	'	'	'
Convertible redeemable participating preferred shares, par value (in dollars per share)	$0.01	$0.01	'
Convertible redeemable participating preferred shares, authorized	2,072,624	2,436,769	'
Convertible redeemable participating preferred shares, issued	2,072,624	2,307,536	'
Convertible redeemable participating preferred shares, outstanding	2,072,624	2,307,536	'
Convertible redeemable participating preferred shares, liquidation value (in dollars)	2,798	3,115	'
Series E convertible redeemable participating preferred shares	'	'	'
CONDENSED BALANCE SHEETS	'	'	'
Convertible redeemable participating preferred shares, par value (in dollars per share)	$0.01	$0.01	'
Convertible redeemable participating preferred shares, authorized	4,289,457	4,289,457	'
Convertible redeemable participating preferred shares, issued	4,289,457	4,289,457	'
Convertible redeemable participating preferred shares, outstanding	4,289,457	4,289,457	'
Convertible redeemable participating preferred shares, liquidation value (in dollars)	22,056	22,056	'
Series E convertible redeemable participating preferred shares | PARENT COMPANY	'	'	'
CONDENSED BALANCE SHEETS	'	'	'
Convertible redeemable participating preferred shares, par value (in dollars per share)	$0.01	$0.01	'
Convertible redeemable participating preferred shares, authorized	4,289,457	4,289,457	'
Convertible redeemable participating preferred shares, issued	4,289,457	4,289,457	'
Convertible redeemable participating preferred shares, outstanding	4,289,457	4,289,457	'
Convertible redeemable participating preferred shares, liquidation value (in dollars)	22,056	22,056	'
Series F convertible redeemable participating preferred shares	'	'	'
CONDENSED BALANCE SHEETS	'	'	'
Convertible redeemable participating preferred shares, par value (in dollars per share)	$0.01	$0.01	'
Convertible redeemable participating preferred shares, authorized	7,204,680	7,500,000	'
Convertible redeemable participating preferred shares, issued	4,654,697	4,654,697	'
Convertible redeemable participating preferred shares, outstanding	7,204,680	4,654,697	'
Convertible redeemable participating preferred shares, liquidation value (in dollars)	93,639	60,000	'
Series F convertible redeemable participating preferred shares | PARENT COMPANY	'	'	'
CONDENSED BALANCE SHEETS	'	'	'
Convertible redeemable participating preferred shares, par value (in dollars per share)	$0.01	$0.01	'
Convertible redeemable participating preferred shares, authorized	7,204,680	7,500,000	'
Convertible redeemable participating preferred shares, issued	7,204,680	4,654,697	'
Convertible redeemable participating preferred shares, outstanding	7,204,680	4,654,697	'
Convertible redeemable participating preferred shares, liquidation value (in dollars)	$93,639	$60,000	'
Class A common shares	'	'	'
CONDENSED BALANCE SHEETS	'	'	'
Common shares, par value (in dollars per share)	$0.01	$0.01	'
Common shares, authorized	37,698,485	36,026,704	'
Common shares, issued	4,911,245	4,911,245	'
Common shares, outstanding	4,599,674	4,599,674	5,116,490
Class A common shares | PARENT COMPANY	'	'	'
CONDENSED BALANCE SHEETS	'	'	'
Common shares, par value (in dollars per share)	$0.01	$0.01	'
Common shares, authorized	37,648,485	36,026,704	'
Common shares, issued	4,599,673	4,911,245	'
Common shares, outstanding	4,599,673	4,911,245	'
Class B common shares	'	'	'
CONDENSED BALANCE SHEETS	'	'	'
Common shares, par value (in dollars per share)	$0.01	$0.01	'
Common shares, authorized	1,570,000	1,570,000	'
Common shares, issued	1,570,000	1,570,000	'
Common shares, outstanding	1,570,000	1,570,000	1,570,000
Class B common shares | PARENT COMPANY	'	'	'
CONDENSED BALANCE SHEETS	'	'	'
Common shares, par value (in dollars per share)	$0.01	$0.01	'
Common shares, authorized	1,570,000	1,570,000	'
Common shares, issued	1,570,000	1,570,000	'
Common shares, outstanding	1,570,000	1,570,000	'

FINANCIAL_STATEMENT_SCHEDULE_I3

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY (Details 2) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Operating expenses:	'	'	'
Selling and marketing	$28,879	$18,486	$14,005
General and administrative	32,053	23,447	14,756
Total operating expenses	62,535	43,203	29,818
Income from operations	33,364	19,589	14,389
Interest income	93	100	101
Interest expense	-1,331	-1,106	-159
Equity in earnings of subsidiaries and VIE entities	-156	'	'
Income before provision for income taxes and loss from equity method investment	32,183	18,583	14,331
Net income attributable to iKang Healthcare Group, Inc.	21,607	12,111	9,702
PARENT COMPANY	'	'	'
Operating expenses:	'	'	'
Selling and marketing	'	'	6
General and administrative	2,457	2,849	668
Total operating expenses	2,457	2,849	674
Income from operations	-2,457	-2,849	-674
Interest income	11	'	'
Interest expense	-18	-169	'
Equity in earnings of subsidiaries and VIE entities	24,071	15,129	10,376
Income before provision for income taxes and loss from equity method investment	21,607	12,111	9,702
Net income attributable to iKang Healthcare Group, Inc.	$21,607	$12,111	$9,702

FINANCIAL_STATEMENT_SCHEDULE_I4

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY (Details 3) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
CONDENSED STATEMENTS OF COMPREHENSIVE INCOME	'	'	'
Net income	$21,607	$12,111	$9,702
Other comprehensive income:	'	'	'
Comprehensive income attributable iKang Healthcare Group, Inc.	20,849	12,695	11,227
PARENT COMPANY	'	'	'
CONDENSED STATEMENTS OF COMPREHENSIVE INCOME	'	'	'
Net income	21,607	12,111	9,702
Other comprehensive income:	'	'	'
Other comprehensive income, foreign currency translation adjustment	-758	584	1,525
Comprehensive income attributable iKang Healthcare Group, Inc.	$20,849	$12,695	$11,227

FINANCIAL_STATEMENT_SCHEDULE_I5

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY (Details 4) (USD $)

12 Months Ended

In Thousands, except Share data, unless otherwise specified

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2014

Mar. 31, 2012

Mar. 31, 2012

Mar. 31, 2012

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2014

Mar. 31, 2012

Mar. 31, 2012

Mar. 31, 2012

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2014

Mar. 31, 2012

Mar. 31, 2012

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2014

Mar. 31, 2012

Mar. 31, 2012

Mar. 31, 2012

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2011

iKang Shanghai Lujiazui

iKang Shanghai Lujiazui

iKang Shanghai Xikang Road

Shenzhen Hospital Management

Shanghai iKang Jianwei Health Management Co., Ltd

PARENT COMPANY

PARENT COMPANY

PARENT COMPANY

PARENT COMPANY

PARENT COMPANY

PARENT COMPANY

PARENT COMPANY

PARENT COMPANY

Common stock

Common stock

Common stock

Common stock

Common stock

Common stock

Additional paid-in capital

Additional paid-in capital

Additional paid-in capital

Additional paid-in capital

Additional paid-in capital

Additional paid-in capital

Additional paid-in capital

Additional paid-in capital

Additional paid-in capital

Additional paid-in capital

Additional paid-in capital

Additional paid-in capital

Additional paid-in capital

Accumulated deficit

Accumulated deficit

Accumulated deficit

Accumulated deficit

Accumulated other comprehensive income

Accumulated other comprehensive income

Accumulated other comprehensive income

Accumulated other comprehensive income

iKang Shanghai Lujiazui

iKang Shanghai Lujiazui

iKang Shanghai Xikang Road

Shenzhen Hospital Management

Shanghai iKang Jianwei Health Management Co., Ltd

PARENT COMPANY

PARENT COMPANY

PARENT COMPANY

iKang Shanghai Lujiazui

iKang Shanghai Lujiazui

iKang Shanghai Xikang Road

PARENT COMPANY

PARENT COMPANY

PARENT COMPANY

PARENT COMPANY

PARENT COMPANY

PARENT COMPANY

PARENT COMPANY

PARENT COMPANY

PARENT COMPANY

PARENT COMPANY

PARENT COMPANY

PARENT COMPANY

PARENT COMPANY

PARENT COMPANY

PARENT COMPANY

iKang Shanghai Lujiazui

iKang Shanghai Lujiazui

iKang Shanghai Xikang Road

Shenzhen Hospital Management

Shanghai iKang Jianwei Health Management Co., Ltd

Increase (Decrease) in Stockholders' Equity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance

($124,195)

'

'

'

'

'

'

'

($124,195)

($52,212)

($48,245)

'

'

'

'

'

'

'

'

$65

$67

$65

'

'

'

'

'

'

$4,341

$4,711

$16,103

'

'

'

'

($133,123)

($60,928)

($66,826)

'

$3,764

$4,522

$3,938

$2,413

Balance (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,481,245

6,686,490

6,476,645

6,481,245

6,686,490

6,476,645

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation

930

2,273

216

'

'

'

'

'

930

2,273

216

'

'

'

'

'

'

'

'

'

'

'

930

2,273

216

'

'

'

930

2,273

216

'

'

'

'

'

'

'

'

'

'

'

'

iKang Healthcare Group, Inc. one common share of US$0.01 entered into a share swap agreement (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Redesignation to Series F convertible redeemable participating preferred shares

-3,749

-2,645

'

'

'

'

'

'

-3,749

-2,645

'

'

'

'

'

'

-4

-2

'

-4

-2

'

-3,745

-2,643

'

'

'

'

-3,745

-2,643

'

'

'

'

'

'

'

'

'

'

'

'

'

Redesignation to Series F convertible redeemable participating preferred shares (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-311,572

-205,245

'

-311,572

-205,245

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Addition of non-controlling interest in connection with acquisition

'

'

'

'

'

'

'

-172

'

'

'

'

'

'

'

-172

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-172

'

'

'

'

Exercise of share options

'

'

136

'

'

'

'

'

'

'

136

'

'

'

'

'

'

'

1

'

'

1

'

'

135

'

'

'

'

'

135

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of share options (in shares)

'

'

75,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

75,000

'

'

75,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of share option to shareholders

'

'

271

'

'

'

'

'

'

'

271

'

'

'

'

'

'

'

1

'

'

1

'

'

1,762

'

'

'

'

'

1,762

'

'

'

'

'

'

-1,492

'

'

'

'

'

Exercise of share option to shareholders (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

134,845

'

'

134,845

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Change in effective ownership of iKang Zhejiang BVI

'

'

-95

'

'

'

'

'

'

'

-95

'

'

'

'

'

'

'

'

'

'

'

'

'

95

'

'

'

'

'

-95

'

'

'

'

'

'

'

'

'

'

'

'

Purchase of non-controlling interest

-142

'

-1,711

-326

-191

-14,721

29

'

'

'

'

-184

-15

-13,157

-238

'

'

'

'

'

'

'

'

'

'

-184

-15

-13,157

'

'

'

-184

-15

-13,157

-238

'

'

'

'

'

'

'

'

Deemed dividend on convertible redeemable preferred shares - accretion of redemption premium

20,436

84,306

2,312

'

'

'

'

'

-20,436

-84,306

-2,312

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-20,436

-84,306

-2,312

'

'

'

'

'

Net income

21,607

12,111

9,702

'

'

'

'

'

21,607

12,111

9,702

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

21,607

12,111

9,702

'

'

'

'

'

Foreign currency translation adjustment

'

'

'

'

'

'

'

'

-758

584

1,525

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-758

584

1,525

'

Balance

($126,957)

($124,195)

'

'

'

'

'

'

($126,957)

($124,195)

($52,212)

'

'

'

'

'

'

'

'

$61

$65

$67

'

'

'

'

'

'

$1,342

$4,341

$4,711

'

'

'

'

($132,124)

($133,123)

($60,928)

'

$3,764

$4,522

$3,938

$2,413

Balance (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,169,674

6,481,245

6,686,490

6,169,674

6,481,245

6,686,490

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

FINANCIAL_STATEMENT_SCHEDULE_I6

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY (Details 4) (Parenthetical) (USD $)	Mar. 31, 2014	Mar. 31, 2013
CONDENSED STATEMENTS OF SHAREHOLDERS' EQUITY(DEFICIT)	'	'
Common shares, par value (in dollars per share)	$0.01	$0.01
PARENT COMPANY	'	'
CONDENSED STATEMENTS OF SHAREHOLDERS' EQUITY(DEFICIT)	'	'
Common shares, par value (in dollars per share)	$0.01	'

FINANCIAL_STATEMENT_SCHEDULE_I7

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY (Details 5) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'	'
Net income	$21,607	$12,111	$9,702
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'
Investment income from subsidiaries	156	'	'
Stock-based compensation	930	2,273	216
Changes in assets and liabilities:	'	'	'
Prepaid expenses and other current assets	-1,193	176	45
Amount due from related party	'	-477	49
Accrued expenses and other current liabilities	2,884	3,071	2,235
Amount due to related parties	'	'	-198
Net cash generated from operating activities	34,303	16,314	14,005
CASH FLOWS FROM INVESTING ACTIVITIES	'	'	'
Loan provided to a related party	-4,306	'	'
Repayment of loan provided to a related party	3,483	'	'
Payment for business acquisitions	-41,311	-6,038	-2,966
Net cash used in investing activities	-96,714	-16,058	-15,706
CASH FLOW FROM FINANCING ACTIVITIES:	'	'	'
Proceeds from issuance of convertible redeemable preferred shares	25,181	45,000	'
Proceeds from convertible loan	'	2,000	'
Repayment of convertible loan	-2,000	'	'
Proceeds from exercise of share options	'	'	136
Proceeds from exercise of share option to shareholders	'	'	269
Proceeds from redesignation of Common A	612	'	'
Proceeds from redesignation of convertible redeemable preferred shares	669	'	'
Payment for convertible preferred shares transaction professional fees	-2,847	'	'
Payment for business acquisitions	-3,010	'	'
Net cash (used in)/ provided by financing activities	29,342	50,824	-1,161
Effect of exchange rate changes	136	199	595
Net increase in cash and cash equivalent	-32,933	51,279	-2,267
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR	63,154	11,875	14,142
CASH AND CASH EQUIVALENTS AT END OF THE YEAR	30,221	63,154	11,875
PARENT COMPANY	'	'	'
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'	'
Net income	21,607	12,111	9,702
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'
Investment income from subsidiaries	-24,071	-15,129	-10,376
Stock-based compensation	930	2,273	216
Changes in assets and liabilities:	'	'	'
Prepaid expenses and other current assets	-316	2,754	-980
Amount due from related party	-17,732	-1,502	1,576
Accrued expenses and other current liabilities	-2,409	-297	-108
Amount due to related parties	'	'	-564
Net cash generated from operating activities	-21,991	210	-534
CASH FLOWS FROM INVESTING ACTIVITIES	'	'	'
Loan provided to a related party	-3,000	'	'
Repayment of loan provided to a related party	3,000	'	'
Payment for business acquisitions	-31,710	'	'
Net cash used in investing activities	-31,710	'	'
CASH FLOW FROM FINANCING ACTIVITIES:	'	'	'
Proceeds from issuance of convertible redeemable preferred shares	25,181	45,000	'
Proceeds from convertible loan	'	2,000	'
Repayment of convertible loan	-2,000	'	'
Proceeds from exercise of share options	'	'	135
Proceeds from exercise of share option to shareholders	'	'	269
Proceeds from redesignation of Common A	669	'	'
Proceeds from redesignation of convertible redeemable preferred shares	612	'	'
Payment for convertible preferred shares transaction professional fees	-2,847	'	'
Payment for business acquisitions	-1,267	'	'
Net cash (used in)/ provided by financing activities	20,348	47,000	404
Net increase in cash and cash equivalent	-33,353	47,210	-130
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR	47,290	80	210
CASH AND CASH EQUIVALENTS AT END OF THE YEAR	$13,937	$47,290	$80

FINANCIAL_STATEMENT_SCHEDULE_I8

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY (Details 7) (PARENT COMPANY)	12 Months Ended
	Mar. 31, 2014
PARENT COMPANY	'
Basis for presentation	'
Restricted net assets of subsidiaries VIE entities as a percentage of consolidated net assets of the Group	25.00%

FINANCIAL_STATEMENT_SCHEDULE_I9

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY (Details 8) (Convertible loan, USD $)	1 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2013	31-May-12
Convertible loans	'	'
Face amount	'	$2,000
Annual interest rate (as a percent)	'	8.00%
Repayment of loan and accrued interest	2,300	'
PARENT COMPANY	'	'
Convertible loans	'	'
Face amount	'	2,000
Annual interest rate (as a percent)	'	8.00%
Repayment of loan and accrued interest	$2,300	'

Recovered_Sheet1

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY (Details 9) (Subsequent events, USD $)

0 Months Ended

In Thousands, except Share data, unless otherwise specified

Apr. 09, 2014

Apr. 09, 2014

Apr. 09, 2014

Apr. 09, 2014

9-May-14

9-May-14

Apr. 08, 2014

Apr. 08, 2014

Apr. 08, 2014

Apr. 08, 2014

9-May-14

9-May-14

IPO

IPO

IPO

Private placement

Green shoe option

Green shoe option

PARENT COMPANY

PARENT COMPANY

PARENT COMPANY

PARENT COMPANY

PARENT COMPANY

PARENT COMPANY

ADS

Class A common shares

Class A common shares

ADS

Class A common shares

IPO

IPO

IPO

Private placement

Green shoe option

Green shoe option

Best Investment Corporation

ADS

Class A common shares

Class A common shares

ADS

Class A common shares

Best Investment Corporation

Subsequent events

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares issued

'

10,904,846

5,452,423

1,428,571

1,029,112

514,556

'

10,904,846

5,452,423

1,428,571

1,029,112

514,556

Net proceeds from issuance of shares

$87,900

'

'

'

$13,400

'

$87,900

'

'

'

$13,400

'

Total purchase price of shares issued

'

'

'

40,000

'

'

'

'

'

40,000

'

'

Net proceeds from issuance of shares

'

'

'

$37,200

'

'

'

'

'

$37,200

'

'

Price of shares issued (in dollars per share)

'

'

'

'

$14

'

'

'

'

'

$14

'